UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) June 20, 2017 (June 19, 2017)
Teladoc, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-37477 |
|
04-3705970 |
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
2 Manhattanville Road, Suite 203 |
|
10577 |
(Address of principal executive offices) |
|
(Zip Code) |
(203) 635-2002
Registrants telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 1.01. Entry into a Material Definitive Agreement.
As previously disclosed, on June 19, 2017, Teladoc, Inc. (the Company) and Barolo Acquisition Corp., a wholly owned subsidiary of the Company, entered into an Agreement and Plan of Merger (the Merger Agreement) with Best Doctors Holdings, Inc. (Best Doctors), Shareholder Representative Services LLC, in its capacity as Stockholder Representative thereunder, BBH Capital Partners IV, L.P. and BBH Capital Partners QP IV, L.P. pursuant to which the Company agreed to acquire Best Doctors.
In connection with the Merger Agreement, the Company entered into a commitment letter, dated June 19, 2017 (the Debt Commitment Letter), with Jefferies Group LLC (Jefferies) and Jefferies Finance LLC (Jefferies Finance and, together with Jefferies, the Commitment Parties), pursuant to which the Commitment Parties have agreed to provide the financing necessary to fund, in part, the consideration to be paid pursuant to the terms of the Merger Agreement and to refinance certain third-party indebtedness of the Company and Best Doctors and to pay fees, commissions and expenses related to the foregoing (the Debt Financing).
The Debt Financing is anticipated to consist of the following:
· the drawing of senior secured term loans under a senior secured term loan facility of the Company in an aggregate principal amount of $150 million;
· commitments under a senior secured revolving credit facility of the Company in an aggregate principal amount of $10 million; and
· the issuance and sale of senior unsecured notes of the Company yielding gross proceeds of $200 million.
Under the Debt Commitment Letter, Jefferies commits to purchase, directly or through one or more of its affiliates, the senior unsecured notes, which commitment shall automatically be reduced, on a dollar for dollar basis, by the aggregate gross proceeds from the issuance or sale of any senior unsecured notes, whether pursuant to the Debt Commitment Letter or otherwise. The funding of the Debt Financing is contingent on the satisfaction or waiver of certain conditions set forth in the Debt Commitment Letter.
A copy of the Debt Commitment Letter is attached as Exhibit 10.1 hereto and is incorporated herein by reference. The foregoing description does not purport to be complete and is qualified in its entirety by reference to such exhibit.
Item 7.01. Regulation FD Disclosure.
In connection with the offering of the notes (as defined below) a preliminary offering memorandum was provided to prospective purchasers containing (i) the unaudited condensed consolidated interim financial statements of Best Doctors as of March 31, 2017 and for the three months ended March 31, 2017 and 2016 (the Best Doctors Interim Financials); (ii) the audited consolidated financial statements of Best Doctors as of December 31, 2016 and 2015 and for the years ended December 31, 2016, 2015 and 2014 (the Best Doctors Audited Financials); and (iii) the unaudited pro forma combined financial statements of the Company giving pro forma effect to the prospective acquisition of Best Doctors as of and for the three months ended March 31, 2017 and giving pro forma effect to the acquisition of HY Holdings, Inc. d/b/a HealthiestYou Corporation and the prospective acquisition of Best Doctors Holdings, Inc. for the year ended December 31, 2016 and the related notes thereto (the Pro Forma Financials). The Best Doctors Interim Financials are attached as Exhibit 99.2 hereto and are incorporated herein by reference, the Best Doctors Audited Financials are attached as Exhibit 99.3 hereto and are incorporated herein by reference and the Pro Forma Financials are attached as Exhibit 99.4 hereto and are incorporated herein by reference.
Item 8.01. Other Events.
On June 20, 2017, the Company issued a press release announcing a proposed offering of $200 million in aggregate principal amount of convertible senior notes due 2022 (the notes) in transactions exempt from registration under the Securities Act of 1933, as amended (the Securities Act).
A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
This report does not constitute an offer to sell or a solicitation of an offer to buy the notes or any other securities, and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. The notes have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Cautionary Statement Regarding Forward-Looking Statements
This current report contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 concerning the Company, Best Doctors, the proposed acquisition of Best Doctors, the financing for the acquisition and other matters. Forward-looking statements can be identified by words such as: anticipate, intend, plan, believe, project, estimate, expect, may, should, will and similar references to future periods. Examples of forward-looking statements include, among others, statements the Company makes regarding its financing plans (including statements related to the entry into the Debt Commitment Letter and the offering of the notes), the intended acquisition of Best Doctors, future revenues, future earnings, future numbers of members or clients, litigation outcomes, regulatory developments, market developments, new products and growth strategies, and the effects of any of the foregoing on the Companys future results of operations or financial conditions.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Companys current beliefs, expectations and assumptions regarding the future of the Companys business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the control of the Company and Best Doctors. The Companys actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Companys actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) risks related to the acquisition of Best Doctors, including failure to obtain applicable regulatory approvals in a timely manner or at all, integration risks, exposure to international operations, the financing thereof (including the offering of the notes) and failure to achieve the anticipated benefits of the acquisition; (ii) changes in laws and regulations applicable to the Companys business model; (iii) changes in market conditions and receptivity to the Companys services and offerings; (iv) results of litigation; (v) the loss of one or more key clients; and (vi) changes to the Companys abilities to recruit and retain qualified providers into the Companys network. Additional relevant risks that may affect the Companys results are described in certain of the Companys filings with the SEC.
Any forward-looking statement made by us in this current report is based only on information currently available to us and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit |
|
Description |
|
|
|
10.1 |
|
Debt Commitment Letter, dated June 20, 2017, by and among Teladoc, Inc., Jefferies Group LLC and Jefferies Finance LLC. |
99.1 |
|
Teladoc, Inc. press release, dated June 20, 2017. |
99.2 |
|
Unaudited condensed consolidated interim financial statements of Best Doctors Holdings, Inc. as |
|
|
of March 31, 2017 and for the three months ended March 31, 2017 and 2016. |
99.3 |
|
Audited consolidated financial statements of Best Doctors Holdings, Inc. as of December 31, 2016 and 2015 and for the years ended December 31, 2016, 2015 and 2014. |
99.4 |
|
Unaudited pro forma combined financial statements of Teladoc, Inc. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
TELADOC, INC. | |
|
|
|
|
Date: June 20, 2017 |
By: |
/s/ Adam C. Vandervoort | |
|
|
Name: |
Adam C. Vandervoort |
|
|
Title: |
Chief Legal Officer and Secretary |
EXHIBIT INDEX
Exhibit |
|
Description |
|
|
|
10.1 |
|
Debt Commitment Letter, dated June 20, 2017, by and among Teladoc, Inc., Jefferies Group LLC and Jefferies Finance LLC. |
99.1 |
|
Teladoc, Inc. press release, dated June 20, 2017 |
99.2 |
|
Unaudited condensed consolidated interim financial statements of Best Doctors Holdings, Inc. as of March 31, 2017 and for the three months ended March 31, 2017 and 2016. |
99.3 |
|
Audited consolidated financial statements of Best Doctors Holdings, Inc. as of December 31, 2016 and 2015 and for the years ended December 31, 2016, 2015 and 2014. |
99.4 |
|
Unaudited pro forma combined financial statements of Teladoc, Inc. |
Exhibit 10.1
Execution Version
JEFFERIES GROUP LLC
JEFFERIES FINANCE LLC
520 Madison Avenue
New York, New York 10022
CONFIDENTIAL
June 19, 2017
Teladoc, Inc.
2 Manhattanville Road, Suite 203
Purchase, New York 10577
Attention: Chief Financial Officer
Project Barolo
Commitment Letter
Ladies and Gentlemen:
You have advised Jefferies Group LLC (Jefferies) and Jefferies Finance LLC (Jefferies Finance and, together with Jefferies, we or us) that Teladoc, Inc., a Delaware corporation (the Acquiror or you), intends to acquire (the Acquisition), directly or indirectly through one or more wholly owned subsidiaries, all of the issued and outstanding capital stock of a company previously identified to us as Barolo (the Target and, together with its subsidiaries, the Acquired Business) from the existing shareholders of the Target (collectively, the Seller) pursuant to that certain Agreement and Plan of Merger among you, the Target and the Stockholder Representative (as defined therein) (as may be amended, modified, supplemented, waived or the subject of any consent in accordance with the terms of this Commitment Letter (as defined below), together with the annexes, schedules, exhibits and attachments thereto, the Purchase Agreement), and to refinance (together with any applicable prepayment premium or fee, with the commitments thereunder being terminated, and all guarantees and security in respect thereof being terminated and released following repayment) (x) the Acquirors (i) Amended and Restated Loan and Security Agreement, dated as of May 2, 2014, by and among the Acquiror, Teladoc Physicians, P.A., Compile, Inc., Stat Health, LLC and HY Holdings, Inc. (collectively, the Teladoc Existing Borrowers), the lenders from time to time party thereto and Silicon Valley Bank, as the lender (as amended, restated, amended and restated, supplemented or otherwise modified) and (ii) Senior Secured Facilities Credit Agreement, dated as of July 11, 2016 by and among the Teladoc Existing Borrowers, Silicon Valley Bank as the lender, and the other lenders and issuing lenders from time to time party thereto (as amended, restated, amended and restated, supplemented or otherwise modified) and (y) the Acquired Business (i) Loan and Security Agreement, dated as of November 25, 2013, by and among Best Doctors, Inc., the other parties from time to time party thereto and Silicon Valley Bank, as the bank (as amended, restated, amended and restated, supplemented or otherwise modified), (ii) Master Lease Agreement, dated as of April 7, 2015, by and among Best Doctors, Inc., Rise Health, Inc., the other parties from time to time party thereto and Eastward Fund Management, LLC, as lessor (as amended, restated, amended and restated, supplemented or otherwise modified) and (iii) 5.000% Subordinated Convertible Promissory Notes due August 29, 2019 (as amended, restated, amended and restated, supplemented or otherwise modified) (the
refinancing of the debt under clauses (x) and (y) is hereinafter referred to as the Refinancing). Capitalized terms used but not defined herein and defined in any exhibit hereto have the meanings assigned to them in such exhibit. As used herein, the term Closing Date means the date of the consummation of the acquisition and the first extension of credit under the Facilities (as defined herein).
You have advised us that the cash portion of the total purchase price due on the Closing Date for the Acquisition (the Purchase Price), the Refinancing, and fees, commissions and expenses related to the Acquisition and the Refinancing, in each case, payable by you or your affiliates on the Closing Date, is anticipated to be financed from the following sources:
(a) the drawing of senior secured term loans (the Term Loans) under a senior secured term loan facility having the terms set forth in Exhibit A hereto (the Term Loan Facility) in an aggregate principal amount of $150.0 million);
(b) commitments under a senior secured revolving credit facility (the Revolving Credit Facility and, together with the Term Loan Facility, the Facilities) in an aggregate principal amount of $10.0 million;
(c) the issuance and sale (the Unsecured Notes Offering) of senior unsecured notes (the Unsecured Notes) of the Acquiror having terms as separately agreed upon between you and us on the date hereof and yielding gross proceeds of $200.0 million; and
(d) cash on hand of the Acquiror and its subsidiaries.
The transactions described in clauses (a) through (c) above are referred to as the Debt Financing; the Debt Financing, together with the Acquisition, the Refinancing and the payment of all related fees, commissions and expenses payable on the Closing Date by you or your affiliates, are collectively referred to herein as the Transactions. You and your subsidiaries and, following the Acquisition, the Target and its subsidiaries are referred to herein collectively as the Company. As used in this Commitment Letter and the other Debt Financing Letters (as defined below), the words include, includes and including shall be deemed to be followed by the phrase without limitation.
1. The Commitments.
We are pleased to inform you that:
(a) Jefferies Finance hereby commits, directly or through one or more if its affiliates, to provide the Facilities (in such capacity, the Initial Lender); and
(b) Jefferies hereby commits, directly or through one or more of its affiliates, to purchase the Unsecured Notes.
The commitments described in this Section 1 are collectively referred to herein as the Commitments. Our Commitments are, in each case, on the terms and subject only to the conditions set forth in (i) this letter (including the exhibits, schedules and annexes hereto, collectively, this Commitment Letter) and (ii) the fee letter, dated the date hereof (the Fee
Letter), among you and us. Notwithstanding anything to the contrary in any Debt Financing Letter, but subject to the Documentation Principles (as defined in Exhibit A hereto), the terms of this Commitment Letter and Fee Letter do not include all of the terms that will be contained in the definitive documents relating to the Debt Financing (collectively, the Definitive Debt Documents); provided that there shall be no closing condition contained in the Definitive Debt Documents that is not specifically set forth in Section 3 hereof, in Exhibit A to this Commitment Letter under the headings Conditions Precedent to Initial Borrowing or in Exhibit B to this Commitment Letter. No party hereto has been authorized by us to make any oral or written statements or representations that are inconsistent with the Debt Financing Letters.
2. Titles and Roles. As consideration for the Commitments, you agree that you hereby retain and will cause your affiliates to retain:
(a) Jefferies (acting through any of its affiliates as it deems appropriate) to act, and Jefferies hereby agrees to act, in the capacities and in connection with the matters set forth in the Engagement Letter (as defined below), and
(b) Jefferies Finance (acting through any of its affiliates as it deems appropriate) to act, and Jefferies Finance hereby agrees to act, as the sole administrative agent, sole collateral agent, sole book-runner and sole lead arranger (in such capacity, the Lead Arranger) for you and your affiliates in connection with the Facilities.
It is understood and agreed that no other titles shall be awarded and no compensation (other than that expressly contemplated by the Debt Financing Letters) shall be paid to any person in connection with the Facilities or Unsecured Notes Offering, unless mutually agreed. You further agree that Jefferies Finance and Jefferies (or their respective applicable affiliates), respectively, shall have left placement in any and all marketing materials or other documentation used in connection with each of the Facilities or Unsecured Notes Offering, as applicable, and shall hold the leading role and responsibilities customarily associated with such left placement.
In addition, pursuant to the Engagement Letter (the Engagement Letter and, together with this Commitment Letter and the Fee Letter, the Debt Financing Letters) between you and Jefferies LLC entered into on or prior to the date hereof, you have engaged Jefferies to act as sole underwriter, sole initial purchaser and/or sole placement agent in connection with any public offering or private placement of any debt, equity or equity-linked securities issued in connection with the Acquisition.
3. Conditions Precedent. The closing of the Facilities, the making of the initial loans under the Facilities and Jefferies purchase of the Unsecured Notes on or prior to the Closing Date are conditioned upon (and solely upon) the satisfaction or waiver by us of each of the following conditions: (i) since the date hereof, no Company Material Adverse Effect (as defined in the Purchase Agreement) shall have occurred; (ii) with respect to the Facilities, the other conditions expressly set forth in Exhibit A under the heading Conditions Precedent to Initial Borrowing; and (iii) the other conditions expressly set forth in Exhibit B to this Commitment Letter.
Notwithstanding anything in the Debt Financing Letters, the Definitive Debt Documents or any other letter agreement or other undertaking concerning the financing of the Transactions to the contrary, (i) the only representations and warranties the accuracy of which shall be a condition to the availability of the Facilities and to the purchase of the Unsecured Notes on the Closing Date shall be (A) such of the representations and warranties with respect to the Acquired Business in the Purchase Agreement as are material to the interests of the Investors (as defined below), but only to the extent that you have (or your applicable affiliate has) the right to terminate your (or its) obligations under the Purchase Agreement or decline to consummate the Acquisition as a result of a breach of such representations and warranties (as determined without giving effect to any waiver, amendment, consent or other modification thereto) (collectively, the Specified Purchase Agreement Representations) and (B) the Specified Representations (as defined below) and (ii) the terms of the Definitive Debt Documents and closing deliverables shall be in a form such that they do not impair availability of the Facilities or the purchase of the Unsecured Notes on the Closing Date if the conditions expressly set forth in the first paragraph of this Section 3 are satisfied or waived by us (it being understood that, to the extent any lien or security interest on or in any Collateral (other than to the extent that a lien on such Collateral may be perfected (x) by the filing of a financing statement under the Uniform Commercial Code or (y) by the delivery of stock certificates of the Borrower and its wholly owned material domestic subsidiaries (which stock certificates shall be delivered on the Closing Date; provided that if after using commercially reasonable efforts the stock certificates of the Target and its subsidiaries cannot be delivered on the Closing Date, then such stock certificates must be delivered within ten business days after the Closing Date, as such period may be extended by the Administrative Agent in its sole discretion) which are required to be delivered under Exhibit A to this Commitment Letter) or is not or cannot be perfected on the Closing Date after your use of commercially reasonable efforts to do so, neither the perfection of such Collateral nor, in the case of real estate Collateral, the delivery of any related title policies, surveys, title insurance documents, endorsements or similar documentation shall constitute a condition precedent to the availability of the Debt Financing and the making of the initial loans on the Closing Date, but shall be required to be perfected within 90 days after the Closing Date (subject to extensions by the Administrative Agent, in its sole discretion). For purposes hereof, Specified Representations means the representations and warranties of the Credit Parties (or the Acquiror with respect to the Unsecured Notes Offering), set forth in the Definitive Debt Documents relating to corporate or other organizational existence of the Borrower and Guarantors (or the Acquiror with respect to the Unsecured Notes Offering), organizational power and authority (as to execution, delivery and performance of the applicable Definitive Debt Documents) of the Borrower and Guarantors (or the Acquiror with respect to the Unsecured Notes Offering), the due authorization, execution, delivery and enforceability of the applicable Definitive Debt Documents, solvency of the Borrower and its subsidiaries (which representation shall be consistent with the representation contained in Exhibit C hereto), no conflicts resulting from the entering into and performance of the Definitive Debt Documents with charter documents of the Borrower and Guarantors (or the Acquiror with respect to the Unsecured Notes Offering), Federal Reserve margin regulations, use of proceeds not in violation of the FCPA, use of proceeds not in violation of OFAC, the PATRIOT Act, the Investment Company Act and, with respect to the Facilities and subject to permitted liens and the limitations set forth in the prior sentence, the creation, validity, perfection and priority of security interests in the Collateral (subject, in each case, to certain customary exceptions to be set forth in the Definitive Debt
Documents and consistent with the Documentation Principles). This paragraph shall be referred to herein as the Certain Funds Provision.
4. Syndication.
(a) We reserve the right, at any time after the date hereof and prior to or after execution of the Definitive Debt Documents, but subject to the limitations set forth herein, to syndicate all or part of our (or our affiliates) Commitments to a syndicate of banks, financial institutions and other entities identified by us in consultation with you (collectively, including the proposed purchasers of the Unsecured Notes in the Unsecured Notes Offering, the Investors); provided that we will not syndicate the Facilities to, or place the Unsecured Notes with, (i) certain competitors of the Acquiror or the Target or certain financial institutions, institutional lenders and other entities, in each case, that have been specified to us by you in writing prior to the date hereof and (ii) any of the affiliates of such persons listed in clause (i) that are either (x) identified in writing by you from time to time or (y) clearly identifiable on the basis of such affiliates names (the parties described in clauses (i) and (ii) above, collectively, Disqualified Institutions); provided, however, that any supplement to the list of Disqualified Institutions after the date hereof shall not apply retroactively to disqualify any parties that have previously acquired an assignment or participation interest in the Facilities or have purchased Unsecured Notes that was permitted hereunder at the time of such assignment or participation interest or purchase; provided further that any bona fide debt fund or investment vehicle (other than a bona fide debt fund or investment vehicle that is separately identified under clause (i) above) that is primarily engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit and debt securities in the ordinary course of business and with respect to which a Disqualified Institution does not, directly or indirectly, possess the power to direct or cause the direction of the investment policies of such entity, shall not be considered to be a Disqualified Institution; provided further that notwithstanding our right to syndicate the Commitments, (i) neither Jefferies nor Jefferies Finance shall be relieved, released or novated from its obligations hereunder (including its obligation to fund the Facilities and purchase the Unsecured Notes on the Closing Date) in connection with any syndication, assignment or participation of any of the Commitments, (ii) no assignment or novation by us shall become effective as between us and you with respect to all or any portion of our Commitments until the initial funding of the Facilities or purchase of the Unsecured Notes and (iii) we shall retain exclusive control over the rights and obligations with respect to our respective Commitments, including all rights with respect to consents, modifications, supplements and amendments, until the Closing Date has occurred, in each case, unless you and we agree in writing. We will exclusively manage all aspects of any such syndication in consultation with you, including decisions as to the selection of prospective Investors to be approached, when they will be approached, when their commitments will be accepted, which prospective Investors will participate, the allocation of the commitments among the Investors and the amount and distribution of fees. Notwithstanding anything to the contrary contained in this Section 4, this Commitment Letter or the other Debt Financing Letters or any other letter agreement or undertaking concerning the financing of the Transactions to the contrary, unless otherwise expressly set forth in Exhibit B hereto, your obligations to assist in syndication efforts as provided herein (including the obtaining of the ratings referenced herein) shall not constitute a condition to the Commitments hereunder or the funding of the Facilities or the purchase of Unsecured Notes on the Closing Date, and the Commitments hereunder are not conditioned upon
the syndication of or receipt of commitments in respect of the Facilities or the purchase of the Unsecured Notes and in no event shall the commencement or successful completion of syndication of the Facilities or the purchase of the Unsecured Notes constitute a condition to the availability of the Facilities and the making of the initial loans and purchase of the Unsecured Notes on the Closing Date.
(b) We intend to commence our syndication efforts with respect to the Facilities promptly upon your execution of this Commitment Letter and you agree to use commercially reasonable efforts to assist us in completing a syndication that is reasonably satisfactory to us and you until the date that is the earlier of (i) 45 days after the Closing Date and (ii) the date on which a Successful Syndication (as defined in the Fee Letter) is achieved (such earlier date referred to in clause (i) and (ii), the Syndication Date). Such assistance shall include:
(i) your using commercially reasonable efforts to ensure that our syndication efforts benefit from your existing lending and investment banking relationships and, to the extent reasonably requested by you, existing lending and investment banking relationships of the Acquired Business to the extent reasonably practical and appropriate;
(ii) your providing direct contact between appropriate members of your senior management, representatives and non-legal advisors, on the one hand, and the proposed Investors, on the other hand (and (x) prior to the consummation of the Acquisition, your using commercially reasonable efforts (subject to the limitations on your rights set forth in the Purchase Agreement, but including exercising your rights thereunder) to cause, and (y) thereafter, your causing, direct contact between appropriate members of senior management of the Acquired Business, on the one hand, and the proposed Investors, on the other hand), in all such cases at times mutually agreed upon;
(iii) your assistance (and (x) prior to the consummation of the Acquisition, your using commercially reasonable efforts to cause, and (y) thereafter, your causing, the Acquired Business to assist) in the preparation of one or more customary confidential information memoranda (each, a Confidential Information Memorandum) and other customary marketing materials to be used in connection with the syndication of our Commitments (together with all Confidential Information Memoranda, the Materials), by providing such information and other customary materials as we may reasonably request in connection with the preparation of such Confidential Information Memoranda, including, in the case of information concerning the Acquired Business, by requiring the furnishing of information required to be furnished under the Purchase Agreement, but subject to the limitations on your rights thereunder;
(iv) your hosting, with us, of meetings with prospective Investors (including one general bank meeting and a reasonable number of one on one meetings), in each case to the extent reasonably requested by us and at such times and places as you and we, acting reasonably, may agree and, to the extent we request that senior management or appropriate representatives of the Acquired Business attend such meetings, you shall use your commercially reasonably efforts to cause them so to attend (without violation of the Purchase Agreement, but including by exercising your rights thereunder); and
(v) ensuring that (or, with respect to the Acquired Business, using commercially reasonable efforts to ensure that) until the later of the Syndication Date and the Closing Date, there shall be no competing offering, placement or arrangement of any debt securities or credit facilities by you, your subsidiaries and, to the extent not in contravention of the Purchase Agreement, the Acquired Business (in each case, other than (1) the Debt Financing, (2) replacements, extensions and renewals of existing indebtedness that matures prior to the Closing Date, (3) other indebtedness permitted to be outstanding or issued under the Purchase Agreement and (4) indebtedness approved by the Lead Arranger (such consent not to be unreasonably withheld, denied, delayed or conditioned)) without the prior written consent of the Lead Arranger if such offering, placement or arrangement would have a materially detrimental effect upon the primary syndication of the Facilities or the placement of the Unsecured Notes (it being understood that the ordinary course short-term working capital facilities (consistent with past practice) and ordinary course capital lease, purchase money and equipment financings of you, your subsidiaries or the Acquired Business will not have a materially detrimental effect upon the syndication of the Facilities or the placement of the Unsecured Notes).
(c) You agree, at our reasonable request, to assist in the preparation of a version of any Materials consisting exclusively of information and documentation that is either (i) publicly available or (ii) not material with respect to you, the Target or any of your or their respective subsidiaries for purposes of United States federal and state securities laws (such information and Materials, Public Information). In addition, you agree that, unless specifically labeled as Public Information, each document to be disseminated by us to any Investor will be deemed to contain Material Non-Public Information (as defined below) and we will not make any such materials available to Investors who do not wish to receive Material Non-Public Information. Any information and documentation that is not Public Information is referred to herein as Material Non-Public Information. It is understood that in connection with your assistance described above, authorization letters will be included in any information package and presentation whereby you authorize the distribution of such information to prospective Investors, it being understood that (x) the authorization letter for Public Information shall contain a representation by you to the Investors that the Public Information does not include any such Material Non-Public Information and each letter shall contain a customary 10b-5 representation and (y) each such information package and presentation shall exculpate you, the Target, your and their respective affiliates and us and our respective affiliates with respect to any liability related to the use of the contents of such information package and presentation or any related marketing material by the recipients thereof. You acknowledge and agree that the following documents contain and shall contain solely Public Information (unless you notify us promptly that any such document contains Material Non-Public Information after such materials have been provided to you and your counsel for review a reasonable period of time): (i) draft and final Definitive Debt Documents with respect to the Debt Financing, (ii) customary administrative materials prepared by us for prospective Investors (including a lender meeting invitation, Lender allocations, if any, and funding and closing memoranda) and (iii) term sheets and notification of changes in the terms of the Debt Financing. You agree to identify (and, with respect to information with respect to the Target, use commercially reasonable efforts to identify) Public Information by clearly and conspicuously marking the same as PUBLIC.
(d) You agree that all Materials and Information (as defined below) (including draft and execution versions of the Definitive Debt Documents and draft or final offering
materials relating to contemporaneous securities issuances by the Company) may be disseminated for syndication purposes in accordance with our standard syndication practices (including through hard copy and via one or more Internet sites (including an IntraLinks, SyndTrak or similar workspace), e-mail or other electronic transmissions). Without limiting the foregoing, you authorize, and will use commercially reasonable efforts to maintain the contractual undertakings from the Acquired Business to authorize, the use of your and (subject to the limitations thereon set forth in the Purchase Agreement) its logos in connection with any such dissemination. You further agree that, at our expense, we may place advertisements in financial and other newspapers and periodicals or on a home page or similar place for dissemination of information on the Internet or worldwide web as we may choose, and circulate similar promotional materials, after the closing of the Transactions in the form of a tombstone or otherwise, containing information customarily included in such advertisements and materials, including (i) the names of the Acquiror, the Target and your and its respective affiliates (or any of them), (ii) our and our respective affiliates titles and roles in connection with the Transactions and (iii) the amount, type and closing date of such Transactions, but subject to the limitations on disclosure of confidential information set forth in Section 9 hereof.
Notwithstanding anything to the contrary contained in this Commitment Letter or the Fee Letter, (i) none of the foregoing requirements of this Section 4 shall constitute a condition to the commitments hereunder or the funding of the Facilities or the purchase of the Unsecured Notes on the Closing Date and (ii) neither the commencement nor the completion of the syndication of the Facilities or the Unsecured Notes Offering shall constitute a condition precedent to the Closing Date or delay or interfere in any way with the negotiation of the Debt Financing and/or the funding thereof. We acknowledge that the Target and its subsidiaries are not restricted from incurring debt or liens prior to the Closing Date, except as specifically set forth in the Purchase Agreement, and that prior to the Closing Date, the Target is obligated to assist you with respect to the Facilities and the Unsecured Notes only to the extent set forth in the Purchase Agreement. Your obligations under the Debt Financing Letters to use commercially reasonable efforts to cause the Target, its subsidiaries or their respective management to take (or to refrain from taking) any action will not require you to (a) take any legal action against the Target, its subsidiaries or their respective management under the Purchase Agreement, (b) take any other action that is in contravention of the terms of the Purchase Agreement or (c) terminate the Purchase Agreement.
5. Information. You represent and warrant with respect to the Acquiror, the Target and your and its respective subsidiaries (provided that, with respect to information relating to the Target and its subsidiaries, such representation and warranty is to your knowledge) that:
(a) all written information (excluding, for this purpose, all immaterial information) and data other than the Projections (as defined below) and information of a general economic or industry-specific nature (the Information) that has been or will be made available to us by or on behalf of you or any of your representatives with respect to the Acquiror, the Target or your or its respective subsidiaries in connection with the Transactions does not and will not, when taken as a whole, when furnished, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements contained therein not materially misleading, taken as a whole, in light of the circumstances under which such statements are made; and
(b) all projections, forecasts and other forward-looking information that have been or will be made available to us by you or on your behalf with respect to you, the Acquired Business or any of your or its respective subsidiaries (collectively, the Projections) have been or will be prepared in good faith based upon assumptions that are believed by you to be reasonable at the time made (it being understood that any such Projections are as to future events and are not to be viewed as facts, are not a guarantee of financial performance and are subject to significant uncertainties and contingencies, many of which are beyond your control, that no assurance can be given that any particular Projections will be realized, that actual results may differ and that such differences may be material).
You agree that, if at any time prior to the later of the Closing Date and the Syndication Date, you become aware that any of the representations and warranties in the preceding sentence would be incorrect in any material respect if the Information or Projections were then being furnished and such representations and warranties were then being made, you shall, at such time, supplement promptly such Information and/or Projections, as the case may be, in order that such representations and warranties (and with respect to the Target and its subsidiaries prior to the Closing Date, to your knowledge) will be correct in all material respects under those circumstances (and any such supplementation shall cure any breach of such representation and warranty).
You shall be solely responsible for Information, including the contents of all Materials. We (i) will be relying on Information and data provided by or on behalf of you and the Acquired Business or any of your or its representatives or otherwise available from generally recognized public sources, without having independently verified the accuracy or completeness of the same, (ii) do not assume responsibility for the accuracy or completeness of any such Information and data and (iii) will not make an appraisal of your assets or liabilities or the assets or liabilities of the Acquired Business.
6. [Reserved].
7. Fees and Expenses. As consideration for the Commitments and our other undertakings hereunder, you hereby agree to pay or cause to be paid to us for reasonable and documented out-of-pocket fees, expenses and other amounts set forth in the Debt Financing Letters on the terms and conditions set forth therein, including all reasonable and documented out-of-pocket fees and expenses (including, without limitation, the reasonable fees and expenses of (x) the primary counsel acting for us, which shall be Davis Polk & Wardwell LLP, and (y) one local counsel and one regulatory counsel for each relevant jurisdiction as may be necessary or advisable in the reasonable judgment of Jefferies) arising in connection with the Facilities and the preparation, negotiation, execution, delivery and enforcement of the Debt Financing Letters and the Definitive Debt Documents related to the Facilities (including in connection with our due diligence and syndication efforts) (and that you shall from time to time upon request from us, reimburse Jefferies and its affiliates for all such reasonable and documented out-of-pocket fees and expenses paid or incurred by them); provided that if the Closing Date does not occur, the aggregate reimbursement by you of such fees, expenses and other amounts shall not exceed $100,000 (excluding any fees and expenses paid to Jefferies on the closing date of the purchase of the Unsecured Notes, regardless of whether the Closing Date occurs).
8. Indemnification and Waivers. You agree to indemnify and hold harmless Jefferies, Jefferies Finance, the Investors and our and their respective affiliates and subsidiaries and each director, officer, trustee, shareholder, employee, advisor, agent, affiliate, successor, assign, attorney in fact, partner, representative and controlling person of each of the foregoing (each an Indemnified Person) from and against any and all actions, suits, investigation, inquiry, claims, actual losses, damages, liabilities or proceedings of any kind or nature whatsoever which may be incurred by or asserted against or involve any such Indemnified Person as a result of or arising out of or in any way related to or resulting from the Debt Financing Letters or the Debt Financing, the use of proceeds thereof, the Transactions or the other transactions contemplated hereby or thereby (regardless of whether any such Indemnified Person is a party thereto and regardless of whether such matter is initiated by a third party or otherwise) (any of the foregoing, a Proceeding), and you agree to reimburse each Indemnified Person within 30 days after written demand therefor (which request shall include reasonably detailed backup documentation) for any reasonable and documented legal or other out-of-pocket expenses incurred in connection with investigating, defending, preparing to defend or participating in any such Proceeding (limited, in the case of legal fees and expenses, to one firm of primary counsel to such Indemnified Persons taken as a whole (and one firm of additional counsel as a result of any actual or reasonably perceived conflicts of interest for each class of similarly situated Indemnified Persons) and, if necessary, one firm of local counsel in each applicable jurisdiction); provided, however, that no Indemnified Person will be indemnified for any such cost, expense or liability to the extent (i) determined by a final non-appealable judgment of a court of competent jurisdiction to have resulted from the gross negligence or willful misconduct of such Indemnified Person or its affiliates or (ii) resulting from any proceeding that does not involve an act or omission by you or any of your affiliates and that is brought by an Indemnified Person against any other Indemnified Person (other than any claims against Jefferies in fulfilling its role as an administrative agent, arranger or any similar role under the Facilities or Unsecured Notes). In the case of any Proceeding to which the indemnity in this paragraph applies, such indemnity and reimbursement obligations shall be effective, whether or not such Proceeding is brought by you, the Target, any of your or their respective affiliates, securityholders or creditors, an Indemnified Person or any other person, or an Indemnified Person is otherwise a party thereto and whether or not any aspect of the Debt Financing Letters, the Debt Financing or any of the Transactions is consummated.
Notwithstanding any other provision of this Commitment Letter, (i) no Indemnified Person shall be liable for any damages arising from the use by others of information or other materials obtained through Internet, electronic, telecommunications or other information transmission systems, except to the extent that such damages have resulted from the gross negligence or willful misconduct of such Indemnified Person or any of such Indemnified Persons affiliates or any of its or their respective officers, directors, employees, agents, advisors or other representatives, in each case who are involved in or aware of the Transactions as determined by a final, non-appealable judgment of a court of competent jurisdiction and (ii) without in any way limiting the indemnification obligations set forth above, none of us, you, the Target or any Indemnified Person shall be liable for any indirect, special, punitive or consequential damages (including, without limitation, any loss of profits, business or anticipated savings) in connection with this Commitment Letter, the Fee Letter or the Transactions (including the Debt Financing and the use of proceeds thereunder) or with respect to any activities related to the Debt Financing, including the preparation of the Debt Financing Letters
and the Definitive Debt Documents; provided, that nothing contained in the preceding clause (ii) shall limit your indemnification obligations set forth herein to the extent that such indirect, special, punitive or consequential damages are included in any third-party claim in connection with which such Indemnified Person is entitled to indemnification hereunder.
You shall not be liable for any settlement of any Proceeding effected without your written consent (which consent shall not be unreasonably withheld or delayed), but if settled with your written consent or if there is a judgment by a court of competent jurisdiction in any such Proceeding, you agree to indemnify and hold harmless each Indemnified Person from and against any and all losses, claims, damages, liabilities and expenses by reason of such settlement or judgment in accordance with the other provisions of this Section 8.
You shall not, without the prior written consent of the affected Indemnified Person (which consent shall not be unreasonably withheld, conditioned or delayed, it being understood that an Indemnified Person may withhold consent to a settlement that does not satisfy the criteria in clauses (i) and (ii) below), effect any settlement of any pending or threatened proceedings in respect of which indemnity could have been sought hereunder by such Indemnified Person unless such settlement (i) includes an unconditional release of such Indemnified Person in form and substance reasonably satisfactory to such Indemnified Person from all liability or claims that are the subject matter of such proceedings and (ii) does not include any statement as to or any admission of fault, culpability, wrong doing or a failure to act by or on behalf of any Indemnified Person.
9. Confidentiality. This Commitment Letter and the Fee Letter are each delivered to you on the understanding that neither this Commitment Letter, any other Debt Financing Letter nor any of their terms or substance will be disclosed, directly or indirectly, to any other person or entity except (a) this Commitment Letter (but not the Fee Letter) may be disclosed as required by the rules and regulations of the Securities and Exchange Commission (the SEC) in connection with any filings with the SEC in connection with the Transactions (in which case you agree to inform us promptly thereof), (b) pursuant to the order of any court or administrative agency in any pending legal or administrative proceeding, or as otherwise required by applicable law or compulsory legal process (and in either such case you agree to inform us promptly thereof and to reasonably cooperate with us in securing a protective order in respect thereof to the extent lawfully permitted to do so), (c) to you and your officers, directors, employees, stockholders, affiliates, agents, attorneys, accountants and advisors on a confidential basis in connection with the Transactions, (d) the information contained in this Commitment Letter (but not that contained in the Fee Letter) may be disclosed in any Confidential Information Memorandum and any offering materials for the Unsecured Notes Offering or in connection with the syndication of the Facilities or the Unsecured Notes Offering, (e) this Commitment Letter (but not the Fee Letter) may be disclosed to the Target, the Seller, their direct and indirect equity holders and their respective officers, directors, employees, attorneys, accountants, agents and advisors, in each case on a confidential basis and only in connection with the Transactions, (f) to the extent portions thereof have been redacted in a manner reasonably agreed by us, you may disclose the Fee Letter and the contents thereof to the Target, the Seller and their respective officers, directors, employees, attorneys, accountants and advisors, in each case on a confidential basis and only in connection with the Transactions, (g) after the Closing Date, you may disclose to the Acquired Businesss auditors the Fee Letter and the contents thereof for customary accounting
purposes, including accounting for deferred financing costs, (h) you may disclose the Commitment Letter and the Fee Letter and the other Debt Financing Letters to the extent necessary in connection with the enforcement of your rights hereunder or thereunder, (i) you may disclose the Commitment Letter to potential Investors or Lenders (but not the Fee Letter) and to rating agencies in connection with obtaining ratings in connection with the Transactions and (j) you may disclose the Commitment Letter if we consent in writing to such proposed disclosure. You may also disclose, on a confidential basis, the aggregate amount of fees (including original issue discount) payable under the Fee Letter as part of a generic disclosure regarding sources and uses (but without disclosing any specific fees or flex or other economic terms set forth therein) in connection with the syndication of the Facilities and/or the Unsecured Notes Offering.
We and our respective affiliates shall use all non-public information received by us and them from you, the Target or your or its respective subsidiaries and representatives in connection with the Transactions solely for the purposes of providing the services contemplated by the Debt Financing Letters and shall treat confidentially all such non-public information; provided, however, that nothing herein shall prevent us from disclosing any such information (a) on a customary basis, to Moodys and S&P in connection with obtaining ratings in connection with the Transactions (including ratings in connection with the Unsecured Notes), (b) to any Investors or participants or prospective Investors or participants (other than persons who have, on the date of disclosure, effectively been designated as Disqualified Institutions) and to any direct or indirect contractual counterparty to any credit default swap or similar derivative product (other than Disqualified Institutions), (c) in any legal, judicial, administrative proceeding or other compulsory process or otherwise as required by applicable law, rule or regulations (in which case we will promptly notify you, in advance, to the extent practicable and permitted by law, rule or regulation, except in connection with any request as part of any regulatory audit or examinations conducted by accountants or any governmental regulatory authority exercising examination or regulatory authority), (d) upon the request or demand of any governmental or regulatory authority (including any self-regulatory authority) having jurisdiction over us or upon the good faith determination by counsel that such information should be disclosed in light of ongoing oversight or review by any governmental or regulatory authority (including any self-regulatory authority) having jurisdiction over us (in which case we shall, to the extent practicable and permitted by law, rule or regulation, except with respect to any audit or examination conducted by accountants or any governmental regulatory authority exercising examination or regulatory authority, promptly notify you, in advance, to the extent lawfully permitted to do so), (e) to our respective officers, directors, employees, legal counsel, independent auditors, professionals and other experts or agents working on the Transactions (collectively, Representatives) and who are informed of the confidential nature of such information and are or have been advised of their obligation to keep information of this type confidential (provided that we shall be responsible for the compliance of our Representatives with the provisions of this paragraph), (f) to any of our respective affiliates or Representatives of our respective affiliates (provided that any such affiliate or Representative is advised of its obligation to retain such information as confidential) solely in connection with the Transactions (provided that we shall be responsible for the compliance of our affiliates and Representatives of our affiliates with the provisions of this paragraph), (g) to the extent any such information is or becomes publicly available other than by reason of improper disclosure by us, our respective affiliates or our respective Representatives in breach of this Commitment Letter, (h) to the extent that any such
information is independently developed by us, any of our respective affiliates or any of our respective Representatives, (i) to the extent that such information is received by us or our affiliates from a third party that is not to our or our respective affiliates knowledge subject to confidentiality obligations to you and (j) to establish a due diligence defense, if applicable; provided that the disclosure of any such information to any Investors or prospective Investors or participants or prospective participants referred to above shall be made subject to the acknowledgment and acceptance by such Investors or prospective Investors or participants or prospective participants that such information is being disseminated on a confidential basis (on substantially the terms set forth in this paragraph or as is otherwise reasonably acceptable to you and us, including, without limitation, as agreed in any confidential information memorandum or other marketing materials) in accordance with our standard syndication processes or customary market standards for dissemination of such type of information. Our obligations under this paragraph shall terminate two years from the date hereof.
Notwithstanding anything herein to the contrary, you and we (and any of your and our respective employees, representatives or other agents) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the transactions contemplated by the Debt Financing Letters and all materials of any kind (including opinions or other tax analyses) that are provided to you or us relating to such tax treatment and tax structure, except that (i) tax treatment and tax structure shall not include the identity of any existing or future party (or any affiliate of such party) to any Debt Financing Letter, and (ii) neither you nor we shall disclose any information relating to such tax treatment and tax structure to the extent nondisclosure is reasonably necessary in order to comply with applicable securities laws. For this purpose, the tax treatment of the transactions contemplated by the Debt Financing Letters is the purported or claimed U.S. federal income tax treatment of such transactions and the tax structure of such transactions is any fact that may be relevant to understanding the purported or claimed U.S. federal income tax treatment of such transactions.
10. Conflicts of Interest; Absence of Fiduciary Relationship. You acknowledge and agree that:
(a) each of us and/or our respective affiliates and subsidiaries, including, in the case of Jefferies Finance, Jefferies and its affiliates (each, a Commitment Party Group), in our and their respective capacities as principal or agent, are involved in a wide range of commercial banking and investment banking activities globally (including investment advisory, asset management, research, securities issuance, trading, and brokerage) from which conflicting interests or duties may arise and, therefore, conflicts may arise between (i) our interests and duties hereunder and (ii) the duties or interests or other duties or interests of another member of our respective Commitment Party Group;
(b) we and any other member of a Commitment Party Group may, at any time, (i) provide services to any other person, (ii) engage in any transaction (on our or its own account or otherwise) with respect to you or any member of the same group as you or (iii) act in relation to any matter for any other person whose interests may be adverse to you or any member of your group (a Third Party), and may retain for our or its own benefit any related remuneration or profit, notwithstanding that a conflict of interest exists or may arise and/or any member of a Commitment Party Group is in possession or has come or comes into possession
(whether before, during or after the consummation of the transactions contemplated hereunder) of information confidential to you; provided that such confidential information shall not be used by us or any other member of a Commitment Party Group in performing services or providing advice to any Third Party. You accept that permanent or ad hoc arrangements/information barriers may be used between and within our divisions or divisions of other members of a Commitment Party Group for this purpose and that locating directors, officers or employees in separate workplaces is not necessary for such purpose;
(c) information that is held elsewhere within us or a member of any Commitment Party Group, but of which none of the individual directors, officers or employees having primary responsibility for the consummation of the transactions contemplated by this Commitment Letter actually has knowledge (or can properly obtain knowledge without breach of internal procedures), shall not for any purpose be taken into account in determining our responsibilities to you hereunder;
(d) neither we nor any other member of a Commitment Party Group shall have any duty to disclose to you, or utilize for your benefit, any non-public information acquired in the course of providing services to any other person, engaging in any transaction (on our or its own account or otherwise) or otherwise carrying on our or its business;
(e) (i) neither we nor any of our respective affiliates have assumed any advisory responsibility or any other obligation in favor of the Acquiror, the Target or any of its or their affiliates except the obligations expressly provided for under the Debt Financing Letters, (ii) we and our respective affiliates, on the one hand, and the Acquiror and its affiliates, on the other hand, have an arms-length business relationship that does not directly or indirectly give rise to, nor does the Acquiror or any of its affiliates rely on, any fiduciary duty on the part of us or any of our respective affiliates and (iii) we are (and are affiliated with) full service financial firms and as such may effect from time to time transactions for our own account or the account of customers, and hold long or short positions in debt, equity-linked or equity securities or loans of companies that may be the subject of the transactions contemplated by this Commitment Letter (and, in particular, we and any other member of a Commitment Party Group may at any time hold debt or equity securities for our or its own account in the Company). With respect to any securities and/or financial instruments so held by us, any of our respective affiliates or any of our respective customers, all rights in respect of such securities and financial instruments, including any voting rights, will be exercised by the holder of such rights, in its sole discretion. You hereby waive and release, to the fullest extent permitted by law, any claims you have, or may have, with respect to (i) any breach or alleged breach of fiduciary duty (and agree that we shall have no liability (whether direct or indirect) to you in respect of such a fiduciary duty claim or to any person asserting a fiduciary duty claim on behalf of or in right of you, including your stockholders, employees or creditors) and (ii) any conflict of interest arising from such transactions, activities, investments or holdings, or arising from our failure or the failure of any of our respective affiliates to bring such transactions, activities, investments or holdings to your attention; and
(f) neither we nor any of our respective affiliates are advising you as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. You shall consult with your own advisors concerning such matters and shall be responsible for making your own
independent investigation and appraisal of the transactions contemplated by the Debt Financing Letters, and neither we nor our respective affiliates shall have responsibility or liability to you with respect thereto. Any review by us, or on our behalf, of the Company, the Transactions, the other transactions contemplated by the Debt Financing Letters or other matters relating to such transactions will be performed solely for our benefit and shall not be on behalf of you or any of your affiliates.
11. Choice of Law; Jurisdiction; Waivers. The Debt Financing Letters, and any claim, controversy or dispute arising under or related to the Debt Financing Letters (whether in contract or tort), shall be governed by, and construed in accordance with, the laws of the State of New York; provided, however, that the interpretation of any provisions of the Purchase Agreement referred to in this Commitment Letter, including the determination of the accuracy of the Specified Purchase Agreement Representations and the definition of Company Material Adverse Effect shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws thereof. To the fullest extent permitted by applicable law, each of the parties hereto hereby irrevocably submits to the exclusive jurisdiction of any New York State court or federal court sitting in the County of New York and the Borough of Manhattan in respect of any claim, suit, action or proceeding arising out of or relating to the provisions of any Debt Financing Letter and irrevocably agrees that all claims in respect of any such claim, suit, action or proceeding may be heard and determined in any such court (provided that suit for the recognition or enforcement of any judgment obtained in any such New York State or Federal court may be brought in any other court of competent jurisdiction) and that service of process therein may be made by certified mail, postage prepaid, to its address set forth above and further agree that a final judgment in any such suit, action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. You and we hereby waive, to the fullest extent permitted by applicable law, any objection that you or we may now or hereafter have to the laying of venue of any such claim, suit, action or proceeding brought in any such court, and any claim that any such claim, suit, action or proceeding brought in any such court has been brought in an inconvenient forum. You and we hereby waive, to the fullest extent permitted by applicable law, any right to trial by jury with respect to any claim, suit, action or proceeding (whether based upon contract, tort or otherwise) arising out of or relating to the Debt Financing Letters, any of the Transactions or any of the other transactions contemplated hereby or thereby. The provisions of this Section 11 are intended to be effective upon the execution of this Commitment Letter without any further action by you or us, and the introduction of a true copy of this Commitment Letter into evidence shall be conclusive and final evidence as to such matters.
12. Miscellaneous.
(a) This Commitment Letter may be executed in one or more counterparts, each of which will be deemed an original, but all of which taken together will constitute one and the same instrument. Delivery of an executed signature page of this Commitment Letter by facsimile, .pdf or other electronic transmission will be effective as delivery of a manually executed counterpart hereof.
(b) You may not assign any of your rights, or be relieved of any of your obligations, under this Commitment Letter without our prior written consent, which may be given or withheld in our reasonable discretion (and any purported assignment without such consent, at our sole option, shall be null and void). We may at any time and from time to time assign all or any portion of our Commitments hereunder to one or more of our respective affiliates (provided that, unless you otherwise consent in writing to such assignment, we will remain liable for our obligations hereunder until the funding of the Debt Financing) or, subject to Sections 2 and 4 hereof, to one or more Investors; provided that such assignment shall not relieve us of our obligation to fund on the Closing Date the portion of our Commitments so assigned to the extent such assignee fails, upon satisfaction or waiver by us of all conditions to such assignee making its initial extensions of credit or purchase of the Unsecured Notes on the Closing Date, to fund such assigned Commitments on the Closing Date. Any and all obligations of, and services to be provided by, us hereunder (including our respective Commitments) may be performed, and any and all of our rights hereunder may be exercised, by or through any of our respective affiliates or branches and we reserve the right to allocate, in whole or in part, to our respective affiliates or branches certain fees payable to us in such manner as we and our respective affiliates may agree in our and their sole discretion. You further acknowledge that we may share with any of our respective affiliates, and such affiliates may share with us, any information relating to the Transactions, you or the Acquired Business (and your and their respective affiliates), or any of the matters contemplated in the Debt Financing Letters.
(c) This Commitment Letter has been and is made solely for the benefit of you, us and the Indemnified Persons and your, our and their respective successors and assigns, and nothing in this Commitment Letter, expressed or implied, is intended to confer or does confer on any other person or entity any rights or remedies under or by reason of this Commitment Letter or your and our agreements contained herein.
(d) The Debt Financing Letters set forth the entire understanding of the parties hereto as to the scope of the Commitments and our obligations hereunder and thereunder. The Debt Financing Letters supersede all prior understandings and proposals, whether written or oral, between us and you relating to any financing or the transactions contemplated hereby and thereby.
(e) You agree that we or any of our respective affiliates may disclose information about the Transactions to market data collectors and similar service providers to the financing community.
(f) We hereby notify you that, pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001) (the PATRIOT Act), each of us and each of the Investors may be required to obtain, verify and record information that identifies the Acquiror and the Guarantors, which information may include their names, addresses, tax identification numbers and other information that will allow each of us and the Investors to identify the Acquiror and the Guarantors in accordance with the PATRIOT Act. This notice is given in accordance with the requirements of the PATRIOT Act and is effective for each of us and the Investors.
13. Amendment; Waiver. This Commitment Letter may not be modified or amended except in a writing duly executed by the parties hereto. No waiver by any party of any breach of,
or any provision of, this Commitment Letter shall be deemed a waiver of any similar or any other breach or provision of this Commitment Letter at the same or any prior or subsequent time. To be effective, a waiver must be set forth in writing signed by the waiving party.
14. Surviving Provisions. Notwithstanding anything to the contrary in this Commitment Letter, except as set forth in the immediately succeeding sentence, Sections, 2, 4 and 7 to and including 15 hereof shall survive the expiration or termination of this Commitment Letter, regardless of whether the Definitive Debt Documents have been executed and delivered or the Transactions consummated; provided, that your obligations under this Commitment Letter (other than your obligations with respect to (a) the syndication of the Debt Financing and the titles and roles related thereto and (b) confidentiality) shall automatically terminated and be superseded in their entirety by those set forth in the Definitive Debt Documents.
15. Acceptance, Expiration and Termination; Reduction. Please indicate your acceptance of the terms of the Debt Financing Letters by returning to us executed counterparts of the Debt Financing Letters not later than 11:59 p.m., New York City time, on June 19, 2017 (the Deadline; the date of receipt of such executed counterparts, the Signing Date). The Debt Financing Letters are conditioned upon your contemporaneous execution and delivery to us, and the contemporaneous receipt by us, of executed counterparts of each Debt Financing Letter on or prior to the Deadline. This Commitment Letter will expire at such time in the event that you have not returned such executed counterparts to us by such time. Thereafter, except with respect to any provision that expressly survives pursuant to Section 14 hereof, this Commitment Letter (but not the other Debt Financing Letters) will terminate automatically on the earliest of (i) the date of termination of the Purchase Agreement prior to the closing of the Acquisition, (ii) the closing of the Acquisition (unless the Initial Lender has failed to fund in breach of its obligations hereunder) and (iii) 5:00 p.m., New York City time, on August 12, 2017. In addition, our Commitments hereunder to purchase Unsecured Notes shall automatically be reduced, on a dollar for dollar basis, by the aggregate gross proceeds from the issuance or sale of any Unsecured Notes, whether pursuant to this Commitment Letter or otherwise upon the closing thereof (whether in escrow or otherwise).
Each of the parties hereto agrees that this Commitment Letter is a binding and enforceable agreement with respect to the subject matter contained herein, including an agreement to negotiate in good faith the Definitive Debt Documents by the parties hereto in a manner consistent with this Commitment Letter, it being acknowledged and agreed that the commitments provided hereunder by the Commitment Parties are subject only to the conditions precedent set forth in Section 3 hereof, including the execution and delivery of the Definitive Debt Documents (which shall be negotiated in good faith as required by the Documentation Principles).
[Signature Pages Follow]
We are pleased to have the opportunity to work with you in connection with this important financing.
|
Very truly yours, | ||
|
| ||
|
JEFFERIES GROUP LLC | ||
|
|
| |
|
|
| |
|
By: |
/s/ Jeffrey R. Whyte | |
|
|
Name: |
Jeffrey R. Whyte |
|
|
Title: |
Assistant Secretary |
|
|
|
|
|
JEFFERIES FINANCE LLC | ||
|
|
| |
|
|
| |
|
By: |
/s/ Jason Kennedy | |
|
|
Name: |
Jason Kennedy |
|
|
Title: |
Managing Director |
[Signature Page to Commitment Letter]
Accepted and agreed to as of the
date first above written:
TELADOC, INC. |
| ||
|
|
| |
|
|
| |
By: |
/s/ Adam C. Vandervoort |
| |
|
Name: |
Adam C. Vandervoort |
|
|
Title: |
Chief Legal Officer and Secretary |
|
[Signature Page to Commitment Letter]
EXHIBIT A
Project Barolo
$150.0 million Term Loan Facility
$10.0 million Revolving Credit Facility
Summary of Principal Terms and Conditions(1)
Borrower: |
|
Teladoc, Inc., a Delaware corporation (the Borrower). |
|
|
|
Administrative Agent: |
|
Jefferies Finance LLC (Jefferies), acting through any of its affiliates as it deems appropriate, will act as sole administrative agent and collateral agent (in such capacities, the Administrative Agent) for a syndicate of banks, financial institutions and other lenders, excluding any Disqualified Institutions (the Lenders), and will perform the duties customarily associated with such roles. |
|
|
|
Sole Lead Arranger and Sole Bookrunner: |
|
Jefferies, acting through any of its affiliates as it deems appropriate, will act as sole lead arranger and sole bookrunner for the Facilities (as defined below), and will perform the duties customarily associated with such roles (the Lead Arranger). |
|
|
|
Term Loan Facility: |
|
1. Amount: A term loan facility in an aggregate principal amount of $150.0 million (the Term Loan Facility).
2. Currency: U.S. dollars.
3. Use of Proceeds: The loans made pursuant to the Term Loan Facility (the Term Loans) may only be incurred on the Closing Date and the proceeds thereof shall be utilized solely to finance, in part, the Acquisition, to consummate the Refinancing and to pay fees and expenses in connection therewith.
4. Maturity: The final maturity date of the Term Loan Facility shall be five (5) years from the Closing Date (the Term Loan Maturity Date).
5. Amortization: (i) Annual amortization (payable in equal quarterly installments, commencing with the first full fiscal quarter ending after the Closing Date) of the Term Loans shall be required in an amount equal to 1.0% of the initial aggregate principal amount of the Term Loans.
(ii) The remaining aggregate principal amount of Term Loans originally incurred shall be due and payable in full on the Term Loan Maturity Date.
6. Availability: Term Loans may only be incurred on the Closing |
(1) All capitalized terms used but not defined herein have the meanings given to them in the Commitment Letter to which this term sheet is attached, including the other Exhibits thereto.
|
|
Date. Once repaid, no amount of Term Loans may be reborrowed. |
|
|
|
Revolving Credit Facility: |
|
1. Amount: A revolving credit facility in an aggregate principal amount of $10.0 million (the Revolving Credit Facility). $5.0 million of the Revolving Credit Facility will be available for the issuance of letters of credit on terms to be agreed.
2. Currency: U.S. dollars.
3. Use of Proceeds: The loans made pursuant to the Revolving Credit Facility (the Revolving Loans and together with the Term Loans, the Loans) may be used for working capital and general corporate purposes, including to fund any original issue discount or fees imposed pursuant to the market flex provisions of the Fee Letter.
4. Maturity: The final maturity date of the Revolving Credit Facility shall be three (3) years from the Closing Date (the Revolver Maturity Date).
5. Availability: Revolving Loans will be available at any time prior to the Revolver Maturity Date, in minimum principal amounts to be agreed. Amounts repaid under the Revolving Credit Facility may be reborrowed. |
|
|
|
Credit Documentation |
|
The definitive documentation governing or evidencing the Facilities (collectively, the Credit Documentation) shall be prepared by counsel to the Administrative Agent and shall be consistent with the Commitment Letter including this Exhibit A and Exhibit B to the Commitment Letter and the Fee Letter, will contain only those conditions to borrowing, mandatory prepayments, representations, warranties, covenants and events of default referred to in the Commitment Letter (including this Exhibit A and Exhibit B to the Commitment Letter) (subject to modification in accordance with the market flex provisions of the Fee Letter) and consistent with loan documentation terms customary and usual for facilities, borrowers and transactions of this type that are reasonably satisfactory to the Borrower and the Lead Arranger (but in no event including any conditions to borrowing not set forth in the Commitment Letter (including this Exhibit A and Exhibit B to the Commitment Letter)) and shall be negotiated in good faith by the Borrower and the Lead Arranger and give due regard to that certain term loan credit agreement as previously agreed between the Borrower and the Lead Arranger, with modifications to reflect (i) the terms set forth herein, (ii) the differences in the business of the borrower under such precedent documentation on the one hand and the Borrower and its subsidiaries on the other hand, (iii) the operational and strategic requirements of the Borrower and its subsidiaries in light of their size, industries, businesses and business |
|
|
practices and (iv) general trends and risks affecting the industry of the Borrower and its subsidiaries. This paragraph and the provisions herein are referred to as the Documentation Principles. |
|
|
|
Uncommitted Incremental Facilities: |
|
The Borrower will have the right to solicit existing Lenders (each of which shall be entitled to agree or decline to participate in its sole discretion) and additional banks, financial institutions and other lenders (each of whom would constitute an Eligible Transferee, as described under the heading Assignments and Participations below) who will become Lenders in connection therewith (the Additional Lenders) to provide (x) an increase in commitments under the Revolving Credit Facility to be made available under the Credit Documentation (each, an Incremental Revolving Commitment Increase; the loans thereunder, the Incremental Revolving Credit Loans) and/or (y) incremental commitments consisting of one or more increases to the Term Loan Facility and/or one or more new tranches of term loans to be made available under the Credit Documentation (hereinafter the Incremental Term Loan Facilities, the loans thereunder the Incremental Term Loans; and the Incremental term Loan Facilities, together with the Incremental Revolving Commitment Increase, the Incremental Facilities) in an aggregate amount not to exceed (x) $50.0 million (the Free and Clear Incremental Basket) plus (y) if the First Lien Leverage Ratio (as defined below), on a pro forma basis measured at the time of incurrence of such Incremental Facility and after giving effect thereto (or in the case of Incremental Term Loan Facilities used to finance a permitted acquisition, the consummation of which is not conditional upon the availability of, or obtaining, third-party financing (a Limited Condition Acquisition), and to the extent the Lenders participating in such Incremental Term Loan Facility agree, measured at the time of the execution of the acquisition agreement related to such permitted acquisition), is less than or equal to 4.00:1.00 (after giving pro forma effect to the Transaction) (assuming, for purposes of such calculations, that all commitments under any Incremental Facility are fully drawn and excluding for purposes of such calculation the cash proceeds of incremental loans from any unrestricted cash permitted to be netted in the calculation of such ratio (but otherwise giving pro forma effect to the application of any such amounts to prepayments of debt)), an unlimited amount (this clause (y), the Incurrence-Based Incremental Basket, and at any time, the sum of the amounts under the Free and Clear Incremental Basket and Incurrence-Based Incremental Basket, the Available Incremental Amount) on terms agreed by the Borrower and the Lender or Lenders providing the respective Incremental Facility; provided that (i) no default or event of default exists or would exist after giving effect thereto; provided that, in the case of Incremental Facilities used to finance a Limited Condition Acquisition and to the extent the Lenders participating in such |
|
|
Incremental Facility agree, this clause (i) shall be tested at the time of the execution of the acquisition agreement related to such Limited Condition Acquisition, (ii) all of the representations and warranties contained in the Credit Documentation shall be true and correct in all material respects (or, in all respects, if qualified by materiality); provided that, in the case of Incremental Facilities used to finance a Limited Condition Acquisition and to the extent the Lenders participating in such Incremental Facility agree, this clause (ii) shall be subject only to Specified Representations, (iii) any such Incremental Facility shall benefit from the same guarantees as, and be secured on an equal and ratable pari passu basis by the same Collateral (as defined below) securing, the Facilities and (iv) the Borrower shall be in pro forma compliance with the Financial Covenants; provided that, in the case of Incremental Facilities the proceeds of which are to be used to finance a Limited Condition Acquisition and to the extent the Lenders participating in such Incremental Facilities agree, this clause (iv) shall be tested at the time of the execution of the acquisition agreement related to such Limited Condition Acquisition. |
|
|
|
|
|
In the case of any Incremental Revolving Commitment Increase, all material terms (including pricing) shall be substantially identical to the Revolving Credit Facility. |
|
|
|
|
|
In the case of Incremental Term Loans, such Incremental Term Loans shall be subject to the same terms as the Term Loans (including voluntary and mandatory prepayment provisions), except that, unless such Incremental Term Loans are made a part of the Term Loan Facility (in which case all terms thereof shall be identical to those of the Term Loan Facility), (1) the interest rate margins and (subject to clauses (2) and (3) below) final maturity and weighted average life to maturity applicable to any Incremental Term Loans shall be determined by the Borrower and the lenders thereunder, provided that, the effective yield on any Incremental Term Loans payable by the Borrower(which, for such purposes only, shall be deemed to take account of applicable margins, interest rate benchmark floors, recurring fees and all upfront or similar fees or original issue discount (amortized over the shorter of (A) the weighted average life of such Incremental Term Loans and (B) four years) payable to all Lenders providing such Incremental Term Loans, but exclusive of any arrangement, structuring, ticking or other fees payable in connection therewith that are not shared with all Lenders providing such Incremental Term Loans) may exceed the then effective yield on Term Loans (determined on the same basis as provided in the preceding parenthetical) if the effective yield on the applicable Term Loans (determined on the same basis as provided in the second preceding parenthetical) is increased to be not less than 0.50% (after giving effect to any increase to the effective yield on any Term Loans) lower than the effective yield on such Incremental Term Loans, (2) |
|
|
the final stated maturity date for such Incremental Term Loans may be identical to or later (but not earlier) than the final stated maturity date applicable to the Term Loans, (3) the average weighted life to maturity of such Incremental Term Loans is no shorter than the average weighted life to maturity applicable to the then outstanding Term Loans and (4) the Incremental Term Loans shall share ratably in all voluntary and mandatory prepayments unless the lenders holding such Incremental Term Loans elect to receive a lesser amount, provided that such Incremental Term Loans shall have covenants and defaults no more restrictive (excluding pricing, optional prepayment or redemption terms, call protections and premiums) than those under the Term Loan Facility (except for covenants or other provisions applicable only to periods after the latest final maturity date of the Term Loan Facility existing at the time of such incurrence of Incremental Term Loans), unless otherwise mutually agreed by the Borrower and the Administrative Agent. |
|
|
|
|
|
Any upfront fees and arrangement fees for any Incremental Facility will be negotiated with the applicable Lenders at the time of any request to provide commitments pursuant to such Incremental Facility. The Administrative Agent shall have consent rights (not to be unreasonably withheld) with respect to such Additional Lender, if the consent of the Administrative Agent would be required under the heading Assignments and Participations for an assignment of Term Loans to such Additional Lender. Nothing contained herein or in the Commitment Letter constitutes, or shall be deemed to constitute, a commitment with respect to any Incremental Facility. |
|
|
|
|
|
First Lien Leverage Ratio, Total Leverage Ratio and Consolidated EBITDA each shall have meanings to be agreed in the Credit Documentation, giving due regard to the Documentation Principles (it being understood that any leverage calculation shall be net of unrestricted domestic cash and cash equivalents that are subject to control agreements for the benefit of the Collateral Agent, subject to a cap on such unrestricted cash and cash equivalents to be agreed). |
|
|
|
Guarantees: |
|
All obligations of (a) the Borrower under the Facilities, (b) the Borrower or any of the Guarantors (as defined below) under (or in respect of) certain interest rate and/or foreign currency swaps or similar agreements entered into with the Administrative Agent, the Lead Arranger, a Lender or an affiliate of any of the foregoing persons, other than Excluded Swap Obligations (as defined below) (the Secured Hedging Agreements and clauses (a) and (b) above, the Borrower Obligations) will be fully and unconditionally guaranteed on a joint and several basis by (i) the Borrower (other than with respect to its own obligations), and (ii) each direct or indirect wholly owned material domestic subsidiary (whether owned on the Closing Date or formed or acquired thereafter) of the Borrower, other than (A) any subsidiary that |
|
|
is prohibited by applicable law or existing contractual obligations from becoming a guarantor, (B) any subsidiary of the Borrower that is a controlled foreign corporation within the meaning of Section 957 of the United States Internal Revenue Code of 1986, as amended (a CFC), a subsidiary of a CFC or a Domestic CFC Holding Company (as defined below), (C) any foreign subsidiary for which the providing of a guarantee could reasonably be expected to result in a violation, or breach of, or conflict with, fiduciary duties of the directors, officers and managers of such subsidiary, (D) immaterial subsidiaries (to be defined on a basis to be mutually agreed upon), (E) any subsidiary acquired pursuant to a permitted acquisition or other similar investment permitted by the Credit Documentation that has assumed secured indebtedness that is permitted pursuant to the Credit Documentation and not incurred in contemplation of such permitted acquisition or other similar investment and any subsidiary thereof that guarantees such secured indebtedness, in each case to the extent (and for so long as) such secured indebtedness prohibits such subsidiary from becoming a Guarantor, and (F) other exceptions and limitations to be mutually agreed (each such person, a Guarantor and, collectively, the Guarantors and together with the Borrower, the Credit Parties).
Notwithstanding the foregoing, subsidiaries may be excluded from the guarantee requirements in circumstances where the Borrower and the Administrative Agent reasonably agree in writing that the cost of providing such a guarantee is excessive in relation to the value afforded thereby.
Excluded Swap Obligations means any obligation of any Guarantor to pay or perform under any agreement, contract, or transaction that constitutes a swap within the meaning of Section 1a(47) of the Commodity Exchange Act (a Swap), if, and to the extent that, all or a portion of the guarantee by such Guarantor of, or the grant by such Guarantor or the Borrower of a security interest to secure, such Swap (or any guarantee thereof) is or becomes illegal under the Commodity Exchange Act or any rule, regulation, or order of the Commodity Futures Trading Commission (or the application or official interpretation of any thereof) by virtue of such Guarantors failure for any reason to constitute an eligible contract participant as defined in the Commodity Exchange Act and the regulations thereunder. |
|
|
|
Security: |
|
Subject to the Funds Certain Provisions and the Documentation Principles, all amounts owing under the Facilities, the Secured Hedging Agreements (and all obligations under the Guarantees) (collectively, the Secured Obligations) will be secured by (x) a perfected security interest, subject only to liens permitted under the Credit Documentation, in all stock, other equity interests and promissory notes owned by the |
|
|
Borrower and the Guarantors (which pledge, in the case of voting stock in any direct or indirect subsidiary of the Borrower that is a first-tier CFC or Domestic CFC Holding Company, shall be limited to 65% of the voting stock (and 100% of the non-voting stock) of such CFC or Domestic CFC Holding Company, as the case may be) and (y) a perfected security interest in and mortgages on, in each case subject only to liens permitted under the Facilities, substantially all other tangible and intangible assets (including, without limitation, receivables, inventory, equipment, contract rights, securities, patents, trademarks, other intellectual property, cash, bank and securities deposit accounts (which accounts shall be required to be made subject to control agreements within a post-closing time period to be agreed) owned by the Borrower and the Guarantors (all of the foregoing, the Collateral)
Notwithstanding anything to the contrary, the Collateral shall exclude the following: (i) motor vehicles and other assets subject to certificates of title (to the extent a lien thereon cannot be perfected by the filing of a UCC financing statement), letter of credit rights (other than to the extent perfection of the security interest therein is accomplished by the filing of a UCC financing statement) and commercial tort claims below a threshold to be mutually agreed; (ii) pledges and security interests in margin stock and, to the extent prohibited by law, or requiring the consent of any person (other than Borrower or any of its subsidiaries) under, or prohibited by the terms of any applicable organizational documents (other than the organizational documents of any Credit Party or any wholly owned subsidiary thereof), joint venture agreement or shareholders agreement, equity interests in any person that is not a wholly owned subsidiary; (iii) any fee owned real property with a fair market value of less than an amount to be agreed (with any required mortgages on properties with a value greater than such amount being permitted to be delivered after the Closing Date within a time period to be agreed) and all leasehold interests in real property; (iv) intent to use trademark applications prior to the filing of a Statement of Use or Amendment to Allege Use with respect thereto, to the extent, if any, that, and solely during the period, if any, in which, the grant of a security interest therein would impair the validity or enforceability of such intent to use trademark application under applicable federal law; (v) (a) deposit accounts of any Credit Party exclusively used for payroll, payroll taxes or employee benefits in the ordinary course of business, (b) deposit accounts that are zero-balance accounts or de minimis disbursement accounts and (c) escrow accounts and deposits to secure letters of credit, surety or performance bonds or similar obligations; (vi) any lease, license, property right or other agreement or any property subject to a purchase money security interest, capital lease obligation or similar arrangements, in each case, to the extent permitted under the Credit Documentation, to the extent that a grant of a security interest |
|
|
therein would violate or invalidate such lease, license, property right or agreement, purchase money, capital lease or a similar arrangement or create a right of termination in favor of any other party thereto (other than the Borrower or a Guarantor) after giving effect to the applicable anti-assignment provisions of the UCC or other applicable law, other than proceeds and receivables thereof; (vii) any assets of a CFC or a Domestic CFC Holding Company and (viii) those assets to the extent a security interest in such assets would result in material adverse tax consequences as reasonably determined by the Borrower, in consultation with the Administrative Agent, or as to which the Administrative Agent and the Borrower agree in writing that the costs of obtaining such a security interest or perfection thereof are excessive in relation to the value to the Lenders of the security to be afforded thereby.
The term Domestic CFC Holding Company shall mean any entity organized under the laws of the United States (or any state thereof) that owns no material assets other than equity interests in or indebtedness of one or more CFCs. |
|
|
|
|
|
Notwithstanding the foregoing, (i) the requirements of the preceding paragraphs of this Security section shall be, as of the Closing Date, subject to the Funds Certain Provisions. (ii) under no circumstances shall landlord waivers, bailee waivers, warehouseman waivers or collateral access agreements, be required and (iii) no actions under the law of any non-U.S. jurisdiction, and no security agreements or pledge agreements governed under the laws of any non-U.S. jurisdiction, shall be required. |
|
|
|
Voluntary Prepayments: |
|
Voluntary prepayments may be made at any time on three business days notice in the case of LIBOR Loans, or one business days notice in the case of Base Rate Loans, without premium or penalty (except as otherwise provided under the heading Call Protection below), in minimum principal amounts to be mutually agreed; provided that (x) voluntary prepayments of LIBOR Loans made on a date other than the last day of an interest period applicable thereto shall be subject to customary breakage costs, and (y) such payments of Term Loans shall be subject to the Call Protection described below. |
|
|
|
Mandatory Repayments: |
|
Mandatory repayments of Term Loans shall be required from
(a) 100% of the cash proceeds (net of taxes directly attributable thereto, reasonable costs and expenses in connection therewith, repayments of debt secured by such asset or (in the case only of other permitted debt (if any) secured by equal and ratable liens on the Collateral) otherwise subject to mandatory prepayment as a result thereof (and limited, in the case of such other debt, to its proportionate share of such prepayment) |
|
|
and the amount of reserves established (for a time period and with recapture provisions to be agreed) to fund contingent liabilities reasonably estimated to be payable and directly attributable thereto) from asset sales by the Borrower and its subsidiaries (including sales of equity interests of any subsidiary of the Borrower) in excess of an amount to be agreed but subject to certain ordinary course exceptions to be agreed as well as a right of the Borrower and its subsidiaries to reinvest 100% of such proceeds, if such proceeds are reinvested (or committed to be reinvested) in assets useful in the business of the Borrower and its subsidiaries (other than ordinary course current assets) within 365 days and, if so committed to be reinvested, so long as such reinvestment is actually completed within 180 days thereafter (the Asset Sale Reinvestment Right),
(b) 100% of the net cash proceeds from issuances or incurrences of debt (other than the other debt permitted under the Credit Documentation,
(c) 50% (with step-downs to 25% and 0% when the First Lien Leverage Ratio is less than or equal to levels to be mutually agreed) of annual Excess Cash Flow (to be defined in a manner to be mutually agreed, but in any event shall be reduced by cash amounts used (or committed to be used within the next succeeding year) for capital expenditures, permitted acquisitions and certain other permitted investments and certain permitted restricted payments to be mutually agreed of the Borrower and its subsidiaries, in each case to the extent financed with internally generated cash flow), commencing with the first full fiscal year of the Borrower ending after the Closing Date (i.e., December 31, 2018); provided that, in any fiscal year, any voluntary prepayments (other than voluntary prepayments applied to prepay future amortization payments that are due in the fiscal year of such prepayment) or repurchases of Term Loans by the Borrower, in each case to the extent financed with internally generated cash flow, shall be credited against Excess Cash Flow prepayment obligations on a dollar-for-dollar basis (but, in the case of repurchases of Term Loans, limited to the amount of cash actually expended to purchase the principal thereof; and
(d) 100% of the net cash proceeds from insurance recovery and condemnation events of the Borrower and its subsidiaries (subject to a right of the Borrower and its subsidiaries to reinvest 100% of such proceeds, if such proceeds are reinvested (or committed to be reinvested) in assets useful in the business of the Borrower and its subsidiaries (other than ordinary course current assets) in assets useful in the business of the Borrower and its subsidiaries (other than ordinary course current assets) within 365 days and, if so committed to be reinvested, so long as such reinvestment is actually completed within 180 days thereafter). |
|
|
Mandatory prepayments made pursuant to clauses (a), (c) and (d) above shall be subject to customary limitations to be agreed (including limitations under local law, e.g. financial assistance, corporate benefit and fiduciary and statutory duties of directors of the relevant non-U.S. subsidiaries) to the extent required to be made from cash at non-U.S. subsidiaries and to the extent the repatriation of which would result in material adverse tax consequences, as reasonably determined by the Borrower in consultation with the Administrative Agent, or would be prohibited or restricted by applicable law; provided that, in any event, (i) the Borrower shall use commercially reasonable efforts to eliminate such tax effect or to permit such repatriation in order to make such prepayments and (ii) solely in the case of prepayments under clause (c) where such prepayments that are limited as a result of material adverse tax consequences, an amount equal to the portion of Excess Cash Flow that is not used for a mandatory prepayment as a result of such limitation, less the amount of additional taxes that would have been payable or reserved for if such amount had been repatriated, shall be applied to prepay the Term Loan Facility within 12 months from the date such prepayment was required. |
|
|
|
|
|
All mandatory repayments of Term Loans made pursuant to clauses (a) through (d), inclusive, above will, subject to the provisions described under the heading Waivable Prepayments below and subject to application of permitted refinancing indebtedness proceeds to the debt being refinanced, be applied, without premium or penalty (other than breakage costs, if applicable), pro rata to each outstanding tranche of Term Loans and Incremental Term Loans (if any) and any Refinancing Facilities (if any), and shall apply to reduce future scheduled amortization payments of the respective Term Loans in direct order of maturity. |
|
|
|
Call Protection: |
|
In the event all or any portion of the Term Loans is voluntarily repaid (or prepaid from the proceeds of any indebtedness, and including any repayment or prepayment following or in connection with any change in control or following any acceleration of the Term Loans) and in connection with any mandatory assignment of a non-consenting lender, such repayments or prepayments shall be made at (i) 103% of the amount repaid or prepaid if such repayment or prepayment occurs prior to the first anniversary of the Closing Date, (ii) 102% of the amount repaid or prepaid if such repayment or prepayment occurs on or after the first anniversary of the Closing Date but prior to the second anniversary of the Closing Date and (iii) 101% of the amount repaid or prepaid if such repayment or prepayment occurs on or after the second anniversary of the Closing Date but prior to the third anniversary of the Closing Date. |
Fees and Interest Rates: |
|
As set forth on Annex A hereto. |
|
|
|
Yield Protection: |
|
The Facilities shall include customary protective provisions for such matters as capital adequacy, increased costs, reserves, liquidity, funding losses, illegality and customary tax gross ups (it being understood that, for purposes of determining increased costs arising in connection with a change in law, the Dodd-Frank Wall Street Reform and Consumer Protection Act, Basel III and the Foreign Account Tax Compliance Act, and all requests, rules, guidelines or directives promulgated under, or issued in connection with, either of the foregoing shall be deemed to have been introduced or adopted after the date of the Credit Documentation, regardless of the date enacted, adopted or issued, but solely for such costs that would have been included if they had been otherwise imposed under the applicable increased cost provisions and only to the extent the applicable Lender is generally imposing such charges on other similarly situated borrowers under comparable syndicated credit facilities). The obligation of the Borrower and the Guarantors to gross up for and/or to indemnify Lenders for taxes imposed on payments will be subject to customary exceptions, including the requirement to provide applicable tax related documentation, and will include customary mitigation provisions. |
|
|
|
Conditions Precedent: |
|
|
|
|
|
Conditions Precedent to Initial Borrowing |
|
The making of each Loan on the Closing Date shall be conditioned solely upon:
Those conditions precedent in Section 3 of the Commitment Letter and in Exhibit B to the Commitment Letter, subject in each case to the Funds Certain Provisions. |
|
|
|
Conditions Precedent to all Borrowings (except on the Closing Date) |
|
Except with respect to borrowings and other credit extensions on the Closing Date and except as otherwise provided above under Uncommitted Incremental Facilities, each borrowing and each other extension of credit under the Credit Documentation shall be subject only to the following conditions precedent: (i) delivery of notice of borrowing; (ii) accuracy of representations and warranties in all material respects (provided, that any representation and warranty that is qualified as to materiality, material adverse effect or similar language shall be true and correct in all respects (after giving effect to any such qualification therein) and any representations and warranties which expressly relate to a given date or period shall be required to be true and correct in all material respects (without duplication of any materiality qualifiers set forth therein) as of the respective date or for the respective period, as the case may be)); and (iii) the absence of defaults or events of default at the time of, or immediately after giving effect to the making of, such extension of credit. |
Representations and Warranties: |
|
Representations and warranties (to be applicable to the Borrower and its subsidiaries) will be limited to the following, in each case with customary exceptions, qualifications and limitations for materiality to be provided in the Credit Documentation to be mutually agreed by the Borrower and the Lead Arranger and consistent with the Documentation Principles: (i) organization and corporate status, (ii) power and authority, (iii) due authorization, execution and delivery and enforceability, (iv) no violation or conflicts with laws, material contracts or charter documents, (v) governmental approvals, franchises, licenses, permits, etc., (vi) financial statements and projections, (vii) absence of a Material Adverse Effect (to be defined in a manner to be mutually agreed), (viii) solvency of the Borrower and its subsidiaries on a consolidated basis as of the Closing Date, (ix) absence of material litigation, (x) true and complete disclosure, (xi) use of proceeds and compliance with Margin Regulations, (xii) tax returns and payments, (xiii) insurance, (xiv) compliance with law, including (without limitation) ERISA and environmental laws, (xv) ownership of property and ownership or rights to use intellectual property, (xvi) equity interests and subsidiaries, (xvii) absence of undisclosed liabilities, (xviii) creation, validity, perfection and ranking of security interests under the security agreements, (xix) inapplicability of Investment Company Act, (xx) employment and labor relations, (xxi) certain regulatory matters, (xxii) PATRIOT Act, (xxiii) OFAC/sanctions and other anti-terrorism laws, (xxiv) FCPA and other anti-corruption laws, anti-money laundering laws and dealings with embargoed persons; and (xxv) no ownership interest in Borrowers affiliated variable interest entities. |
|
|
|
Covenants: |
|
Affirmative and negative covenants (to be applicable to the Borrower and its subsidiaries) will be limited to the following, in each case with customary exceptions, qualifications and baskets to be mutually agreed by the Borrower and Lead Arranger and consistent with the Documentation Principles: |
|
|
|
|
|
(a) Affirmative Covenants - (i) Compliance with laws, regulations (including, without limitation, ERISA and environmental laws) and material contractual obligations; (ii) payment of material taxes and other material obligations; (iii) maintenance of adequate insurance (but not, for the avoidance of doubt, flood insurance except to the extent required by applicable law); (iv) preservation of existence, rights (charter and statutory), franchises, permits, licenses and approvals; (v) visitation and inspection rights and information regarding collateral (subject to frequency (so long as there is no ongoing event of default) and cost reimbursement limitations); (vi) keeping of proper books in accordance with GAAP; (vii) maintenance of properties (subject to casualty, condemnation and normal wear and tear); (viii) further assurances as to perfection and priority of security interests and additional guarantors and |
|
|
security; (ix) notice of defaults, material litigation, certain other material events and other customary reporting requirements; (x) financial and other reporting requirements (including, without limitation, unaudited quarterly (for the first three fiscal quarters) and audited annual financial statements for the Borrower and its subsidiaries on a consolidated basis (which, for each quarterly statement, shall be certified to have been prepared in accordance with GAAP) and a budget prepared by management of the Borrower and provided on an annual basis, in the case of the unaudited quarterly and audited annual financial statements with accompanying management discussion and analysis and, in the case of the audited annual financial statements, accompanied by an opinion of a nationally recognized accounting firm (which opinion shall not be subject to any qualification as to going concern or scope of the audit, but that may contain a going concern statement that is solely due to (a) the impending maturity of the Facilities scheduled to occur within one year or (b) any potential inability to satisfy the Financial Covenants on a future date or in a future period)); (xi) quarterly lender calls; (and (xii) use of proceeds. |
|
|
|
|
|
(b) Negative Covenants Limitations on: (i) indebtedness (including guarantees and indebtedness of non-wholly owned subsidiaries and other non-Guarantors) and preferred or disqualified stock (with exceptions to include an ability to incur (a) [reserved], (b) [reserved], (c) Incremental Facilities, (d) unsecured indebtedness, subject to (i) a starter basket to be agreed, (ii) customary limitations on tenor and covenants and a cap to be agreed on the amount thereof that may be incurred by subsidiaries that are not Credit Parties and (iii) the Borrowers pro forma compliance with a Total Leverage Ratio of not greater than a ratio to be agreed and (e) the Unsecured Notes); (ii) liens; (iii) asset dispositions; (iv) restricted payments, investments (with exceptions to include a general investment basket equal to an amount to be agreed (which can be utilized, amongst other things, to consummate permitted acquisitions of entities who will not become Guarantors)), loans, advances, guarantees and acquisitions (with exceptions to include an ability to do Permitted Acquisitions (as defined below); (v) swap agreements; (vi) transactions with affiliates; (vii) restrictions affecting subsidiaries; (viii) prepayments of subordinated, junior lien and unsecured indebtedness and certain other material indebtedness; (ix) sale and leaseback transactions; (x) mergers and consolidations; (xi) amendment, modification or waiver of charter documents of the Borrower and its subsidiaries and material subordinated indebtedness in any manner that is materially adverse to the interests of the Lenders; (xii) changes in business; (xiii) accounting changes; (xiv) changes to fiscal year; (xv) further negative pledges; and (xvi) PATRIOT Act and violations of anti-terrorism, anti-corruption, anti-money laundering laws and dealing with embargoed persons, in each case with customary qualifiers, exceptions and limitations to be mutually agreed. |
|
|
The Credit Documentation will include an Available Amount builder basket based upon (i) retained excess cash flow (to be defined in the Credit Documentation) of the Borrower and its subsidiaries and (ii) proceeds from qualified equity contribution received by the Borrower after the Closing Date, usage of which will be subject to pro forma compliance with the Financial Covenants and a Total Leverage Ratio not in excess of a level to be agreed, and otherwise on terms and conditions to be mutually agreed. |
|
|
|
Permitted Acquisition: |
|
The Borrower or any subsidiary will be permitted to make acquisitions (each, a Permitted Acquisition), subject solely to the following terms and conditions: (i) except with respect to any Limited Condition Acquisition to the extent provided below, there is no default or event of default immediately before and immediately after giving pro forma effect to such acquisition, (ii) after giving effect thereto, the Borrower is in compliance with the permitted lines of business covenant, (iii) solely to the extent required by, and subject to the limitations set forth in, Guarantees and Security above, the acquired company and its subsidiaries will become Guarantors and pledge their Collateral to the Administrative Agent, (iv) acquisitions of entities or assets that will not be Guarantors or do not constitute Collateral as set forth in Guarantees and Security shall not exceed an aggregate amount to be agreed and (v) the Borrower shall be in pro forma compliance with the Financial Covenants. |
|
|
|
Financial Covenants: |
|
Only the following:
1. Minimum Liquidity: At any time, Liquidity (to be defined in the Credit Documentation as the sum of (x) unrestricted cash plus (y) undrawn amounts under any committed revolving credit facilities) shall be not less than $15.0 million.
2. Minimum LTM Revenue Growth: As of the end of any fiscal quarter, Recurring Revenue Growth shall be not less than 10%.
Recurring Revenue Growth shall have a meaning to be agreed in the Credit Documentation and shall be consistent with the definition set forth in that certain Amended and Restated Loan and Security Agreement dated as of May 2, 2014 by and between Silicon Valley Bank and the Borrower. |
|
|
|
Limited Condition Acquisition |
|
In the case of the incurrence of any indebtedness (including any Incremental Facilities) or liens or the making of any Permitted Acquisitions or other similar investments in connection with a Limited Condition Acquisition, at the Borrowers option, the relevant ratios shall be determined, and any default or event of default blocker shall be tested, as of the date the definitive acquisition agreements for such Limited |
|
|
Condition Acquisition are entered into and calculated as if the acquisition and other pro forma events in connection therewith were consummated on such date; provided that if the Borrower has made such an election, in connection with the calculation of any ratio with respect to the incurrence of any debt (including any Incremental Facilities) or liens, or the making of any Permitted Acquisitions or other similar investments on or following such date and prior to the earlier of the date on which such Limited Condition Acquisition is consummated or the definitive agreement for such Limited Condition Acquisition is terminated, any such ratio shall be calculated on a pro forma basis assuming such Limited Condition Acquisition and other pro forma events in connection therewith (including any incurrence of indebtedness) have been consummated and have not been consummated. |
|
|
|
Events of Default: |
|
Events of Default (to be applicable to the Borrower and its subsidiaries) will be subject to customary thresholds and grace periods and limited to the following, in each case, with exceptions and qualifications to be mutually agreed by the Borrower and Lead Arranger and consistent with the Documentation Principles: (i) (x) nonpayment of principal or premium when due or (y) nonpayment of interest, fees or other amounts after a grace period to be mutually agreed by the Borrower and Lead Arranger; (ii) failure to perform or observe covenants set forth in the Facilities, subject, in the case of affirmative covenants (where customary and appropriate), to notice and an appropriate grace period; (iii) any representation or warranty proving to have been incorrect in any material respect (or, in any respect, if qualified by materiality) when made or confirmed; (iv) cross-defaults and cross-acceleration to other indebtedness in an aggregate principal amount in excess of an amount to be mutually agreed; (v) bankruptcy, insolvency proceedings, etc. (with a grace period for involuntary proceedings to be mutually agreed by the Borrower and the Lead Arranger); (vi) inability to pay debts, attachment, etc.; (vii) monetary judgment defaults in an amount in excess of an aggregate amount to be mutually agreed; (viii) customary ERISA defaults; (ix) actual or asserted invalidity of Credit Documentation or impairment of security interests in the Collateral; and (x) Change of Control (to be defined in a manner to be mutually agreed, it being understood that such definition shall provide that a Change of Control shall also occur if a certain Change of Control or other similar events occurs under any agreement or instrument governing or evidencing any other material indebtedness of the Borrower or its subsidiaries but shall not include any continuing director prong or similar triggers based on a change to the Borrowers board of directors). |
|
|
|
Assignments and Participations: |
|
Neither the Borrower nor any Guarantor may assign their rights or obligations under the Facilities. After the Closing Date, any Lender may assign, and may sell participations in, its rights and obligations under the Facilities, subject (x) in the case of participations, to customary |
|
|
restrictions on the voting rights of the participants and restrictions on participations to natural persons, Disqualified Institutions and to the Borrower and its affiliates and (y) in the case of assignments, to limitations to be agreed (including (i) a minimum assignment amount to be agreed (or, if less, the entire amount of such assignors outstanding Loans at such time), (ii) an assignment fee in the amount of $3,500 to be paid by the respective assignor or assignee to the Administrative Agent, (iii) restrictions on assignments to any entity that is not an Eligible Transferee (to be defined to exclude, among others, Disqualified Institutions and the Borrower and its affiliates (except in connection with a Permitted Buy-Back (as defined below))) or a natural person, (iv) the receipt of the consent of the Administrative Agent (not to be unreasonably withheld, conditioned or delayed) and (v) the receipt of the consent of the Borrower (such consent, in any such case, not to be unreasonably withheld, delayed or conditioned)); provided that, the Borrowers consent shall not be so required if (x) such assignment is to any Lender, its affiliates or an approved fund of a Lender, (y) such assignment is during the primary syndication of the Facilities, or (z) an event of default exists under the Facilities; provided, further, that such consent of the Borrower shall be deemed to have been given if the Borrower has not responded within ten business days of a written request for such consent. |
|
|
|
|
|
The Credit Documentation shall also provide that Term Loans may be purchased by, and assigned to, the Borrower on a non-pro rata basis through Dutch auctions open to all Lenders with Term Loans of the respective tranche on a pro rata basis in accordance with procedures to be mutually agreed by the Borrower and the Lead Arranger; provided that (i) no default or event of default then exists under the Facilities or would result therefrom, (ii) the Borrower shall make a representation that it is not in possession of any material non-public information and (iii) any such Term Loans shall be automatically and permanently cancelled immediately upon purchase by the Borrower (without any increase to Consolidated EBITDA as a result of any gains associated with cancellation of debt) (any such purchase and assignment, a Permitted Buy-Back). |
|
|
|
Waivers and Amendments: |
|
Amendments and waivers of the provisions of the Credit Documentation will require the approval of Lenders holding commitments and/or outstandings (as appropriate) representing more than 50% of the aggregate commitments and outstandings under the Facilities (the Required Lenders), except that (a) the consent of each Lender directly affected thereby will be required with respect to (i) increases in commitment amounts of such Lender, (ii) reductions of principal, interest, premium or fees owing to such Lender, (iii) extensions of scheduled payments of any Loans (including at final maturity) of such Lender or times for payment of interest, premium or fees owing to such |
|
|
Lender, (iv) modifications to the pro rata sharing, payment by set-off and payment waterfall provisions and (v) the subordination of the liens securing, or the rights to receive payments under, the Facilities to any other indebtedness not permitted under the Credit Documentation on the Closing Date, (b) the consent of all of the Lenders shall be required with respect to (i) releases of all or substantially all of the collateral or the value of the Guarantees provided by the Guarantors taken as a whole, and (ii) modifications to the assignment provisions or the voting percentages and (c) the approval of Lenders holding commitments and/or outstandings (as appropriate) representing more than 50% of the aggregate commitments and outstandings under a particular class or tranche of the Facilities shall be required with respect to any amendment or waiver that would result in the Lenders under such class or tranche receiving a lesser prepayment, repayment or commitment reduction relative to any other class or tranche of the Facilities; provided that, if any of the matters described in clause (a) or (b) above is agreed to by the Required Lenders, the Borrower shall have the right to substitute any non-consenting Lender by requiring such non-consenting Lenders Loans to be assigned, without further action of such non-consenting Lender, at par, to one or more other institutions, subject to the assignment provisions described above, subject to repayment in full of all obligations of the Borrower owed to such Lender relating to the Term Loans held by such Lender together with the payment by the Borrower to each non-consenting Lender of the applicable Call Protection described above. |
|
|
|
|
|
The Credit Documentation will contain customary amend and extend provisions pursuant to which the Borrower may extend commitments and/or outstandings and make technical changes and amendments to accomplish same with only the consent of the respective consenting Lenders; provided that, such offers to extend such commitments and/or outstandings is made to all similarly situated Lenders and, provided, further, that, it is understood that no existing Lender will have any obligation to commit to any such extension. |
|
|
|
Defaulting Lenders: |
|
Customary for transactions of this type. |
|
|
|
Indemnification; Expenses: |
|
The Credit Documentation will contain customary indemnities for the Administrative Agent, the Lead Arranger, the Lenders, any other agent and their respective affiliates and their and their respective affiliates employees, directors, officers and agents (including, without limitation, all reasonable costs and expenses of the Lenders incurred after the occurrence, and during the continuance of, an event of default under the Facilities), in each case other than as a result of such persons (or any of its related persons) gross negligence or willful misconduct as determined by a court of competent jurisdiction in a final and non- |
|
|
appealable decision |
|
|
|
|
|
The Credit Documentation will require the Borrower to pay all reasonable and documented out-of-pocket expenses of the Administrative Agent, the Lead Arranger and the Lenders associated with the syndication of the Facilities and the preparation, execution, delivery and administration of the Credit Documentation and any amendment or waiver with respect thereto and in connection with the enforcement of the Credit Documentation. |
|
|
|
|
|
Notwithstanding the foregoing, the Credit Parties shall not be responsible for the fees and expenses of more than one primary counsel to the Administrative Agent and the Lenders (and up to one local counsel and one regulatory counsel in each applicable jurisdiction), unless a Lender, the Administrative Agent or its counsel, as applicable, determines that it would create actual or potential conflicts of interest to not have individual counsel, in which case each Lender or the Administrative Agent, as applicable, may have its own counsel which shall be reimbursed in accordance with the foregoing. Notwithstanding anything to the contrary herein, this paragraph shall not apply with respect to Taxes other than any Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim. |
|
|
|
Governing Law and Forum; Submission to Exclusive Jurisdiction: |
|
All Credit Documentation shall be governed by the internal laws of the State of New York. The Borrower and the Guarantors will submit to the exclusive jurisdiction and venue of any New York State court or Federal court sitting in the County of New York, Borough of Manhattan, and appellate courts thereof (except to the extent the Administrative Agent requires submission to any other jurisdiction in connection with the exercise of any rights under any security document or the enforcement of any judgment). |
|
|
|
Counsel to Administrative Agent and Lead Arranger: |
|
Davis Polk & Wardwell LLP. |
Annex A to Exhibit A
to Commitment Letter
Interest and Certain Fees
Interest Rate Options |
|
At the Borrowers option, Term Loans and Revolving Loans may be maintained from time to time as (x) Loans that shall bear interest at the Base Rate (Base Rate Loans) (or, if greater at any time, the Base Rate Floor (as defined below)) in effect from time to time plus the Applicable Margin (as defined below) or (y) Loans that shall bear interest at Adjusted LIBOR (LIBOR Loans) (or, if greater at any time, the LIBOR Floor (as defined below)), plus the Applicable Margin. |
|
|
|
|
|
Adjusted LIBOR means the rate per annum (adjusted for statutory reserve requirements for Eurocurrency liabilities) at which Eurodollar deposits are offered in the interbank Eurodollar market for the applicable interest period, as quoted on Reuters Screen LIBOR01 Page (or any successor page or service). |
|
|
|
|
|
Applicable Margin shall mean a percentage per annum equal to (i) in the case of Term Loans and Revolving Loans (A) maintained as Base Rate Loans, 6.50%, and (B) maintained as LIBOR Loans, 7.50%; and (ii) in the case of any Incremental Loans incurred pursuant to an Incremental Facility (other than (x) any Incremental Term Loans which are added to (and form part of) the Term Loan Facility and (y) Incremental Revolving Credit Loans which are added to (and form part of) the Revolving Credit Facility, all of which shall have the same Applicable Margins as provided in the preceding clause (i), as the same may be adjusted as provided below), such rates per annum as may be agreed to among the Borrower and the Lender(s) providing such Incremental Term Loans; provided that the Applicable Margin for Term Loans shall be subject to adjustment as provided in clause (iii) of the section hereof entitled Uncommitted Incremental Facilities. |
|
|
|
|
|
Base Rate shall mean the highest of (x) the U.S. Prime Lending Rate as published in The Wall Street Journal, (y) 1/2 of 1% in excess of the overnight federal funds rate, and (z) Adjusted LIBOR for an interest period of one month plus 1.00%. |
|
|
|
|
|
Base Rate Floor shall mean 2.00% per annum. |
|
|
|
|
|
LIBOR Floor shall mean 1.00% per annum. |
|
|
|
|
|
Interest periods of 1, 2, 3 and 6 months or, to the extent agreed to by all applicable Lenders, 12 months or, to the extent agreed to by all applicable Lenders, periods shorter than 1 month shall be available in the case of LIBOR Loans. |
|
|
Interest in respect of Base Rate Loans shall be payable quarterly in arrears on the last business day of each calendar quarter. Interest in respect of LIBOR Loans shall be payable in arrears at the end of the applicable interest period and every three months in the case of interest periods in excess of three months. Interest will also be payable at the time of repayment of any Loans and at maturity. All interest on Base Rate Loans, LIBOR Loans and commitment fees and any other fees shall be based on a 360-day year and actual days elapsed (or, in the case of Base Rate Loans determined by reference to the prime lending rate, a 365/366-day year and actual days elapsed). |
|
|
|
Default Interest: |
|
Overdue principal, interest and other amounts shall bear interest, after as well as before judgment, at a rate per annum equal to (i) in the case of overdue principal or interest of any Term Loan, 2.00% plus the rate otherwise applicable to such Term Loan or (ii) in the case of any other amount, 2.00% plus the rate applicable to Base Rate Loans. Such interest shall be payable on demand. |
|
|
|
Revolving Credit Facility Commitment Fees: |
|
A percentage per annum equal to 0.50% on the average daily undrawn portion of the commitments in respect of the Revolving Credit Facility, payable quarterly in arrears after the Closing Date and upon the termination of the commitments and calculated as set forth above. |
|
|
|
Agent/Lender Fees: |
|
The Administrative Agent, the Lead Arranger and the Lenders shall receive such fees as have been separately agreed upon. |
EXHIBIT B
Exhibit B to Commitment Letter
Closing Conditions
Capitalized terms used but not defined in this Exhibit B have the meanings assigned to them elsewhere in this Commitment Letter. The closing of the Facilities and the making of the initial loans thereunder and the initial purchase by Jefferies of the Unsecured Notes are conditioned upon satisfaction of the relevant conditions precedent contained in Section 3 of this Commitment Letter, the other conditions expressly set forth in this Commitment Letter, in Exhibit A under Conditions Precedent to Initial Borrowing (with respect to the Facilities) and those identified below. For purposes of this Exhibit B, references to we, us or our means Jefferies, Jefferies Finance and their respective affiliates.
1. Subject to the Certain Funds Provisions, (x) the execution and delivery of the Definitive Debt Documents by the applicable Credit Parties (or the Acquiror with respect to the Unsecured Notes Offering) and (y) delivery to the Lead Arranger (or Jefferies with respect to the Unsecured Notes Offering) of (i) borrowing notices (if applicable), customary legal opinions, customary officers closing certificates, organizational documents, customary evidence of authorization and good standing certificates in jurisdictions of formation/organization, in each case with respect to the Credit Parties (to the extent applicable) (or the Acquiror with respect to the Unsecured Notes Offering), and (ii) a solvency certificate, substantially in the form attached hereto as Exhibit C, dated the Closing Date and after giving effect to the Transactions from a senior financial officer of the Borrower, relating to the solvency of the Borrower and its subsidiaries on a consolidated basis. Subject to the Certain Funds Provisions, with respect to the Facilities, all documents and instruments required to create and perfect the Administrative Agents security interest in the Collateral shall have been executed and delivered by the Credit Parties and, if applicable, be in proper form for filing.
2. Substantially concurrently with the initial funding under the Facilities and the purchase of the Unsecured Notes (if any Unsecured Notes are being purchased on the Closing Date), the Acquisition shall be consummated in accordance with the terms and conditions of the Purchase Agreement without giving effect to any alteration, amendment, modification, supplement or express waiver or consent granted by the Acquiror or any of its subsidiaries, if such alteration, amendment, modification, supplement or express waiver or consent granted by the Acquiror or any of its subsidiaries is materially adverse to the interests of Jefferies or its affiliates, without the prior written consent of Jefferies Finance (such consent not to be unreasonably withheld, delayed or conditioned) (it being understood and agreed that any alteration, amendment, modification, supplement or express waiver or consent granted by the Acquiror or any of its subsidiaries under the Purchase Agreement that results in (a) a reduction in the Purchase Price shall be deemed not to be materially adverse to the interests of Jefferies if such reduction is applied to reduce the Term Loan Facility or (if any Unsecured Notes are being purchased on the Closing Date) the Unsecured Notes, (b) an increase in the Purchase Price shall be deemed not to be materially adverse to the interests of Jefferies so long as any such increases shall not be funded with proceeds of any indebtedness, (c) any change in the Purchase Price shall be deemed not to be materially adverse to the interests of Jefferies if such change is pursuant to any purchase price adjustment provisions, including, without limitation, working capital adjustments, set forth in the Purchase Agreement or (d) an amendment, modification or express
waiver with respect to the definition of Company Material Adverse Effect shall be deemed materially adverse to the interests of Jefferies.
3. The Refinancing shall have been consummated or, substantially concurrently with the initial borrowings and initial purchases under the Debt Financing, shall be consummated; provided that up to $50,000 aggregate principal amount of the Acquired Business 5.000% Subordinated Convertible Promissory Notes due August 29, 2019 (as amended, restated, amended and restated, supplemented or otherwise modified) may remain outstanding.
4. Jefferies shall have received (a) audited consolidated balance sheets of each of the Acquiror and its consolidated subsidiaries and of the Target and its consolidated subsidiaries, in each case as at the end of, and related audited statements of income and cash flows and stockholders equity of each of the Acquiror and its consolidated subsidiaries and the Target and its consolidated subsidiaries, in each case for, the most recent three fiscal years ended at least 90 days prior to the Closing Date and (b) unaudited consolidated balance sheets of each of the Acquiror and its consolidated subsidiaries and of the Target and its consolidated subsidiaries, in each case as at the end of, and related statements of income and cash flows and stockholders equity of each of the Acquiror and its consolidated subsidiaries and the Target and its consolidated subsidiaries, in each case, for each fiscal quarter after the date of the most recent financial statements delivered pursuant to clause (a) above and ended at least 45 days before the Closing Date. Jefferies hereby confirms receipt of (x) the audited financial statements of the Acquiror referred to in clause (a) above for the fiscal years ended December 31, 2014, December 31, 2015 and December 31, 2016 and the unaudited financial statements of the Acquiror referred to in clause (b) above for the fiscal quarter ended March 31, 2017, (y) the audited financial statements of the Target and its subsidiaries referred to in clause (a) above for the fiscal years ended December 31, 2014, December 31, 2015 and December 31, 2016 and the unaudited financial statements of the Target and its subsidiaries referred to in clause (b) above for the fiscal quarter ended March 31, 2017.
5. Jefferies shall have received a pro forma consolidated balance sheet of the Acquiror as of the last day of the most recently completed fiscal quarter for which financial information pursuant to paragraph 4 above has been delivered and pro forma consolidated statement of income of the Acquiror for the most recently completed fiscal quarter and most recently completed fiscal year, in each case for which financial information pursuant to paragraph 4 above has been delivered and prepared after giving effect to the Transactions as if the Transactions had occurred as of such date (in the case of such balance sheet) or at the beginning of such period (in the case of such income statements).
6. With respect to the Unsecured Notes, (a) Jefferies shall have received (i) not later than close of business on the date this Commitment Letter is countersigned by you, a complete (as determined by us) initial draft of an offering memorandum relating to the issuance of the Unsecured Notes, containing all Required Information (as defined below) as would be customary in an offering of the Unsecured Notes under Rule 144A under the Securities Act of 1933, as amended (the Securities Act), and (ii) as soon as practicable and in no event later than two Business Days after the date hereof a preliminary offering memorandum (the Preliminary Offering Memorandum) usable in a customary road show relating to the issuance of the Unsecured Notes that contains all Required Information as would be customary in an offering of
the Unsecured Notes under Rule 144A under the Securities Act and (b) senior management and representatives of the Acquiror shall have participated in a customary road show (which may, in the sole discretion of Jefferies, be telephonic) for the Unsecured Notes. We shall have been afforded a period of at least 15 consecutive Business Days (as defined below) following delivery to us of a complete Preliminary Offering Memorandum relating to the Unsecured Notes and the draft comfort letters contemplated by paragraph 7(i) below to seek to place the Unsecured Notes; provided that neither July 3, 2017 nor July 5, 2017 shall constitute Business Days for the purposes of such 15-Business-Day period (though such period shall not be required to restart as a result of the occurrence of such days). For purposes of this Exhibit B, Business Day shall have the meaning set forth in the Purchase Agreement. Required Information means all financial statements of the Acquiror or the Target, as applicable, and other data to be included therein (including all audited financial statements, all unaudited financial statements (each of which shall have undergone a SAS 100 review or the equivalent) and all appropriate pro forma financial statements (it being understood that pro forma financial statements giving effect to the Acquisition shall only be required to be prepared using the financial statements of the Acquiror and the Target identified in paragraph 4 above)) prepared in accordance with, or reconciled to, generally accepted accounting principles in the United States, and all other data (including selected financial data) and other information, in each case, of the type and form customarily included in offering memoranda customarily used in Rule 144A offerings, and shall not include, for the avoidance of doubt, other information or financial data customarily excluded from a Rule 144A offering memorandum. Jefferies hereby confirms receipt of the initial draft offering memorandum referred to in subclause (a)(i) of this paragraph 6.
7. With respect to the Unsecured Notes, the independent accountants for the Acquiror and Target that have audited the financial statements contained in the offering memorandum relating to the issuance of the Unsecured Notes shall each make available and have delivered to us, (i) no later than the delivery to us of the Preliminary Offering Memorandum in accordance with preceding paragraph, in a form they are prepared to execute, a draft, in customary form for registered or Rule 144A offerings of securities like the Unsecured Notes (including, without limitation, customary negative assurance and the items included in the circle-up and the degree of comfort provided with respect thereto), of a comfort letter prepared in accordance with the requirements of AS 6101 covering the financial statements and other data included and incorporated by reference in each confidential offering memorandum (the Comfort Letter), (ii) no later than the pricing of the Unsecured Notes Offering, an executed copy of the Comfort Letter, and (iii) the date of consummation of the issuance of the Unsecured Notes Offering, a customary bring down comfort letter satisfactory to us in our sole discretion
8. All costs, fees, expenses (including reasonable and documented legal fees and out-of-pocket expenses and recording taxes and fees) and other compensation and amounts payable on the Closing Date to us, the Investors or any of our or their respective affiliates pursuant to the Commitment Letter or the Fee Letter, shall have been (or concurrently with the initial funding of the Debt Financing will be) paid to the extent due and payable in accordance with the terms, respectively, thereof and (other than in the case of fees) invoiced at least two Business Days (unless otherwise reasonably agreed by the Borrower) prior to the Closing Date. The Debt Financing Letters shall be in full force and effect
9. You shall have delivered, at least two Business Days prior to the Closing Date, all documentation and other information about the Acquiror and the Credit Parties that is required by U.S. regulatory authorities under applicable know your customer and anti-money laundering rules and regulations, including the PATRIOT Act, to the extent requested by the Commitment Parties at least ten Business Days prior to the Closing Date.
10. The Specified Representations shall be true and correct in all material respects, or, to the extent qualified by materiality or Material Adverse Effect, in all respects, as of the Closing Date (except in the case of any such representation which expressly relates to a given date or period, such representation shall be true and correct in all material respects (or in all respects, as the case may be) as of the respective date or period) and, subject to the Certain Funds Provisions, the Specified Acquisition Representations shall be true and correct in all respects.
11. With respect to the Facilities, the Closing Date shall not occur prior to July 19, 2017.
Exhibit C
EXHIBIT C TO COMMITMENT LETTER
SOLVENCY CERTIFICATE
[BORROWER]
[ ], 20[ ]
Pursuant to Section [ ] of the Credit Agreement, dated as of the date hereof (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the Credit Agreement), among [ ], the undersigned [chief accounting officer][other officer with equivalent duties] of the Borrower hereby certifies to the [Administrative Agent] as of the date hereof, solely on behalf of the Borrower and not in his or her individual capacity and without assuming any personal liability whatsoever, that:
I am familiar with the finances, properties, businesses and assets of the Borrower and its Subsidiaries and the Target and its Subsidiaries.(2) I have reviewed the Loan Documents and such other documentation and information and have made such investigation and inquiries as I have deemed necessary and prudent therefor. I have also reviewed the consolidated financial statements of the Borrower and its Subsidiaries and the Target and its Subsidiaries, including projected financial statements and forecasts relating to statements of operations and cash flow statements of the Borrower and its Subsidiaries and the Target and its Subsidiaries, respectively.
On the Closing Date, after giving effect to the Transactions, the Borrower and its Subsidiaries (on a consolidated basis) (a) have property with fair value greater than the total amount of their debts and liabilities, contingent (it being understood that the amount of contingent liabilities at any time shall be computed as the amount that, in light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability), subordinated or otherwise, (b) have assets with present fair salable value not less than the amount that will be required to pay their liability on their debts as they become absolute and matured, (c) will be able to pay their debts and liabilities, subordinated, contingent or otherwise, as they become absolute and matured and (d) are not engaged in business or a transaction, and are not about to engage in business or a transaction, for which their property would constitute an unreasonably small capital.
All capitalized terms used but not defined in this certificate shall have the meanings set forth in the Credit Agreement.
IN WITNESS WHEREOF, I have executed this Certificate as of the date first written above
|
TELADOC, INC. | |
|
| |
|
By: |
|
|
Name: |
|
|
Title: |
|
(2) NTD: Subsidiaries to be defined in a manner consistent with the Documentation Principles.
Exhibit 99.1
Teladoc Announces Proposed Offering of $200 Million of Convertible Senior Notes due 2022
PURCHASE, NY, June 20, 2017 (GLOBE NEWSWIRE) Teladoc, Inc. (NYSE:TDOC) today announced its intention to offer, subject to market conditions and other factors, $200 million aggregate principal amount of Convertible Senior Notes due 2022 (the Notes) in a private offering to qualified institutional buyers pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the Securities Act). In connection with the offering of the Notes, Teladoc expects to grant the initial purchaser of the Notes an option to purchase up to an additional $30 million aggregate principal amount of Notes on the same terms and conditions solely to cover over-allotments.
Teladoc intends to use the proceeds from the offering to finance a portion of the cash consideration payable in connection with Teladocs previously announced acquisition of Best Doctors Holdings, Inc. (the Acquisition), to refinance existing indebtedness and to pay related fees and expenses. Any remaining proceeds will be used for working capital purposes or other general corporate purposes.
The Notes will be unsecured, senior obligations of Teladoc, and interest on the Notes will be payable semi-annually in arrears on June 15 and December 15 of each year, beginning on December 15, 2017. Prior to June 15, 2022, the Notes will be convertible only under certain circumstances and during certain periods. On or after June 15, 2022, the Notes will be convertible at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Except as described in the immediately following sentence, Teladoc may not redeem the Notes prior to December 22, 2020. If the Acquisition is not consummated by August 12, 2017 (or Teladocs board of directors reasonably determines in good faith that the Acquisition will not be consummated by such date), or if the agreement and plan of merger with respect to the Acquisition is terminated, Teladoc may, at its option, redeem all (but not less than all) of the Notes, in cash, on a redemption date occurring on or prior to November 13, 2017 at a redemption price equal to 101% of the principal amount of the Notes plus a premium determined based on the price of Teladocs common stock prior to the redemption date. On or after December 22, 2020, Teladoc may redeem, for cash, all or part of the Notes if the last reported sale price of its common stock equals or exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days.
Teladoc will settle conversions of the Notes by paying or delivering, as the case may be, cash, shares of its common stock, or a combination of cash and shares of its common stock, at its election. Final terms of the Notes, including interest rate, conversion rate and other terms, will be determined at the time of pricing.
The offering is being made to qualified institutional buyers pursuant to Rule 144A under the Securities Act. Neither the Notes nor any shares of Teladocs common stock issuable upon conversion of the Notes have been or will be registered under the Securities Act or under any state securities laws and, unless so registered, may not be offered or sold in the United States or to U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.
About Teladoc, Inc.
Teladoc, Inc. (NYSE:TDOC) is the nations first and largest telehealth platform. Recognized by MIT Technology Review as one of the 50 Smartest Companies, Teladoc is forging a new healthcare experience with an innovative portfolio of virtual care delivery solutions. Currently, Teladoc serves some 7,500 clients from payers to providers to employers and more than 20 million members who connect within minutes to Teladocs network of more than 3,100 board-certified, state-licensed physicians and therapists, 24/7. Teladocs services and solutions marry a highly engaging consumer experience with the latest in data & analytics, and a highly flexible technology platform. Teladoc has delivered more than 2.5 million medical visits for general medical, dermatology, counseling, psychiatry, sexual health, and tobacco cessation.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 concerning Teladoc, Best Doctors Holdings, Inc., the Acquisition, the financing for the Acquisition and other matters. Forward-looking statements can be identified by words such as: anticipate, intend, plan, believe, project, estimate, expect, may, should, will and similar references to future periods. Examples of forward-looking statements include, among others, statements Teladoc makes regarding its financing plans (including statements related to the offering of the Notes), the Acquisition, future revenues, future earnings, future numbers of members or clients, litigation outcomes, regulatory developments, market developments, new products and growth strategies, and the effects of any of the foregoing on Teladocs future results of operations or financial conditions.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Teladocs current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the control of Teladoc or Best Doctors Holdings, Inc. Teladocs actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause Teladocs actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) risks related to the Acquisition, including failure to obtain applicable regulatory approvals in a timely manner or at all, integration risks, exposure to international operations, the financing thereof (including the offering of the Notes) and failure to achieve the anticipated benefits of the Acquisition; (ii) changes in laws and regulations applicable to Teladocs business model; (iii) changes in market conditions and receptivity to Teladocs services and offerings; (iv) results of litigation; (iv) the loss of one or more key clients; and (v) changes to Teladocs abilities to recruit and retain qualified providers into Teladocs network. For a detailed discussion of the risk factors that could affect Teladocs actual results, please refer to the risk factors identified in Teladocs filings with the Securities and Exchange Commission, including, but not limited to Teladocs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
Any forward-looking statement made by Teladoc in this press release is based only on information currently available to Teladoc and speaks only as of the date on which it is made. Teladoc undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Contacts:
Investors:
Jisoo Suh
914-265-6706
jsuh@teladoc.com
Media:
Courtney McLeod
914-265-6789
cmcleod@teladoc.com
Exhibit 99.2
HISTORICAL FINANCIAL STATEMENTS OF BEST DOCTORS HOLDINGS, INC.
Index to Condensed Consolidated Financial Statements
Contents |
|
Page |
Unaudited Interim Condensed Consolidated Financial Statements as of March 31, 2017 and for the three months ended March 31, 2017 and 2016 |
|
|
Condensed Consolidated Balance Sheets |
|
2 |
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) |
|
4 |
Condensed Consolidated Statements of Cash Flows |
|
5 |
Notes to Condensed Consolidated Financial Statements |
|
6 |
BEST DOCTORS HOLDINGS, INC.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands, except share data)
|
|
March 31, |
|
December 31, |
| ||
Assets |
|
|
|
|
| ||
Current assets: |
|
|
|
|
| ||
Cash and cash equivalents |
|
$ |
14,756 |
|
$ |
20,151 |
|
Accounts receivable, net |
|
9,895 |
|
9,567 |
| ||
Current income taxes receivable |
|
632 |
|
|
| ||
Prepaid expenses and other current assets |
|
2,098 |
|
1,788 |
| ||
Total current assets |
|
27,381 |
|
31,506 |
| ||
Property and equipment |
|
31,021 |
|
29,718 |
| ||
Less accumulated depreciation and amortization |
|
(21,287 |
) |
(20,887 |
) | ||
Total property and equipment, net |
|
9,734 |
|
8,831 |
| ||
Other assets: |
|
|
|
|
| ||
Intangible assets: |
|
|
|
|
| ||
Goodwill |
|
23,316 |
|
23,316 |
| ||
Intangible assets, net |
|
5,477 |
|
5,801 |
| ||
Total Intangible assets, net |
|
28,793 |
|
29,117 |
| ||
Security deposits and other assets |
|
532 |
|
526 |
| ||
Long term deferred tax assets |
|
116 |
|
117 |
| ||
Other receivable |
|
2,882 |
|
2,858 |
| ||
Total assets |
|
$ |
69,438 |
|
$ |
72,955 |
|
See accompanying notes to condensed consolidated financial statements.
BEST DOCTORS HOLDINGS, INC.
Condensed Consolidated Balance Sheets (Continued)
(Unaudited)
(In thousands, except share data)
|
|
March 31, |
|
December 31, |
| ||
Liabilities, Preferred Stock and Stockholders Deficit |
|
|
|
|
| ||
Current liabilities: |
|
|
|
|
| ||
Accounts payable |
|
$ |
1,232 |
|
$ |
1,439 |
|
Accrued expenses |
|
7,121 |
|
7,755 |
| ||
Accrued payroll and commissions |
|
3,943 |
|
8,912 |
| ||
Current portion of notes payable and line of credit |
|
3,908 |
|
4,101 |
| ||
Deferred revenue |
|
1,316 |
|
1,886 |
| ||
Current portion of income tax payable |
|
27 |
|
751 |
| ||
Warrant liability |
|
3,049 |
|
3,131 |
| ||
Total current liabilities |
|
20,596 |
|
27,975 |
| ||
Other liabilities: |
|
|
|
|
| ||
Long term convertible notes payable |
|
20,100 |
|
19,302 |
| ||
Long term notes payable |
|
4,191 |
|
4,941 |
| ||
Long term tax liability |
|
1,124 |
|
1,124 |
| ||
Long term deferred revenue |
|
128 |
|
103 |
| ||
Long term deferred tax liability |
|
779 |
|
779 |
| ||
Total liabilities |
|
46,918 |
|
54,224 |
| ||
Commitments and Contingencies (note 11) |
|
|
|
|
| ||
Preferred stock: |
|
|
|
|
| ||
Series G, I, J, K and K-1 $0.01 par value, 5,449,491 shares authorized at March 31, 2017 and December 31, 2016; 1,946,824 shares issued and outstanding (liquidation preferences of $43,983) at March 31, 2017; 1,903,474 shares issued and outstanding (liquidation preferences of $43,529) and December 31, 2016. |
|
39,790 |
|
38,923 |
| ||
Stockholders deficit: |
|
|
|
|
| ||
Common stock: |
|
|
|
|
| ||
$0.01 par value, 10,000,000 shares authorized at March 31, 2017 and December 31, 2016; 6,656,460 shares issued and outstanding at March 31, 2017; 6,636,460 shares issued and outstanding at December 31, 2016. |
|
67 |
|
67 |
| ||
Additional paid-in capital |
|
61,214 |
|
60,838 |
| ||
Accumulated other comprehensive loss |
|
(2,468 |
) |
(3,004 |
) | ||
Accumulated deficit |
|
(76,083 |
) |
(78,093 |
) | ||
Total stockholders deficit |
|
(17,270 |
) |
(20,192 |
) | ||
Total liabilities, preferred stock and stockholders deficit |
|
$ |
69,438 |
|
$ |
72,955 |
|
See accompanying notes to condensed consolidated financial statements.
BEST DOCTORS HOLDINGS, INC.
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(Unaudited)
(In thousands)
|
|
Three Months Ended |
| ||||
|
|
2017 |
|
2016 |
| ||
Services revenue |
|
$ |
24,056 |
|
$ |
22,668 |
|
Cost of services revenue |
|
8,530 |
|
8,085 |
| ||
Gross margin |
|
15,526 |
|
14,583 |
| ||
Selling, general, and administrative expenses |
|
14,053 |
|
13,369 |
| ||
Income from operations |
|
1,473 |
|
1,214 |
| ||
Other Income (expenses): |
|
|
|
|
| ||
Foreign currency transaction loss |
|
(32 |
) |
(156 |
) | ||
Gain on sale |
|
2,369 |
|
|
| ||
Interest expense, net |
|
(1,392 |
) |
(1,446 |
) | ||
Other income (expense), net |
|
35 |
|
(120 |
) | ||
Other income (expense) |
|
980 |
|
(1,722 |
) | ||
Income (loss) from operations before income tax expense |
|
2,453 |
|
(508 |
) | ||
Income tax expense |
|
(151 |
) |
(50 |
) | ||
Net income (loss) |
|
$ |
2,302 |
|
$ |
(558 |
) |
Comprehensive income (loss): |
|
|
|
|
| ||
Net income (loss) |
|
$ |
2,302 |
|
$ |
(558 |
) |
Foreign currency translation adjustment |
|
536 |
|
(1,037 |
) | ||
Other comprehensive income (loss), net of tax |
|
536 |
|
(1,037 |
) | ||
Comprehensive income (loss) |
|
$ |
2,838 |
|
$ |
(1,595 |
) |
See accompanying notes to condensed consolidated financial statements.
BEST DOCTORS HOLDINGS, INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In thousands)
|
|
Three Months Ended |
| ||||
|
|
2017 |
|
2016 |
| ||
Cash flows from operating activities: |
|
|
|
|
| ||
Net income (loss) |
|
$ |
2,302 |
|
$ |
(558 |
) |
Adjustments to reconcile net income (loss) to net cash used in operating activities: |
|
|
|
|
| ||
Depreciation and amortization |
|
735 |
|
794 |
| ||
Gain on sale of business |
|
(2,369 |
) |
|
| ||
Stock-based compensation expense |
|
328 |
|
351 |
| ||
Change in warrant liability |
|
10 |
|
60 |
| ||
Change in fair value of convertible notes payable |
|
749 |
|
655 |
| ||
Changes in operating assets and liabilities, net of effects of acquisition: |
|
|
|
|
| ||
Accounts receivable |
|
(898 |
) |
(1,090 |
) | ||
Prepaid expenses and other assets |
|
(415 |
) |
161 |
| ||
Other noncurrent assets |
|
(28 |
) |
(562 |
) | ||
Accounts payable, accrued expenses and other current liabilities |
|
(6,690 |
) |
(1,081 |
) | ||
Deferred revenue |
|
88 |
|
236 |
| ||
Net cash used in operating activities |
|
(6,188 |
) |
(1,034 |
) | ||
Cash flows from investing activities: |
|
|
|
|
| ||
Proceeds from sale of business, net of $1,545 cash transferred out with sale (note 12) |
|
2,481 |
|
|
| ||
Purchases of property and equipment |
|
(1,414 |
) |
(299 |
) | ||
Net cash (used in) provided by investing activities |
|
1,067 |
|
(299 |
) | ||
Cash flows from financing activities: |
|
|
|
|
| ||
Proceeds from exercise of options to purchase common stock |
|
48 |
|
66 |
| ||
Repayments on note payable and line of credit |
|
(987 |
) |
(561 |
) | ||
Proceeds from issuance of Series K Preferred Stock |
|
575 |
|
|
| ||
Net cash used in financing activities |
|
(364 |
) |
(495 |
) | ||
Effect of exchange rate changes on cash |
|
90 |
|
197 |
| ||
Net decrease in cash and cash equivalents |
|
(5,395 |
) |
(1,631 |
) | ||
Cash and cash equivalents, beginning of period |
|
20,151 |
|
7,151 |
| ||
Cash and cash equivalents, end of period |
|
$ |
14,756 |
|
$ |
5,520 |
|
See accompanying notes to condensed consolidated financial statements.
(1) Organization and Nature of Business
Best Doctors Holdings, Inc. (the Company) provides technology innovations and services to help employers, health plans and provider organizations ensure that their members combat medical uncertainty with access to the best medical minds. Core services include, but are not limited to, Critical Care InterConsultation® (addresses the highly complex, time-sensitive needs of members requiring acute, in-patient care via immediate expert guidance), InterConsultation® (provides members and their treating physicians with an in-depth analysis and complete case review from nationally renowned experts in the members condition), Ask the ExpertSM (enables members to get specific answers to personal health care questions from nationally renowned experts), and Find a Best DoctorSM (identifies expert physicians best suited to help initiate hands-on care for members who do not yet have a diagnosis, or who are looking for a new treating physician). These services are sold mainly in the United States (U.S.), Europe, Canada and Japan. The Workers Compensation CatCare Program and Legacy Program, available in the U.S., provide case review with guidance from top experts in trauma, rehabilitation and other specialties, helping to reduce errors and ensure that best practices are being followed (collectively, these services are referred to herein as Services).
(2) Significant Accounting Policies
(a) Basis of Presentation and Principles of Consolidation
These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and applicable rules and regulations of the Securities and Exchange Commission regarding interim financial reporting, and include the accounts of the Companys wholly owned subsidiaries. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations.
The interim condensed consolidated balance sheet as of March 31, 2017, and the condensed consolidated statements of operations and comprehensive loss, and cash flows for the three months ended March 31, 2017 and 2016 are unaudited.
The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all normal recurring adjustments necessary to present fairly the Companys consolidated financial position and the consolidated results of operations, comprehensive loss and cash flows for the interim periods presented but are not necessarily indicative of the results of operations to be anticipated for the full year ending December 31, 2017 or any other period. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted for interim reporting purposes.
The condensed consolidated balance sheet as of December 31, 2016 included herein was derived from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2016.
All intercompany transactions and balances have been eliminated in consolidation.
(b) Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures in the
(2) Significant Accounting Policies (Continued)
condensed consolidated financial statements. Estimates also impact the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
(c) Foreign Currency
The functional currency for each of the Companys foreign subsidiaries is the local currency. All assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are translated at the weighted average exchange rate during the period. Cumulative translation gains or losses are included as a separate component of stockholders equity and reported as a part of accumulated other comprehensive income.
Foreign currency gains and losses on transactions denominated in a currency other than the respective subsidiarys functional currency are included in other income (loss) in the accompanying condensed consolidated statements of operations and comprehensive loss.
For the quarters ended March 31, 2017 and 2016, the Company recorded foreign currency transaction losses of $32 and $156, respectively. The Company has not utilized hedging strategies with respect to such foreign exchange exposure.
(d) Comprehensive Loss
Comprehensive loss includes all changes in stockholders equity during a period other than those resulting from investments by and distributions to stockholders. Comprehensive loss includes net loss and other comprehensive loss. The Companys other comprehensive loss includes foreign currency translation adjustments and unrealized loss on investments.
The accumulated balances for each item of other comprehensive loss are as follows:
|
|
Foreign |
|
Accumulated |
| ||
Ending balance, December 31, 2016 |
|
(3,004 |
) |
(3,004 |
) | ||
Net period other comprehensive loss net of tax effect of $0 |
|
536 |
|
536 |
| ||
Ending balance, March 31, 2017 |
|
$ |
(2,468 |
) |
$ |
(2,468 |
) |
(e) Services Revenue Recognition
Revenues are recognized when persuasive evidence of an arrangement exists, the services are performed, the price is fixed or determinable, and there is a reasonable assurance of collection. Services revenues, other than per case fees from customers, are recognized ratably over the contract period. Per case fees are recognized when cases are completed.
Certain services revenue contracts entered into by the Company and its customers have measurable performance guarantees that may require the Company to return partial payment to the customer if certain customer service goals or savings are not realized in a given period. The Company has recorded a reserve in accrued expenses of $1,920 and $1,665 at March 31, 2017 and December 31, 2016, respectively. The Company has recorded a reduction to service revenue of $333 and $347 for the quarters ended March 31, 2017 and 2016, respectively, relating to these performance guarantees.
Deferred revenue is recorded in situations where payments are received from customers in advance of providing services. Such amounts are recognized as revenue when the associated services are provided.
(2) Significant Accounting Policies (Continued)
(f) Fair Value of Financial Instruments
Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurement for assets and liabilities which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk.
The carrying amounts reported on the condensed consolidated balance sheets for cash and cash equivalents approximate fair value based on the on-demand nature of cash and the short-term maturity and the daily pricing mechanisms for cash equivalents. Other assets and liabilities with short-term and intermediate-term maturities and defined settlement amounts, including receivables, payables, and accrued liabilities, are reported at their contractual amounts, which approximate fair value. Debt balances, other than convertible notes which are reported using the fair value option, approximate the carrying amount.
(g) Concentration of Credit Risk
The Company places its cash and cash equivalents in highly rated financial institutions, which are continually reviewed by senior management for financial stability. Generally, the Companys cash and cash equivalents in U.S. interest-bearing accounts and in foreign countries exceed financial depository insurance limits. Based on the institutions in which funds are held, the Company believes that its cash and cash equivalents are not exposed to significant credit risk.
(h) Goodwill and Intangible Assets
Goodwill represents the excess of the aggregate purchase price over the fair value of the net assets acquired in a business combination and is reviewed for impairment at least annually. Accounting Standards Codification Topic 350, Intangibles Goodwill and Other, (ASC 350) permits the assessment of qualitative factors to determine whether events and circumstances lead to the conclusion that it is necessary to perform the two-step goodwill impairment test required under ASC 350. The qualitative assessment management performs takes into consideration the following factors: general economic conditions, industry specific performance, and changes in carrying value of the reporting unit.
In the first step of the two-step test, the fair value of the reporting unit is compared with its carrying value (including goodwill). If the fair value of the reporting unit is less than its carrying value, an indication of goodwill impairment exists for the reporting unit and the enterprise must perform step two of the impairment test (measurement). In step two, an impairment loss is recognized for any excess of the carrying amount of the reporting units goodwill over the implied fair value of that goodwill. The implied fair value of goodwill is determined by allocating the fair value of the reporting unit in a manner similar to a purchase price allocation. The residual fair value after this allocation is the implied fair value of the reporting unit goodwill.
Fair value of the reporting unit is determined using income and market methodologies based on managements estimates of forecasted cash flows and market value. If the fair value of the reporting unit exceeds its carrying value, step two need not be performed.
Goodwill and intangible assets with indefinite lives are evaluated annually for impairment and whenever changes in conditions indicate that the fair value is more likely than not below its carrying value. No impairment charges were recorded during the quarters ended March 31, 2017 and 2016.
(2) Significant Accounting Policies (Continued)
Identifiable intangible assets with definite lives are amortized on a straight-line basis over their estimated useful lives, which are 3 to 10 years from the date of original acquisition. Identifiable intangible assets consist of customer contracts, acquired technology, noncompetition contracts, and trade names.
(i) Long-Lived Assets
Long-lived assets, such as property and equipment, and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment expense is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.
(j) Stock-Based Compensation
Stock-based compensation is measured at the grant date, based upon the fair value of the award, and is recognized as an expense over the employees requisite service period (generally the vesting period of the equity grant).
The Company periodically grants stock options for a fixed number of shares of common stock to its employees, directors, and nonemployee contractors, with an exercise price greater than or equal to the fair market value of its common stock at the date of the grant. The Companys stock-based compensation arrangements vest over periods of up to four years.
The Company recorded stock-based compensation expense of $328 and $351 for the quarters ended March 31, 2017 and 2016, respectively, which is included in selling, general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss.
The Company estimates the fair value of stock options using a Black-Scholes valuation model. Key inputs used to estimate the fair value of stock options include the exercise price of the award, the expected option term, expected stock price volatility which is calculated using the volatility rates of comparable companies as the Company is not publicly traded, the risk-free interest rate from U.S. Treasury bonds, and the Companys expected annual dividend yield. The total fair value is reduced by estimated forfeitures.
(k) Recent Accounting Pronouncements
In May 2014 the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which requires us to recognize revenue when a customer obtains control rather than when we have transferred substantially all risks and rewards of a good or service and requires expanded disclosures. ASU 2014-09, as amended, is effective for us beginning January 1, 2019. We have not yet determined whether we will adopt the provisions of ASU 2014-09 on a retrospective basis or through a cumulative adjustment to equity. We continue to assess the overall impact the adoption of ASU 2014-09 will have on our consolidated financial statements.
In February 2016, the FASB issued ASU No. 2016-02, Leases, replacing existing lease accounting guidance. The new standard introduces a lessee model that would require entities to recognize assets and liabilities for most leases, but recognize expenses on their income statements in a manner similar to current accounting. The ASU does not make fundamental changes to existing lessor accounting. However, it modifies what qualifies as a sales-type and direct financing lease and related accounting and aligns a number of the underlying principles with those of the new revenue standard, ASU No. 2014-09, such as
(2) Significant Accounting Policies (Continued)
evaluating how collectability should be considered and determining when profit can be recognized. The guidance eliminates existing real estate-specific provisions and requires expanded qualitative and quantitative disclosures. The standard requires modified retrospective transition by which it is applied at the beginning of the earliest comparative period presented in the year of adoption. For Best Doctors, the ASU is effective January 1, 2020. The Company is currently assessing this ASUs impact on Best Doctors consolidated results of operations and financial condition.
In March 2016, the FASB issued ASU 2016-09, Compensation Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU No. 2016-09 changed aspects of the accounting for share-based payment award transactions, including: (1) accounting for income taxes; (2) classification of excess tax benefits on the statement of cash flows; (3) forfeitures; (4) minimum statutory tax withholding requirements; and (5) classification of employee taxes paid on the statement of cash flows when an employer withholds shares for tax-withholding purposes. The provisions of ASU 2016-02 are effective for annual periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04, Intangibles Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment. ASU 2017-04 eliminates Step 2 of the two-step impairment test, which requires entities to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Rather, entities will record an impairment charge based on the excess of a reporting units carrying amount over its fair value, as computed in Step 1. Entities may continue to perform the qualitative goodwill impairment assessment to determine whether the quantitative impairment test is necessary. The provisions of ASU 2017-04 are effective for annual periods beginning after December 15, 2021, with early adoption permitted for annual goodwill impairment tests performed after January 1, 2017.
(3) Related Party Transactions
The Company earns revenues from certain investors in the Company. During the quarters ended March 31, 2017 and 2016, the Company recorded $2,084 and $117 of revenue pursuant to such agreements which were included in service revenues in the condensed consolidated statements of operations and comprehensive loss, respectively.
(4) Property and Equipment
Property and equipment as of March 31, 2017 and December 31, 2016 are as follows:
|
|
2017 |
|
2016 |
| ||
Equipment and hardware |
|
$ |
4,844 |
|
$ |
4,772 |
|
Software |
|
20,650 |
|
19,427 |
| ||
Furniture and fixtures |
|
1,108 |
|
1,100 |
| ||
Capital equipment lease |
|
1,869 |
|
1,869 |
| ||
Leasehold improvements |
|
2,550 |
|
2,550 |
| ||
Accumulated depreciation and amortization |
|
(21,287 |
) |
(20,887 |
) | ||
Total property and equipment, net |
|
$ |
9,734 |
|
$ |
8,831 |
|
The Company recorded depreciation and amortization expense of $735 and $794 for the quarters ended March 31, 2017 and 2016, respectively.
(5) Goodwill and Intangible Assets
The following table presents the carrying amount of goodwill and indefinite-lived intangible assets:
|
|
Goodwill |
|
Indefinite-lived |
| ||
Balance at December 31, 2016 |
|
$ |
23,316 |
|
$ |
733 |
|
2017 Additions |
|
|
|
|
| ||
Balance at March 31, 2017 |
|
$ |
23,316 |
|
$ |
733 |
|
The following table presents changes in the carrying amount of definite-lived intangible assets for 2017 and 2016:
|
|
Trademarks |
|
Technology |
|
Customer |
|
Noncompete |
| ||||
Balance at December 31, 2016 |
|
$ |
315 |
|
$ |
7,130 |
|
$ |
1,683 |
|
$ |
342 |
|
Accumulated amortization |
|
(304 |
) |
(2,364 |
) |
(1,392 |
) |
(342 |
) | ||||
December 31,2016, net |
|
$ |
11 |
|
$ |
4,766 |
|
$ |
291 |
|
$ |
|
|
Balance at December 31, 2016 |
|
$ |
315 |
|
$ |
7,130 |
|
$ |
1,683 |
|
$ |
342 |
|
2017 Additions |
|
|
|
|
|
|
|
|
| ||||
Balance at March 31, 2017 |
|
315 |
|
7,130 |
|
1,683 |
|
342 |
| ||||
Accumulated amortization |
|
(304 |
) |
(2,579 |
) |
(1,501 |
) |
(342 |
) | ||||
March 31, 2017, net |
|
$ |
11 |
|
$ |
4,551 |
|
$ |
182 |
|
$ |
|
|
Amortization expense of $325 and $314 was recorded in the quarters ended March 31, 2017 and 2016, respectively.
Future annual amortization expense of intangible assets is as follows:
2017 remainder of year |
|
$ |
678 |
|
2018 |
|
608 |
| |
2019 |
|
608 |
| |
2020 |
|
608 |
| |
2021 |
|
608 |
| |
Thereafter |
|
1,634 |
| |
|
|
$ |
4,744 |
|
(6) Convertible Notes
2014 Notes
On August 29, 2014, the Company entered into a Loan and Security Agreement for $21,535 of convertible promissory notes (the Convertible Notes or Notes), maturing on August 29, 2019. The Notes were issued to the owners of Rise in connection with the acquisition of Rise by the Company.
The Notes bear interest at 5% per annum, which is payable quarterly in arrears and accrued until the outstanding principal is paid in full at maturity. The notes are voluntarily pre-payable by the Company (in full) at any time and become due 180 days following an initial public offering. The Convertible Notes and any accrued and unpaid interest are convertible at the option of the holder at any time following an initial public offering or change in control into shares of the Companys common stock, up to a conversion cap. The conversion price is 85% of the consideration per share of Company common stock to be paid in such initial public offering, or consideration per share to be paid in such change of control, determined on a fully diluted basis assuming conversion of all Convertible Notes. The conversion cap is the number of shares of Company common stock equal to the sum of (a) a specified number of shares of Company common stock plus (b) a percentage of the number of additional shares of Companys common stock issued between July 8, 2014 and the date of such initial public offering or change in control.
Under provisions of the Convertible Notes, without the prior written consent of the majority of the holders of the Notes, the Company shall not (a) repurchase or redeem any stock or other security (other than employee or director stock subject to a stock repurchase agreement or stock restriction agreement upon termination of employment), (b) incur over $16,000 of debt, (c) pay dividends or distributions of over $2,000 in any given year, (d) incur certain indebtedness to affiliates, (e) pay management or similar fees in excess of customary compensation in the ordinary course of business, or (f) enter into affiliate agreements on terms less favorable than third party arms-length terms. The Company also is required to reserve for the shares of common stock issuable under the conversion terms of the Convertible Notes.
In November 2015, the Company entered into an amendment with the Note Holders to raise the debt cap to $19,000 and defer payment of interest for 1 year. The Company agreed to raise the interest rate from 5% to 6% for that year. In addition, upon the execution of the amendment in November 2015, the Company issued the lenders warrants to purchase 60,000 shares of common stock at a per share exercise price of $15.63. The warrants are immediately exercisable upon issuance, and other than in connection with an IPO, will expire on the ten-year anniversary of the date of issuance. The fair value of the warrants was estimated at $487 at the issuance date of November 5, 2015 using a Black-Scholes model and assuming: (i) expected volatility of 39%, (ii) risk free interest rate of 2.26%, (iii) an expected life of 10 years and (iv) no dividend payments. The fair value of the warrants was recorded as debt financing costs on the consolidated balance sheet, and will be amortized to interest expense over the term of the loan. All such warrants were outstanding as of December 31, 2016 and March 31, 2017.
In April 2016, the Company awarded the Note Holders with an additional 30,000 warrants as the Series K financing had not completed in time per the November 2015 amendment. The warrants are immediately exercisable upon issuance, and other than in connection with an IPO, will expire on the ten-year anniversary of the date of issuance. The fair value of the warrants was estimated at $235 at the issuance date of November 5, 2015 using a Black-Scholes model and assuming: (i) expected volatility of 39%, (ii) risk free interest rate of 1.88%, (iii) an expected life of 10 years and (iv) no dividend payments. The fair value of the warrants was recorded as debt financing costs on the consolidated balance sheet, and will be amortized to interest expense over the term of the loan. All such warrants were outstanding as of December 31, 2016 and March 31, 2017.
Upon issuance, the Company elected to record the Convertible Notes at fair value, which was $20,578 and $19,829 as of March 31, 2017 and December 31, 2016, respectively.
(6) Convertible Notes (Continued)
The gain recognized in interest income as a result of the change in the fair value of the Companys Convertible Notes was $749 and $655 for the quarters ended March 31, 2017 and 2016, respectively. Contractual interest expense recorded on the Companys Convertible Notes was $282 and $327 for the quarters ended March 31, 2017 and 2016, respectively.
Fair Value Option
ASC Subtopic 825-10 provides entities with an option to measure many financial instruments and certain other items at fair value. Under this guidance, unrealized gains and losses on items for which the fair value option has been elected are reported in earnings at each reporting period. As a result of the Company electing this option, the Company records the Convertible Notes at fair value. The Company records these notes at fair value in order to measure the liability at an amount that more accurately reflect the current economic environment in which the Company operates.
The following table presents the difference between the aggregate fair value and the aggregate unpaid principal balance of the Convertible Notes recorded at fair value:
|
|
Aggregate |
|
Aggregate |
|
Fair value |
| |||
Total Convertible Notes |
|
$ |
20,578 |
|
$ |
22,832 |
|
$ |
2,254 |
|
Less unamortized debt issuance cost |
|
478 |
|
|
|
|
| |||
Note payable, net |
|
$ |
20,100 |
|
$ |
22,832 |
|
$ |
2,254 |
|
(7) Fair Value Measurements
All financial instruments are measured and reported at fair value. The fair value hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:
· Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.
· Level 2 Inputs: Other than quoted prices included in Level 1, inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.
· Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.
(7) Fair Value Measurements (Continued)
Fair Value Hierarchy
A description of the valuation techniques applied to the Companys major categories of assets and liabilities measured at fair value on a recurring basis are as follows:
The fair value of the Convertible Notes was determined by utilizing a probability weighted discounted cash flow analysis which took into consideration market and general economic events as well as the Companys financial results and other data available. This analysis determined the amount to be paid on the notes in either cash or shares at the occurrence of certain events in which the Convertible Notes would be converted into shares of the Companys common stock or would be repaid to the holders of the Notes in cash. The probability weighted discounted cash flow analysis utilized assumptions related to the probability of the occurrence of each of the various events and appropriate discount rates for each of the scenarios.
Given that the valuation of the Convertible Notes utilized several unobservable inputs, the Company determined that the valuation of the Convertible Notes is a Level 3 valuation.
The following table presents a roll-forward of the fair value of Level 3 (significant unobservable inputs) Convertible Notes:
|
|
Total |
| |
Balance at December 31, 2016 |
|
$ |
19,829 |
|
Change in fair value included in interest expense |
|
749 |
| |
Balance at March 31, 2017 |
|
$ |
20,578 |
|
(8) Debt
Note Payable and Line of Credit
The Company entered into a Note Payable Pledge and Assignment Agreement (Loan and Security Agreement) with Silicon Valley Bank (SVB) totaling $5,000 in 2013. In 2014, the Company entered into a line of credit arrangement with SVB for advances up to approximately $3,000, secured by qualifying accounts receivable and subject to certain covenants and additional reporting requirements. LIBOR advances under the arrangement bear interest at the greater of 3.75% or LIBOR plus 2.5%. Prime-rate based advances bear interest at the Prime Rate plus 0.5%. As part of the Loan and Security Agreement, SVB issued standby letters of credit on behalf of the Company. The Company executed amendments to the Loan and Security Agreement during 2015, in which terms were amended to include the following: (i) borrowing capacity of $9,000, (ii) payment of interest only through June 30, 2016, and then straight-line amortization through December 1, 2018, (iii) interest rate for the revolving line of credit equal to the Prime Rate plus 0.5%, and interest for the term loan equal to the Prime Rate plus 0.75%, (iv) prepayment or termination fee of 3% if such payment occurs prior to December 17, 2016, 2% if such payment occurs prior to December 17, 2017, and 1% if such payment occurs on or after December 17, 2017, (v) final payment fee of 7% of the term loan amount. As of March 31, 2017 and December 31, 2016, the outstanding balance for the SVB Loan and Security Agreement was $1,493 and $1,706, respectively. As of March 31, 2017 and December 31, 2016 the interest rate for the revolving line and term loan was 4.5%.
(8) Debt (Continued)
Upon the amendments of the Loan and Security Agreement in December 2015, the Company issued the lenders warrants to purchase 3,199 shares of Preferred Series J at a per share exercise price of $20. The warrants are immediately exercisable upon issuance, and other than in connection with an IPO, will expire on the ten-year anniversary of the date of issuance. The fair value of the warrants was estimated at $45 at the issuance date of December 17, 2015. The fair value of the warrants was recorded as a liability on the consolidated balance sheet, which is being marked-to-market each reporting period, and the value of the warrants at the issuance date was recorded as a debt discount and will be amortized to interest expense over the term of the loan. All such warrants were outstanding as of March 31, 2017 and December 31, 2016. The estimated fair value of the warrants at March 31, 2017 and December 31, 2016 was $59 and $60, respectively.
Loan Agreement
On April 7, 2015, the Company entered into a loan agreement with Eastward Capital (Loan Agreement) maturing on January 31, 2019. The Loan Agreement required payments of interest through December 2015, at which point straight line amortization commenced for three years. The interest rate is 12.5% per annum, payable monthly. This facility has an 8% final payment fee and the Lender has a second priority security interest in the collateral subordinated to Silicon Valley Bank. As of March 31, 2017 and December 31, 2016, the outstanding balance was $6,479 and $7,254, respectively.
In connection with the Loan Agreement, the Company issued Eastward Capital warrants to purchase 50,000 shares of its Series J preferred stock at a per share exercise price of $20.00. The warrants are immediately exercisable upon issuance, and other than in connection with an IPO, will expire on the ten-year anniversary of the date of issuance. The fair value of the warrants was estimated at $605 at the issuance date. The fair value of the warrants was recorded as a liability on the consolidated balance sheet, which is being marked-to-market each reporting period, and the value of the warrants at the issuance date was recorded as a debt discount and will be amortized to interest expense over the term of the loan. All such warrants were outstanding as of March 31, 2017 and December 31, 2016. The estimated fair value of the warrants at March 31, 2017 and December 31, 2016 was $895 and $977, respectively.
The Company recorded interest expense of $308 and $289 in the quarters ended March 31, 2017 and 2016, respectively, related to the Eastward and SVB loan arrangements.
The following is a schedule of approximate future minimum principal payments under all lines of credit and note payable agreements at March 31, 2017:
2017 remainder of year |
|
$ |
3,113 |
|
2018 |
|
4,531 |
| |
2019 |
|
328 |
| |
Total |
|
$ |
7,972 |
|
(9) Preferred Stock
The Companys Board of Directors has authorized the issuance of 5,449,491 shares of $0.01 par value preferred stock.
(9) Preferred Stock (Continued)
Shares of preferred stock issued and outstanding are as follows:
|
|
March 31, |
| |
Series: |
|
|
| |
Series G |
|
|
369,822 |
|
Series I |
|
751,510 |
| |
Series J |
|
27,981 |
| |
Series K and K1 |
|
797,511 |
| |
Total issued and outstanding |
|
|
1,946,824 |
|
The liquidation preference for each of the preferred stock series are as follows:
|
|
March 31, |
|
December 31, |
| ||
Series J |
|
$ |
755 |
|
$ |
739 |
|
Series K |
|
15,374 |
|
15,083 |
| ||
Series I |
|
20,000 |
|
20,000 |
| ||
Series G |
|
7,854 |
|
7,707 |
| ||
|
|
$ |
43,983 |
|
$ |
43,529 |
|
The Series I liquidation preference does not include accruing dividends of $11,584 as of March 31, 2017. Such dividends are payable only upon declaration by the Board of Directors.
(10) Income Taxes
The Companys tax provision for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items arising in that quarter.
In each quarter, the Company updates its estimate of the annual effective tax rate, and if the estimated annual tax rate changes, the Company makes a cumulative adjustment in that quarter.
The Companys provision for income taxes and effective tax rates were as follows:
|
|
Quarter ended |
| ||||
|
|
2017 |
|
2016 |
| ||
Provision for income taxes |
|
$ |
151 |
|
$ |
50 |
|
Income before income taxes |
|
2,453 |
|
(508 |
) | ||
Effective tax rate |
|
6 |
% |
(10 |
)% | ||
(10) Income Taxes (Continued)
The Company maintained a valuation allowance against its deferred tax assets in certain jurisdictions as of March 31, 2017 and December 31, 2016. The Company will continue to evaluate all evidence in all jurisdictions in future periods to determine if a change in valuation allowance against its deferred tax assets is warranted.
(11) Commitments and Contingencies
Legal Proceedings
There are no legal proceedings pending against or involving the Company that in managements opinion, based on the current known facts and circumstances, are expected to have a material adverse effect on the Companys condensed consolidated financial position, cash flow, or results from operations.
(12) Divestiture
On January 31, 2017, the Company completed the sale of two legal entities comprising the Companys GCM business for total consideration of $4,025, and recorded a gain on sale of approximately $2,369 in the condensed consolidated statement of operations and comprehensive income (loss) during the quarter ended March 31, 2017.
(13) Subsequent Events
The Company has assessed the impact of subsequent events through June 20, 2017, the date of issuance of the condensed consolidated financial statements for the quarter ended March 31, 2017, and identified the following subsequent event.
On June 19, 2017, Teladoc, Inc. announced that they have entered into an agreement under which Teladoc, Inc. will acquire the Company for approximately $440 million. Under the terms of the transaction, Teladoc, Inc. will acquire 100% of the equity of the Company for approximately $375 million in cash and $65 million of Teladoc, Inc. common stock. The consummation of the sale is subject to certain customary closing conditions and regulatory approvals.
Exhibit 99.3
HISTORICAL FINANCIAL STATEMENTS OF BEST DOCTORS HOLDINGS, INC.
Index to Consolidated Financial Statements
Contents |
|
Page |
Audited Consolidated Financial Statements as of December 31, 2016 and 2015 and for the years ended December 31, 2016, 2015 and 2014 |
|
|
Independent Auditors Report |
|
2 |
Consolidated Balance Sheets |
|
3 |
Consolidated Statements of Operations and Comprehensive Loss |
|
5 |
Consolidated Statements of Preferred Stock and Stockholders Deficit |
|
6 |
Consolidated Statements of Cash Flows |
|
7 |
Notes to Consolidated Financial Statements |
|
|
Independent Auditors Report
The Board of Directors
Best Doctors Holdings, Inc.:
We have audited the accompanying consolidated financial statements of Best Doctors Holdings, Inc. and its subsidiaries, which comprise the consolidated balance sheets as of December 31, 2016 and 2015, and the related consolidated statements of operations and comprehensive loss, preferred stock and stockholders deficit, and cash flows for each of the years in the three-year period ended December 31, 2016, and the related notes to the consolidated financial statements.
Managements Responsibility for the Financial Statements
Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.
Auditors Responsibility
Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entitys preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entitys internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Opinion
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Best Doctors Holdings, Inc. and its subsidiaries as of December 31, 2016 and 2015, and the results of their operations and their cash flows for each of the years in the three-year period ended December 31, 2016, in accordance with U.S. generally accepted accounting principles.
/s/ KPMG LLP
Cambridge, Massachusetts
May 5, 2017, except for the reclassification of preferred stock as described in Note 11(h), which is as of June 20, 2017.
BEST DOCTORS HOLDINGS, INC.
Consolidated Balance Sheets
December 31, 2016 and 2015
(In thousands, except share data)
|
|
2016 |
|
2015 |
| ||
Assets |
|
|
|
|
| ||
Current assets: |
|
|
|
|
| ||
Cash and cash equivalents |
|
$ |
20,151 |
|
$ |
7,151 |
|
Accounts receivable, net |
|
9,567 |
|
9,982 |
| ||
Current income taxes receivable |
|
|
|
9 |
| ||
Prepaid expenses and other current assets |
|
1,788 |
|
1,719 |
| ||
Total current assets |
|
31,506 |
|
18,861 |
| ||
Property and equipment |
|
29,718 |
|
27,190 |
| ||
Less accumulated depreciation and amortization |
|
(20,887 |
) |
(19,058 |
) | ||
Total property and equipment, net |
|
8,831 |
|
8,132 |
| ||
Other assets: |
|
|
|
|
| ||
Intangible assets: |
|
|
|
|
| ||
Goodwill |
|
23,316 |
|
23,316 |
| ||
Intangible assets, net |
|
5,801 |
|
7,058 |
| ||
Total Intangible assets, net |
|
29,117 |
|
30,374 |
| ||
Security deposits and other assets |
|
526 |
|
587 |
| ||
Long term deferred tax assets |
|
117 |
|
183 |
| ||
Other receivable |
|
2,858 |
|
2,692 |
| ||
Total assets |
|
$ |
72,955 |
|
$ |
60,829 |
|
See accompanying notes to consolidated financial statements.
BEST DOCTORS HOLDINGS, INC.
Consolidated Balance Sheets
December 31, 2016 and 2015
(In thousands, except share data)
|
|
2016 |
|
2015 |
| ||
Liabilities, Preferred Stock and Stockholders Deficit |
|
|
|
|
| ||
Current liabilities: |
|
|
|
|
| ||
Accounts payable |
|
$ |
1,439 |
|
$ |
1,068 |
|
Accrued expenses |
|
7,755 |
|
7,578 |
| ||
Accrued payroll and commissions |
|
8,912 |
|
5,428 |
| ||
Current portion of notes payable and line of credit |
|
4,101 |
|
8,600 |
| ||
Deferred revenue |
|
1,886 |
|
2,117 |
| ||
Current portion of income tax payable |
|
751 |
|
1,176 |
| ||
Warrant liability |
|
3,131 |
|
722 |
| ||
Total current liabilities |
|
27,975 |
|
26,689 |
| ||
Other liabilities: |
|
|
|
|
| ||
Long term convertible notes payable |
|
19,302 |
|
18,415 |
| ||
Long term notes payable |
|
4,941 |
|
8,451 |
| ||
Long term tax liability |
|
1,124 |
|
1,384 |
| ||
Long term deferred revenue |
|
103 |
|
107 |
| ||
Long term deferred tax liability |
|
779 |
|
656 |
| ||
Total liabilities |
|
54,224 |
|
55,702 |
| ||
Commitments and Contingencies (note 14) |
|
|
|
|
| ||
Preferred stock: |
|
|
|
|
| ||
Series G, I, J, K, and K-1 $0.01 par value, 5,449,491 shares authorized at December 31,2016; 1,903,474 shares issued and outstanding (liquidation preferences of $43,529) at December 31, 2016; $0.01 par value, 5,517,417 shares authorized at December 31, 2015; 1,149,313 shares issued and outstanding (liquidation preferences of $27,795) at December 31, 2015 |
|
38,923 |
|
23,785 |
| ||
Stockholders deficit: |
|
|
|
|
| ||
Common stock: |
|
|
|
|
| ||
$0.01 par value, 10,000,000 shares authorized at December 31, 2016; 6,636,460 shares issued and outstanding at December 31, 2016; 6,558,617 shares issued and outstanding at December 31, 2015 |
|
67 |
|
66 |
| ||
Additional paid-in capital |
|
60,838 |
|
57,398 |
| ||
Accumulated other comprehensive loss |
|
(3,004 |
) |
(2,075 |
) | ||
Accumulated deficit |
|
(78,093 |
) |
(74,047 |
) | ||
Total stockholders deficit |
|
(20,192 |
) |
(18,658 |
) | ||
Total liabilities, preferred stock and stockholders deficit |
|
$ |
72,955 |
|
$ |
60,829 |
|
See accompanying notes to consolidated financial statements.
BEST DOCTORS HOLDINGS, INC.
Consolidated Statements of Operations and Comprehensive Loss
Years ended December 31, 2016, 2015, and 2014
(In thousands)
|
|
2016 |
|
2015 |
|
2014 |
| |||
Services revenue |
|
$ |
96,849 |
|
$ |
84,585 |
|
$ |
81,305 |
|
Cost of services revenue |
|
34,699 |
|
35,279 |
|
30,427 |
| |||
Gross margin |
|
62,150 |
|
49,306 |
|
50,878 |
| |||
Selling, general, and administrative expenses |
|
57,479 |
|
67,970 |
|
66,284 |
| |||
Income (loss) from operations |
|
4,671 |
|
(18,664 |
) |
(15,406 |
) | |||
Other expense: |
|
|
|
|
|
|
| |||
Foreign currency transaction loss |
|
(236 |
) |
(674 |
) |
(429 |
) | |||
Interest (expense) income, net |
|
(6,489 |
) |
(1,697 |
) |
224 |
| |||
Other expense, net |
|
(1,150 |
) |
(369 |
) |
(204 |
) | |||
Other expense |
|
(7,875 |
) |
(2,740 |
) |
(409 |
) | |||
Loss from continuing operations before income tax (expense) benefit |
|
(3,204 |
) |
(21,404 |
) |
(15,815 |
) | |||
Income tax (expense) benefit |
|
(704 |
) |
4,555 |
|
4,954 |
| |||
Loss from continuing operations |
|
(3,908 |
) |
(16,849 |
) |
(10,861 |
) | |||
Discontinued operations, net of income taxes (note 15): |
|
|
|
|
|
|
| |||
Income from discontinued operations (including 2015 gain on sale of $2,807) |
|
|
|
7,812 |
|
7,155 |
| |||
Income tax expense |
|
|
|
(5,518 |
) |
(5,586 |
) | |||
Net loss |
|
$ |
(3,908 |
) |
$ |
(14,555 |
) |
$ |
(9,292 |
) |
Comprehensive loss: |
|
|
|
|
|
|
| |||
Net loss |
|
$ |
(3,908 |
) |
$ |
(14,555 |
) |
$ |
(9,292 |
) |
Foreign currency unrealized loss on translation adjustment |
|
(929 |
) |
(1,863 |
) |
(777 |
) | |||
Unrealized gain (loss) on investments from discontinued operations |
|
|
|
(395 |
) |
1,408 |
| |||
Other comprehensive income (loss), net of tax |
|
(929 |
) |
(2,258 |
) |
631 |
| |||
Comprehensive loss |
|
$ |
(4,837 |
) |
$ |
(16,813 |
) |
$ |
(8,661 |
) |
See accompanying notes to consolidated financial statements.
BEST DOCTORS HOLDINGS, INC.
Consolidated Statements of Preferred Stock and Stockholders Deficit
Years ended December 31, 2016, 2015 and 2014
(In thousands, except share data)
|
|
Preferred stock |
|
|
Common stock |
|
Additional |
|
Accumulated |
|
Accumulated |
|
Total |
| ||||||||||
|
|
Shares |
|
Value |
|
|
Shares |
|
Value |
|
capital |
|
income (loss) |
|
deficit |
|
deficit |
| ||||||
Balances at December 31, 2013 |
|
3,649,313 |
|
$ |
68,375 |
|
|
3,070,951 |
|
$ |
31 |
|
$ |
3,491 |
|
$ |
(448 |
) |
$ |
(49,765 |
) |
$ |
(46,691 |
) |
Accretion of issuance costs |
|
|
|
216 |
|
|
|
|
|
|
|
|
|
|
(216 |
) |
(216 |
) | ||||||
Stock-based compensation expense |
|
|
|
|
|
|
|
|
|
|
1,542 |
|
|
|
|
|
1,542 |
| ||||||
Conversion of preferred stock to common stock |
|
|
|
|
|
|
119,937 |
|
1 |
|
2,062 |
|
|
|
|
|
2,063 |
| ||||||
Warrant Issuance |
|
|
|
|
|
|
788,277 |
|
8 |
|
1,299 |
|
|
|
|
|
1,307 |
| ||||||
Exercise of stock options |
|
|
|
|
|
|
|
|
|
|
753 |
|
|
|
|
|
753 |
| ||||||
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9,292 |
) |
(9,292 |
) | ||||||
Other comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
631 |
|
|
|
631 |
| ||||||
Balances at December 31, 2014 |
|
3,649,313 |
|
68,591 |
|
|
3,979,165 |
|
40 |
|
9,147 |
|
183 |
|
(59,273 |
) |
(49,903 |
) | ||||||
Accretion of issuance costs |
|
|
|
219 |
|
|
|
|
|
|
|
|
|
|
(219 |
) |
(219 |
) | ||||||
Stock-based compensation expense |
|
|
|
|
|
|
|
|
|
|
2,443 |
|
|
|
|
|
2,443 |
| ||||||
Conversion of preferred stock to common stock |
|
(2,500,000 |
) |
(45,025 |
) |
|
2,500,000 |
|
25 |
|
45,000 |
|
|
|
|
|
45,025 |
| ||||||
Warrant Issuance |
|
|
|
|
|
|
|
|
|
|
487 |
|
|
|
|
|
487 |
| ||||||
Exercise of stock options |
|
|
|
|
|
|
79,452 |
|
1 |
|
321 |
|
|
|
|
|
322 |
| ||||||
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(14,555 |
) |
(14,555 |
) | ||||||
Other comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
(2,258 |
) |
|
|
(2,258 |
) | ||||||
Balances at December 31, 2015 |
|
1,149,313 |
|
23,785 |
|
|
6,558,617 |
|
66 |
|
57,398 |
|
(2,075 |
) |
(74,047 |
) |
(18,658 |
) | ||||||
Accretion of issuance costs |
|
|
|
55 |
|
|
|
|
|
|
|
|
|
|
(55 |
) |
(55 |
) | ||||||
Stock-based compensation expense |
|
|
|
|
|
|
|
|
|
|
1,399 |
|
|
|
|
|
1,399 |
| ||||||
Issuance of Series K Preferred Stock |
|
750,000 |
|
15,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Accrued Dividends Series K-1 Preferred Stock |
|
4,161 |
|
83 |
|
|
|
|
|
|
|
|
|
|
(83 |
) |
(83 |
) | ||||||
Beneficial conversion feature and Warrant Issuance |
|
|
|
|
|
|
|
|
|
|
1,940 |
|
|
|
|
|
1,940 |
| ||||||
Exercise of stock options |
|
|
|
|
|
|
77,843 |
|
1 |
|
101 |
|
|
|
|
|
102 |
| ||||||
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,908 |
) |
(3,908 |
) | ||||||
Other comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
(929 |
) |
|
|
(929 |
) | ||||||
Balances at December 31, 2016 |
|
1,903,474 |
|
$ |
38,923 |
|
|
6,636,460 |
|
$ |
67 |
|
$ |
60,838 |
|
$ |
(3,004 |
) |
$ |
(78,093 |
) |
$ |
(20,192 |
) |
BEST DOCTORS HOLDINGS, INC.
Consolidated Statements of Cash Flows
Years ended December 31, 2016, 2015, and 2014
(In thousands)
|
|
2016 |
|
2015 |
|
2014 |
| |||
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(3,908 |
) |
$ |
(14,555 |
) |
$ |
(9,292 |
) |
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: |
|
|
|
|
|
|
| |||
Provision for bad debts |
|
516 |
|
148 |
|
47 |
| |||
Depreciation and amortization |
|
3,102 |
|
5,075 |
|
6,297 |
| |||
Amortization of investments |
|
|
|
153 |
|
271 |
| |||
Excess tax benefit from share-based compensation |
|
|
|
|
|
(753 |
) | |||
Change in warrant liability |
|
4,234 |
|
722 |
|
|
| |||
Gain (Loss) on investments and other noncash income |
|
|
|
405 |
|
(262 |
) | |||
Gain on sale of business |
|
|
|
(2,808 |
) |
|
| |||
Stock-based compensation expense |
|
1,399 |
|
2,443 |
|
1,542 |
| |||
Change in fair value of convertible notes payable |
|
(350 |
) |
(1,255 |
) |
(892 |
) | |||
Changes in operating assets and liabilities, net of effects of acquisition: |
|
|
|
|
|
|
| |||
Accounts receivable |
|
182 |
|
(6,654 |
) |
(2,389 |
) | |||
Deferred policy acquisition costs |
|
|
|
(1,434 |
) |
(4,905 |
) | |||
Prepaid expenses and other assets |
|
(467 |
) |
(580 |
) |
565 |
| |||
Other noncurrent assets |
|
559 |
|
(148 |
) |
(310 |
) | |||
Income tax receivable |
|
|
|
|
|
232 |
| |||
Long-term tax liability |
|
|
|
|
|
(2,111 |
) | |||
Accounts payable, accrued expenses and other current liabilities |
|
4,539 |
|
(4,330 |
) |
6,588 |
| |||
Deferred revenue |
|
(44 |
) |
9,959 |
|
15,458 |
| |||
Deferred taxes |
|
(221 |
) |
164 |
|
(1,462 |
) | |||
Reserve for outstanding losses and loss adjustment expenses |
|
|
|
2,339 |
|
2,322 |
| |||
Net cash (used in) provided by operating activities |
|
9,541 |
|
(10,356 |
) |
10,946 |
| |||
Cash flows from investing activities: |
|
|
|
|
|
|
| |||
Proceeds from sales of investments |
|
|
|
23,980 |
|
77,419 |
| |||
Purchases of investments |
|
|
|
(28,212 |
) |
(86,425 |
) | |||
Acquisition of business, net of cash |
|
|
|
|
|
110 |
| |||
Release of restricted cash |
|
|
|
(42 |
) |
434 |
| |||
Proceeds from sale of business, net of $20,761 cash transferred out with sale (note 14) |
|
|
|
(13,277 |
) |
|
| |||
Purchases of property and equipment |
|
(2,542 |
) |
(4,612 |
) |
(4,564 |
) | |||
Net cash used by investing activities |
|
(2,542 |
) |
(22,163 |
) |
(13,026 |
) | |||
Cash flows from financing activities: |
|
|
|
|
|
|
| |||
Proceeds from exercise of options to purchase common stock |
|
101 |
|
324 |
|
1,306 |
| |||
Proceeds from (repayments on) note payable and line of credit, net |
|
(3,872 |
) |
9,585 |
|
7,000 |
| |||
Proceeds from issuance of Series K Preferred Stock |
|
10,000 |
|
|
|
|
| |||
Issuance of Warrants |
|
|
|
|
|
|
| |||
Excess tax benefit from share based compensation |
|
|
|
|
|
753 |
| |||
Repayment of capital lease obligations |
|
|
|
(104 |
) |
(267 |
) | |||
Net cash provided by financing activities |
|
6,229 |
|
9,805 |
|
8,792 |
| |||
Effect of exchange rate changes on cash |
|
(228 |
) |
(573 |
) |
(491 |
) | |||
Net (decrease) increase in cash and cash equivalents |
|
13,000 |
|
(23,287 |
) |
6,221 |
| |||
Cash and cash equivalents continuing operations, beginning of year |
|
7,151 |
|
9,214 |
|
10,098 |
| |||
Cash and cash equivalents discontinued operations, beginning of year |
|
|
|
21,224 |
|
14,119 |
| |||
Cash and cash equivalents, beginning of year |
|
7,151 |
|
30,438 |
|
24,217 |
| |||
Cash and cash equivalents continuing operations, end of year |
|
20,151 |
|
7,151 |
|
9,214 |
| |||
Cash and cash equivalents discontinued operations, end of year |
|
|
|
|
|
21,224 |
| |||
Cash and cash equivalents, end of year |
|
$ |
20,151 |
|
$ |
7,151 |
|
$ |
30,438 |
|
See accompanying notes to consolidated financial statements.
BEST DOCTORS HOLDINGS, INC.
Consolidated Statements of Cash Flows (Continued)
Years ended December 31, 2016, 2015, and 2014
(In thousands)
|
|
2016 |
|
2015 |
|
2014 |
| |||
Supplemental disclosures of cash flow information: |
|
|
|
|
|
|
| |||
Cash paid for interest |
|
$ |
1,441 |
|
$ |
2,497 |
|
$ |
255 |
|
Cash paid for income and other taxes |
|
622 |
|
416 |
|
4,310 |
| |||
Supplemental disclosures of noncash transactions: |
|
|
|
|
|
|
| |||
Accretion of issuance costs on preferred stock |
|
$ |
55 |
|
$ |
219 |
|
$ |
216 |
|
Beneficial conversion feature and warrant issuance |
|
1,940 |
|
1,136 |
|
|
| |||
Accrued purchases of property and equipment |
|
364 |
|
324 |
|
725 |
| |||
Issuance of convertible notes payable as consideration for purchase of Rise |
|
|
|
|
|
21,535 |
| |||
Issuance of common stock as consideration for purchase of Rise |
|
|
|
|
|
2,062 |
|
See accompanying notes to consolidated financial statements.
(1) Organization and Nature of Business
Best Doctors Holdings, Inc. (the Company) provides technology innovations and services to help employers, health plans and provider organizations ensure that their members combat medical uncertainty with access to the best medical minds. Core services include, but are not limited to, Critical Care InterConsultation® (addresses the highly complex, time-sensitive needs of members requiring acute, in-patient care via immediate expert guidance), InterConsultation® (provides members and their treating physicians with an in-depth analysis and complete case review from nationally renowned experts in the members condition), Ask the ExpertSM (enables members to get specific answers to personal health care questions from nationally renowned experts), and Find a Best DoctorSM (identifies expert physicians best suited to help initiate hands-on care for members who do not yet have a diagnosis, or who are looking for a new treating physician). These services are sold mainly in the United States (U.S.), Europe, Canada and Japan. The Workers Compensation CatCare Program and Legacy Program, available in the U.S., provide case review with guidance from top experts in trauma, rehabilitation and other specialties, helping to reduce errors and ensure that best practices are being followed (collectively, these services are referred to herein as Services).
On June 30, 2015, the Company sold its insurance business, and as such determined that the insurance business qualified for discontinued operations presentation in these consolidated financial statements. See note 15 to the consolidated financial statements, which includes the presentation of the associated financial position and results of operations of the Companys insurance operations which have been separately reported as discontinued operations for all periods presented.
(2) Significant Accounting Policies
(a) Basis of Presentation and Principles of Consolidation
The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP).
The consolidated financial statements include the accounts of Best Doctors Holdings, Inc. and its wholly owned subsidiaries.
All intercompany transactions and balances have been eliminated in consolidation.
(b) Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures in the consolidated financial statements. Estimates also impact the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
(c) Foreign Currency
The functional currency for each of the Companys foreign subsidiaries is the local currency. All assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are translated at the weighted average exchange rate during the period. Cumulative translation gains or losses are included as a separate component of stockholders equity and reported as a part of accumulated other comprehensive income.
Foreign currency gains and losses on transactions denominated in a currency other than the respective subsidiarys functional currency are included in other income (loss) in the accompanying consolidated statements of operations and comprehensive loss.
For the years ended December 31, 2016, 2015 and 2014, the Company recorded foreign currency transaction losses of $236 and $674 and $429, respectively. The Company has not utilized hedging strategies with respect to such foreign exchange exposure.
(2) Significant Accounting Policies (Continued)
(d) Comprehensive Loss
Comprehensive loss includes all changes in stockholders equity during a period other than those resulting from investments by and distributions to stockholders. Comprehensive loss includes net loss and other comprehensive loss. The Companys other comprehensive loss includes foreign currency translation adjustments and unrealized loss on investments.
The accumulated balances for each item of other comprehensive loss are as follows:
|
|
Foreign |
|
Unrealized |
|
Accumulated |
| |||
Beginning balance, January 1, 2014 |
|
$ |
565 |
|
$ |
(1,013 |
) |
$ |
(448 |
) |
Net current period other comprehensive income/(loss), net of Tax effect of $0 |
|
(777 |
) |
1,408 |
|
631 |
| |||
Ending balance, December 31, 2014 |
|
(212 |
) |
395 |
|
183 |
| |||
Net period other comprehensive loss net of tax effect of $0 |
|
(1,863 |
) |
(395 |
) |
(2,258 |
) | |||
Ending balance, December 31, 2015 |
|
(2,075 |
) |
|
|
(2,075 |
) | |||
Net period other comprehensive loss net of tax effect of $0 |
|
(929 |
) |
|
|
(929 |
) | |||
Ending balance, December 31, 2016 |
|
$ |
(3,004 |
) |
$ |
|
|
$ |
(3,004 |
) |
(e) Services Revenue Recognition
Revenues are recognized when persuasive evidence of an arrangement exists, the services are performed, the price is fixed or determinable, and there is a reasonable assurance of collection. Services revenues, other than per case fees from customers, are recognized ratably over the contract period. Per case fees are recognized when cases are completed.
Certain services revenue contracts entered into by the Company and its customers have measurable performance guarantees that may require the Company to return partial payment to the customer if certain customer service goals or savings are not realized in a given period. The Company has recorded a reserve in accrued expenses of $1,665 and $1,322, and a reduction to service revenue of $360, $881, and $2,002 for the years ended December 31, 2016, 2015 and 2014, respectively, relating to these performance guarantees.
Deferred revenue is recorded in situations where payments are received from customers in advance of providing services. Such amounts are recognized as revenue when the associated services are provided.
(f) Fair Value of Financial Instruments
Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurement for assets and liabilities which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk.
The carrying amounts reported on the consolidated balance sheets for cash and cash equivalents approximate fair value based on the on-demand nature of cash and the short-term maturity and the daily
(2) Significant Accounting Policies (Continued)
pricing mechanisms for cash equivalents. Other assets and liabilities with short-term and intermediate-term maturities and defined settlement amounts, including receivables, payables, and accrued liabilities, are reported at their contractual amounts, which approximate fair value. Debt balances, other than convertible notes which are reported using the fair value option, approximate the carrying amount.
(g) Concentration of Credit Risk
The Company places its cash and cash equivalents in highly rated financial institutions, which are continually reviewed by senior management for financial stability. All noninterest bearing transaction accounts held in the U.S. are fully insured, regardless of the balance of the account. Generally, the Companys cash and cash equivalents in U.S. interest-bearing accounts and in foreign countries exceed financial depository insurance limits. Based on the institutions in which funds are held, the Company believes that its cash and cash equivalents are not exposed to significant credit risk.
(h) Cash and Cash Equivalents
Cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. Cash equivalents consist of money market funds as of December 31, 2016 and 2015.
(i) Allowance for Doubtful Accounts
Accounts receivable are presented net of an allowance for doubtful collections of approximately $637 and $292 at December 31, 2016 and 2015, respectively. In determining this allowance, objective evidence that any receivable is uncollectible, as well as a historical pattern of collections on the entire face amount of the portfolio of accounts receivable, is used to estimate what may not be collectible at the balance sheet date.
(j) Property and Equipment
Property and equipment are reported at cost, net of accumulated depreciation, and are depreciated over the assets estimated useful lives, primarily 5 years, using the straight-line method. Depreciation of leasehold improvements is computed using the straight-line method over the lesser of the estimated useful life of the asset or the term of the lease. Repairs and maintenance are expensed as incurred.
(k) Internally Developed Software Costs
The Company capitalizes certain costs incurred in connection with developing or modifying software for internal use. Qualifying internally developed software costs are capitalized and amortized over the estimated useful life of the software, typically 5 years. The Company evaluates internally developed software for impairment at least annually, and whenever changes in circumstances indicate impairment could exist.
(l) Goodwill and Intangible Assets
Goodwill represents the excess of the aggregate purchase price over the fair value of the net assets acquired in a business combination and is reviewed for impairment at least annually. Accounting Standards Codification Topic 350, Intangibles Goodwill and Other, (ASC 350) permits the assessment of qualitative factors to determine whether events and circumstances lead to the conclusion that it is necessary to perform the two-step goodwill impairment test required under ASC 350. The qualitative assessment management performs takes into consideration the following factors: general economic conditions, industry specific performance, and changes in carrying value of the reporting unit.
In the first step of the two-step test, the fair value of the reporting unit is compared with its carrying value (including goodwill). If the fair value of the reporting unit is less than its carrying value, an indication of goodwill impairment exists for the reporting unit and the enterprise must perform step two of the impairment test (measurement). In step two, an impairment loss is recognized for any excess of the carrying amount of the reporting units goodwill over the implied fair value of that goodwill. The implied fair value of goodwill is determined by allocating the fair value of the reporting unit in a manner similar to a purchase price allocation. The residual fair value after this allocation is the implied fair value of the reporting unit goodwill.
(2) Significant Accounting Policies (Continued)
Fair value of the reporting unit is determined using income and market methodologies based on managements estimates of forecasted cash flows and market value. If the fair value of the reporting unit exceeds its carrying value, step two need not be performed.
Goodwill and intangible assets with indefinite lives are evaluated annually for impairment and whenever changes in conditions indicate that the fair value is more likely than not below its carrying value. No impairment charges were recorded during the years ended December 31, 2016, 2015 and 2014 including upon disposal of the Companys insurance business in June 2015. See note 15.
Identifiable intangible assets with definite lives are amortized on a straight-line basis over their estimated useful lives, which are 3 to 10 years from the date of original acquisition. Identifiable intangible assets consist of customer contracts, acquired technology, noncompetition contracts, and trade names. In 2015, the Company accelerated amortization associated with a tradename that will no longer be in use going forward. Refer to note 5.
(m) Long-Lived Assets
Long-lived assets, such as property and equipment, and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment expense is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.
(n) Stock-Based Compensation
Stock-based compensation is measured at the grant date, based upon the fair value of the award, and is recognized as an expense over the employees requisite service period (generally the vesting period of the equity grant).
The Company periodically grants stock options for a fixed number of shares of common stock to its employees, directors, and nonemployee contractors, with an exercise price greater than or equal to the fair market value of its common stock at the date of the grant. The Companys stock-based compensation arrangements vest over periods of up to four years.
The Company recorded stock-based compensation expense of $1,399, $2,443 and $1,542 for the years ended December 31, 2016, 2015 and 2014, respectively, which is included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss.
The Company estimates the fair value of stock options using a Black-Scholes valuation model. Key inputs used to estimate the fair value of stock options include the exercise price of the award, the expected option term, expected stock price volatility which is calculated using the volatility rates of comparable companies as the Company is not publicly traded, the risk-free interest rate from U.S. Treasury bonds, and the Companys expected annual dividend yield. The total fair value is reduced by estimated forfeitures.
(o) Income Taxes
The Company accounts for income taxes using the asset and liability method, under which deferred tax assets and liabilities are recorded based on the expected future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to be in effect
(2) Significant Accounting Policies (Continued)
when those temporary differences are expected to reverse. A valuation allowance is established when management believes it is more likely than not that a deferred tax asset will not be realized.
An entity is permitted to recognize the benefits of uncertain tax positions only when the position is more likely than not to be sustained in the event of examination by tax authorities based on the technical merits of the position. For tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced by the largest benefit that has a greater than fifty percent likelihood of being realized upon the ultimate settlement with the relevant taxing authority.
(p) Advertising Costs
Advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss. Advertising expenses of $351, $569 and $638 were recorded in fiscal 2016, 2015 and 2014, respectively.
(q) Acquisitions
In an acquisition of a business, acquired assets and liabilities, including any future contingent payments, are recorded at fair value as of the acquisition date, and the difference between the purchase consideration and the net assets acquired is recorded as goodwill. Intangible assets are identified and recognized separately from goodwill. Professional service expenses related to acquisitions are expensed as incurred and included in selling, general and administrative expenses, on the consolidated statements of operations and comprehensive loss.
(r) Fair Value Option
Under the Fair Value Option Subsections of FASB ASC Subtopic 825-10, Financial Instruments Overall, the Company has the irrevocable option to report most financial assets and financial liabilities at fair value on an instrument-by-instrument basis, with changes in fair value reported in earnings. See notes 6 and 7 to the consolidated financial statements.
(s) Recent Accounting Pronouncements
In April 2015, the FASB issued ASU 2015-03, Interest Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. This ASU requires that debt issuance costs are to be presented in the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with debt discounts or premiums. The ASU is effective for financial statements issued for fiscal years beginning after December 15, 2015, with early adoption permitted. The Company adopted ASU 2015-03 on a prospective basis for the year ended December 31, 2015.
In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes, which eliminates the current requirement for companies to present deferred tax liabilities and assets as current and noncurrent in a classified balance sheet. Instead, companies will be required to classify all deferred tax assets and liabilities as noncurrent. The amendment is effective for annual fiscal periods beginning after December 15, 2017, with early adoption permitted. Upon adoption, the ASU may be applied either prospectively or retrospectively to all prior periods presented. The Company adopted ASU 2015-17 during the year ending December 31, 2015, on a prospective basis.
In May 2014 the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which requires us to recognize revenue when a customer obtains control rather than when we have transferred substantially all risks and rewards of a good or service and requires expanded disclosures. ASU 2014-09, as amended, is effective for us beginning January 1, 2019. We have not yet determined whether we will adopt the provisions of ASU 2014-09 on a retrospective basis or through a cumulative adjustment to equity. We continue to assess the overall impact the adoption of ASU 2014-09 will have on our consolidated financial statements.
(2) Significant Accounting Policies (Continued)
In February 2016, the FASB issued ASU No. 2016-02, Leases, replacing existing lease accounting guidance. The new standard introduces a lessee model that would require entities to recognize assets and liabilities for most leases, but recognize expenses on their income statements in a manner similar to current accounting. The ASU does not make fundamental changes to existing lessor accounting. However, it modifies what qualifies as a sales-type and direct financing lease and related accounting and aligns a number of the underlying principles with those of the new revenue standard, ASU No. 2014-09, such as evaluating how collectability should be considered and determining when profit can be recognized. The guidance eliminates existing real estate-specific provisions and requires expanded qualitative and quantitative disclosures. The standard requires modified retrospective transition by which it is applied at the beginning of the earliest comparative period presented in the year of adoption. For Best Doctors, the ASU is effective January 1, 2020. The Company is currently assessing this ASUs impact on Best Doctors consolidated results of operations and financial condition.
In March 2016, the FASB issued ASU 2016-09, Compensation Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU No. 2016-09 changed aspects of the accounting for share-based payment award transactions, including: (1) accounting for income taxes; (2) classification of excess tax benefits on the statement of cash flows; (3) forfeitures; (4) minimum statutory tax withholding requirements; and (5) classification of employee taxes paid on the statement of cash flows when an employer withholds shares for tax-withholding purposes. The provisions of ASU 2016-02 are effective for annual periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04, Intangibles Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment. ASU 2017-04 eliminates Step 2 of the two-step impairment test, which requires entities to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Rather, entities will record an impairment charge based on the excess of a reporting units carrying amount over its fair value, as computed in Step 1. Entities may continue to perform the qualitative goodwill impairment assessment to determine whether the quantitative impairment test is necessary. The provisions of ASU 2017-04 are effective for annual periods beginning after December 15, 2021, with early adoption permitted for annual goodwill impairment tests performed after January 1, 2017.
(3) Acquisition
On August 29, 2014, the Company completed the acquisition of Rise Health, Inc. (Rise), a leading population health management company. Among other assets, Rise has built a comprehensive technology platform that develops intelligent, actionable insights regarding data at a population health level, and supports care delivery teams in taking action at the member level. Rise also provides tools to help payers and providers manage the transition from fee-for-service to value-based care. Together with Rise, the Company has added increased data integration and advanced analytics capabilities to its medical expertise solutions. Rise was acquired to provide a synergistic technological platform to bring together data analytics and help consumers get the right diagnosis and treatment. The total purchase price for the acquisition was $23,091.
(3) Acquisition (Continued)
The Company accounted for the acquisition of Rise as a business combination using the acquisition method. The following table summarizes the consideration issued to acquire Rise, the amounts of identified assets acquired and the liabilities assumed at the acquisition date:
Fair value of convertible promissory notes issued |
|
$ |
21,029 |
|
Fair value of Company common stock issued |
|
2,062 |
| |
Fair value of total consideration transferred |
|
$ |
23,091 |
|
Recognized amounts of identifiable assets acquired and liabilities assumed included:
Current assets |
|
$ |
355 |
|
Fixed assets |
|
19 |
| |
Intangible assets |
|
7,680 |
| |
Deferred taxes |
|
(1,550 |
) | |
Accrued expenses and other current liabilities |
|
(970 |
) | |
Total identifiable net assets Acquired |
|
5,534 |
| |
Goodwill |
|
17,557 |
| |
Total |
|
$ |
23,091 |
|
The Company believes the resulting amount of goodwill reflects the synergistic benefits expected to result from the application of the Companys experience and resources to the operations at Rise, which the Company believes will lead to enhanced growth and operating margins. Acquisition related costs included in selling, general and administrative expenses were $255.
(4) Related Party Transactions
The Company earns revenues from certain investors in the Company. During fiscal 2016, 2015 and 2014, the Company recorded $914, $668 and $496 of revenue pursuant to such agreements which were included in service revenues in the consolidated statements of operations and comprehensive loss, respectively.
(5) Property and Equipment
Property and equipment as of December 31, 2016 and 2015 are as follows:
|
|
2016 |
|
2015 |
| ||
Equipment and hardware |
|
$ |
4,772 |
|
$ |
4,608 |
|
Software |
|
19,427 |
|
17,094 |
| ||
Furniture and fixtures |
|
1,100 |
|
1,073 |
| ||
Capital equipment lease |
|
1,869 |
|
1,869 |
| ||
Leasehold improvements |
|
2,550 |
|
2,546 |
| ||
Accumulated depreciation and amortization |
|
(20,887 |
) |
(19,058 |
) | ||
Total property and equipment, net |
|
$ |
8,831 |
|
$ |
8,132 |
|
The Company recorded depreciation and amortization expense of $1,841, $3,401 and $6,297 for the years ended December 31, 2016, 2015 and 2014, respectively.
(6) Goodwill and Intangible Assets
The following table presents the carrying amount of goodwill and indefinite-lived intangible assets.
|
|
Goodwill |
|
Indefinite-lived |
| ||
Balance at December 31, 2013 |
|
$ |
5,759 |
|
$ |
733 |
|
2014 Additions |
|
17,557 |
|
|
| ||
Balance at December 31, 2014 |
|
23,316 |
|
733 |
| ||
2015 Additions |
|
|
|
|
| ||
Balance at December 31, 2015 |
|
23,316 |
|
733 |
| ||
2016 Additions |
|
|
|
|
| ||
Balance at December 31, 2016 |
|
$ |
23,316 |
|
$ |
733 |
|
(6) Goodwill and Intangible Assets (Continued)
The following table presents changes in the carrying amount of definite-lived intangible assets for fiscal 2016 and 2015:
|
|
Trademarks |
|
Technology |
|
Customer |
|
Noncompete |
| ||||
Balance at December 31, 2013 |
|
$ |
22 |
|
$ |
1,050 |
|
$ |
375 |
|
$ |
340 |
|
2014 Additions |
|
293 |
|
6,080 |
|
1,308 |
|
2 |
| ||||
Balance at December 31, 2014 |
|
315 |
|
7,130 |
|
1,683 |
|
342 |
| ||||
Accumulated amortization |
|
(36 |
) |
(728 |
) |
(471 |
) |
(285 |
) | ||||
Balance at December 31, 2014, net |
|
$ |
279 |
|
$ |
6,402 |
|
$ |
1,212 |
|
$ |
57 |
|
Balance at December 31, 2014 |
|
$ |
315 |
|
$ |
7,130 |
|
$ |
1,683 |
|
$ |
342 |
|
2015 Additions |
|
|
|
|
|
|
|
|
| ||||
Balance at December 31, 2015 |
|
315 |
|
7,130 |
|
1,683 |
|
342 |
| ||||
Accumulated amortization |
|
(301 |
) |
(1,546 |
) |
(956 |
) |
(342 |
) | ||||
Balance at December 31, 2015, net |
|
$ |
14 |
|
$ |
5,584 |
|
$ |
727 |
|
$ |
|
|
Balance at December 31, 2015 |
|
$ |
315 |
|
$ |
7,130 |
|
$ |
1,683 |
|
$ |
342 |
|
2016 Additions |
|
|
|
|
|
|
|
|
| ||||
Balance at December 31, 2016 |
|
315 |
|
7,130 |
|
1,683 |
|
342 |
| ||||
Accumulated amortization |
|
(304 |
) |
(2,364 |
) |
(1,392 |
) |
(342 |
) | ||||
December 31, 2016, net |
|
$ |
11 |
|
$ |
4,766 |
|
$ |
291 |
|
$ |
|
|
Amortization expense of $1,257, $1,623 and $825 was recorded in fiscal 2016, 2015 and 2014, respectively. Included in the 2015 amortization is an impairment charge of $171 related to the abandonment of the Rise Health tradename.
Future annual amortization expense of intangible assets is as follows:
2017 |
|
$ |
1,005 |
|
2018 |
|
608 |
| |
2019 |
|
608 |
| |
2020 |
|
608 |
| |
2021 |
|
608 |
| |
Thereafter |
|
1,631 |
| |
|
|
$ |
5,068 |
|
(7) Convertible Notes
2014 Notes
On August 29, 2014, the Company entered into a Loan and Security Agreement for $21,535 of convertible promissory notes (the Convertible Notes or Notes), maturing on August 29, 2019. The Notes were issued to the owners of Rise in connection with the acquisition of Rise by the Company.
(7) Convertible Notes (Continued)
The Notes bear interest at 5% per annum, which is payable quarterly in arrears and accrued until the outstanding principal is paid in full at maturity. The notes are voluntarily pre-payable by the Company (in full) at any time and become due 180 days following an initial public offering. The Convertible Notes and any accrued and unpaid interest are convertible at the option of the holder at any time following an initial public offering or change in control into shares of the Companys common stock, up to a conversion cap. The conversion price is 85% of the consideration per share of Company common stock to be paid in such initial public offering, or consideration per share to be paid in such change of control, determined on a fully diluted basis assuming conversion of all Convertible Notes. The conversion cap is the number of shares of Company common stock equal to the sum of (a) a specified number of shares of Company common stock plus (b) a percentage of the number of additional shares of Companys common stock issued between July 8, 2014 and the date of such initial public offering or change in control.
Under provisions of the Convertible Notes, without the prior written consent of the majority of the holders of the Notes, the Company shall not (a) repurchase or redeem any stock or other security (other than employee or director stock subject to a stock repurchase agreement or stock restriction agreement upon termination of employment), (b) incur over $16,000 of debt, (c) pay dividends or distributions of over $2,000 in any given year, (d) incur certain indebtedness to affiliates, (e) pay management or similar fees in excess of customary compensation in the ordinary course of business, or (f) enter into affiliate agreements on terms less favorable than third party arms-length terms. The Company also is required to reserve the shares of common stock issuable under the conversion terms of the Convertible Notes.
In November 2015, the Company entered into an amendment with the Note Holders to raise the debt cap to $19,000 and defer payment of interest for 1 year. The Company agreed to raise the interest rate from 5% to 6% for that year. In addition, upon the execution of the amendment in November 2015, the Company issued the lenders warrants to purchase 60,000 shares of common stock at a per share exercise price of $15.63. The warrants are immediately exercisable upon issuance, and other than in connection with an IPO, will expire on the ten-year anniversary of the date of issuance. The fair value of the warrants was estimated at $487 at the issuance date of November 5, 2015 using a Black-Scholes model and assuming: (i) expected volatility of 39%, (ii) risk free interest rate of 2.26%, (iii) an expected life of 10 years and (iv) no dividend payments. The fair value of the warrants was recorded as debt financing costs on the consolidated balance sheet, and will be amortized to interest expense over the term of the loan. All such warrants were outstanding as of December 31, 2016 and 2015.
In April 2016, the Company awarded the Note Holders with an additional 30,000 warrants as the Series K financing had not completed in time per the November 2015 amendment. The warrants are immediately exercisable upon issuance, and other than in connection with an IPO, will expire on the ten-year anniversary of the date of issuance. The fair value of the warrants was estimated at $235 at the issuance date of November 5, 2015 using a Black-Scholes model and assuming: (i) expected volatility of 39%, (ii) risk free interest rate of 1.88%, (iii) an expected life of 10 years and (iv) no dividend payments. The fair value of the warrants was recorded as debt financing costs on the consolidated balance sheet, and will be amortized to interest expense over the term of the loan. All such warrants were outstanding as of December 31, 2016 and 2015.
Upon issuance, the Company elected to record the Convertible Notes at fair value, which was $19,829 and $18,882 as of December 31, 2016 and 2015, respectively.
The gain recognized in interest income as a result of the change in the fair value of the Companys Convertible Notes was $350 for the period from December 31, 2015 to December 31, 2016. Contractual interest expense recorded on the Companys Convertible Notes was $1,258, $1,131 and $363 for 2016, 2015 and 2014, respectively.
(7) Convertible Notes (Continued)
Fair Value Option
ASC Subtopic 825-10 provides entities with an option to measure many financial instruments and certain other items at fair value. Under this guidance, unrealized gains and losses on items for which the fair value option has been elected are reported in earnings at each reporting period. As a result of the Company electing this option, the Company records the Convertible Notes at fair value. The Company records these notes at fair value in order to measure the liability at an amount that more accurately reflect the current economic environment in which the company operates.
The following table presents the difference between the aggregate fair value and the aggregate unpaid principal balance of the Convertible Notes recorded at fair value:
|
|
Aggregate |
|
Aggregate |
|
Fair value |
| |||
Total Convertible Notes |
|
$ |
19,829 |
|
$ |
22,832 |
|
$ |
3,003 |
|
Less unamortized debt issuance cost |
|
527 |
|
|
|
|
| |||
Note payable, net |
|
$ |
19,302 |
|
$ |
22,832 |
|
$ |
3,003 |
|
2016 Notes and Warrants
On May 9, 2016, the Company entered into two Loan Agreements for a total value of $5,000 of subordinated convertible promissory notes (the 2016 Notes), maturing on May 09, 2020. The 2016 Notes were issued to BBH Capital Partners IV, L.P and BBH Capital IV QP, L.P (BBH) in the amount of $400 and $4,620 respectively.
The 2016 Notes bear interest at 15% per annum, which is payable quarterly in arrears and accrued until the outstanding principal is paid in full at maturity. In the event of default, the Company would incur additional interest of 2% per annum. The 2016 Notes contain a make-whole provision whereby if the 2016 Notes are repaid by the Company for any reason prior to the maturity date, an amount equal to the principal amount being repaid by the Company or redeemed by the investor multiplied by 0.75 is due and payable in addition to the unpaid principal and interest. The 2016 Notes are convertible at the option of the holder at any time during the term of the 2016 Notes into shares of the Companys preferred stock at a conversion price of $20.00 per share. The preferred stock in which the shares are converted are equivalent to the most senior equity security of the Company. The number of shares issuable upon conversion is determined by the total obtained by dividing the outstanding principal amount of the note to be converted by the conversion price. On the commitment date (May 09, 2016), the Series I shares were the most senior shares of the Company.
Under the provisions of the 2016 Notes, without the prior written consent of the majority of the holders of the 2016 Notes, the Company shall not (a) repurchase or redeem any stock or other security (other than employee or director stock subject to a stock repurchase agreement or stock restriction agreement upon termination of employment), (b) incur over $40,000 of debt (including senior indebtedness, but excluding up to an aggregate of $15,000 of initial principal amount of the note), (c) pay dividends or distributions in any given year, (d) incur certain indebtedness to affiliates, (e) pay management or similar fees in excess of customary compensation in the ordinary course of business, or (f) enter into affiliate agreements on terms
(7) Convertible Notes (Continued)
less favorable than third party arms-length terms. The Company also is required to reserve for the number of the shares of common stock issuable under the conversion terms of the 2016 Notes.
The 2016 Notes contain a beneficial conversion feature (BCF) of $3,296 at commitment date. Because the conversion feature calls for the option to be settled in the most senior series of preferred stock, the conversion option also contains a contingent BCF. The BCF was calculated based on the on the Series I preferred stock, since they were the most senior preferred shares on commitment date. As of the issuance date of the Series K preferred stock, which became the most senior shares of preferred stock, the unamortized portion of the BCF was revised to reflect a BCF value for the conversion into Series K preferred stock of $1,704.
On May 9, 2016, the Company also issued two warrant agreements exercisable into shares of the Companys common stock equal to a percentage of the fully-diluted capital stock of the Company. The percentages were 0.07599% and 0.92401% for the warrants to BBH Capital Partners IV, L.P and BBH Capital IV QP, L.P respectively. If by June 15, 2016, (i) the Company received all required approvals to create a new class of preferred stock that is equivalent to the Companys most senior class of preferred stock that has terms acceptable to investors and (ii) the beginning of the redemption period for the Companys Series I preferred stock is delayed until March 31, 2019, the warrant would only have been exercisable for a number of shares of common stock equal to a lower percentage of the Fully-Diluted Capital Stock as of the exercise date. The lower percentages are 0.03799% and 0.46201% related to BBH Capital Partners IV, L.P and BBH Capital IV QP, L.P respectively. On December 5, 2016, the warrants became exercisable into 108,912 shares of common stock. The warrants expire on May 09, 2026 and are exercisable at any time.
The warrants were recorded as liabilities on the Companys balance sheet at fair value, with a corresponding debt discount, and shall be remeasured at fair value at each reporting date. Changes in fair value will be recorded in the Companys statement of operations and comprehensive loss. The fair value of the warrants was estimated at $1,704 at the issuance date of May 9, 2016 using the Black Scholes model and assuming: (i) expected volatility of 40%, (ii) risk free interest rate of 2.25%, (iii) an expected life of 10 years and (iv) no dividend payments. The fair value of the warrants was recorded as debt financing costs on the consolidated balance sheet, and will be amortized to interest expense over the term of the agreement. All such warrants were outstanding as of December 31, 2016. The fair value of the warrants as of December 31, 2016 was $2,095.
On December 5, 2016, the Series K financing was completed and $5,000 of the 2016 Notes (100% of the 2016 Notes) were converted into 250,000 shares of Series K preferred stock. Upon conversion, BBH elected to have the $438 of accrued interest paid-in-kind in the form of new notes pursuant to the terms of the note agreement. Upon conversion of the 2016 Notes, the Company recorded the immediate accretion of the unamortized discount of $3,409 as interest expense and the balance of the notes was recorded to Series K preferred stock. During the year ended December 31, 2016, the Company recorded total interest expense related to the Notes of $438 in the statement of operations and comprehensive loss.
The $438 of accrued interest paid-in-kind was converted into new notes and there was no discount from warrants or lender fees associated with the new notes. These notes do not have a BCF as the conversion price was $20.00 per share and the fair value of the Series K preferred stock was $20.00 per share.
(8) Fair Value Measurements
All financial instruments are measured and reported at fair value. The fair value hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:
· Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.
· Level 2 Inputs: Other than quoted prices included in Level 1, inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.
· Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.
Fair Value Hierarchy
A description of the valuation techniques applied to the Companys major categories of assets and liabilities measured at fair value on a recurring basis are as follows:
The fair value of the Convertible Notes was determined by utilizing a probability weighted discounted cash flow analysis which took into consideration market and general economic events as well as the Companys financial results and other data available as of December 31, 2015 and 2016. This analysis determined the amount to be paid on the notes in either cash or shares at the occurrence of certain events in which the Convertible Notes would be converted into shares of the Companys common stock or would be repaid to the holders of the Notes in cash. The probability weighted discounted cash flow analysis utilized assumptions related to the probability of the occurrence of each of the various events and appropriate discount rates for each of the scenarios.
Given that the valuation of the Convertible Notes utilized several unobservable inputs, the Company determined that the valuation of the Convertible Notes is a Level 3 valuation.
The following table presents a roll-forward of the fair value of Level 3 (significant unobservable inputs) Convertible Notes:
|
|
Total |
| |
Balance at December 31, 2013 |
|
$ |
|
|
Issuances of convertible Notes |
|
21,029 |
| |
Change in fair value included in interest income |
|
(892 |
) | |
Balance at December 31, 2014 |
|
20,137 |
| |
Change in fair value included in interest expense |
|
(1,255 |
) | |
Balance at December 31, 2015 |
|
18,882 |
| |
Capitalized interest expense |
|
1,297 |
| |
Change in fair value included in interest expense |
|
(350 |
) | |
Balance at December 31, 2016 |
|
$ |
19,829 |
|
(9) Debt
Note Payable and Line of Credit
The Company entered into a Note Payable Pledge and Assignment Agreement (Loan and Security Agreement) with Silicon Valley Bank (SVB) totaling $5,000 in 2013. In 2014, the Company entered into a line of credit arrangement with SVB for advances up to approximately $3,000, secured by qualifying accounts receivable and subject to certain covenants and additional reporting requirements. LIBOR advances under the arrangement bear interest at the greater of 3.75% or LIBOR plus 2.5%. Prime-rate based advances bear interest at the Prime Rate plus 0.5%. As part of the Loan and Security Agreement, SVB issued standby letters of credit on behalf of the Company. The Company executed amendments to the Loan and Security Agreement during 2015, in which terms were amended to include the following: (i) borrowing capacity of $9,000, (ii) payment of interest only through June 30, 2016, and then straight-line amortization through December 1, 2018, (iii) interest rate for the revolving line of credit equal to the Prime Rate plus 0.5%, and interest for the term loan equal to the Prime Rate plus 0.75%, (iv) prepayment or termination fee of 3% if such payment occurs prior to December 17, 2016, 2% if such payment occurs prior to the December 17, 2017, and 1% if such payment occurs on or after December 17, 2017, (v) final payment fee of 7% of the term loan amount. As of December 31, 2016 and 2015, the outstanding balance for the SVB Loan and Security Agreement was $1,706 and $7,585, respectively. As of December 31, 2016 and 2015 the interest rate for the revolving line and term loan was 4.5% and 4% respectively.
Upon the amendments of the Loan and Security Agreement in December 2015, the Company issued the lenders warrants to purchase 3,199 shares of Preferred Series J at a per share exercise price of $20. The warrants are immediately exercisable upon issuance, and other than in connection with an IPO, will expire on the ten-year anniversary of the date of issuance. The fair value of the warrants was estimated at $45 at the issuance date of December 17, 2015 using a Black-Scholes model and assuming: (i) expected volatility of 39%, (ii) risk free interest rate of 2.24%, (iii) an expected life of 10 years and (iv) no dividend payments. The fair value of the warrants was recorded as a liability on the consolidated balance sheet, which is being marked-to-market each reporting period, and the value of the warrants at the issuance date was recorded as a debt discount and will be amortized to interest expense over the term of the loan. All such warrants were outstanding as of December 31, 2016 and 2015. The estimated fair value of the warrants at December 31, 2016 and 2015 was $60 and $45, respectively.
Loan Agreement
On April 7, 2015, the Company entered into a loan agreement with Eastward Capital (Loan Agreement) maturing on January 31, 2019. The Loan Agreement required payments of interest through December 2015, at which point straight line amortization commenced for three years. The interest rate is 12.5% per annum, payable monthly. This facility has an 8% final payment fee and the Lender has a second priority security interest in the collateral subordinated to Silicon Valley Bank. As of December 31, 2016 and 2015, the outstanding balance was $7,254 and $10,000, respectively.
In connection with the Loan Agreement, the Company issued Eastward Capital warrants to purchase 50,000 shares of its Series J preferred stock at a per share exercise price of $20.00. The warrants are immediately exercisable upon issuance, and other than in connection with an IPO, will expire on the ten-year anniversary of the date of issuance. The fair value of the warrants was estimated at $605 using a Black-Scholes model and assuming: (i) expected volatility of 39%, (ii) risk free interest rate of 1.91%, (iii) an expected life of 10 years and (iv) no dividend payments. The fair value of the warrants was recorded as a liability on the consolidated balance sheet, which is being marked-to-market each reporting period, and the value of the warrants at the issuance date was recorded as a debt discount and will be amortized to interest expense over the term of the loan. All such warrants were outstanding as of December 31, 2016, and 2015. The estimated fair value of the warrants at December 31, 2016 and 2015 was $977 and $677, respectively.
(9) Debt (Continued)
The Company recorded interest expense of $1,469, $1,669 and $182 in 2016, 2015 and 2014, respectively, related to the Eastward and SVB loan arrangements.
The following is a schedule of approximate future minimum principal payments under all lines of credit and note payable agreements at December 31, 2016:
2017 |
|
$ |
4,101 |
|
2018 |
|
4,531 |
| |
2019 |
|
328 |
| |
Total |
|
$ |
8,960 |
|
(10) Stock Option Plans
The Company grants awards under the 2007 Stock Option and Incentive Plan (the 2007 Plan). The 2007 Plan provides for 1,250,000 shares of common stock that may be issued as ISOs, nonqualified stock options, and stock grants. All terminated, repurchased or expired options under prior stock option plans are available for grant under the 2007 Plan. Options under the 2007 Plan may be granted to employees, directors, officers, advisors and consultants, as defined. Nonqualified options and other stock rights may be granted at no less than fair value per share of common stock. ISOs may be granted at no less than fair market value on the date of the grant, as determined by the Companys Board of Directors, subject to certain limitations, as defined in the 2007 Plan. Options granted under the 2007 Plan are exercisable at varying dates and have terms as determined by the Companys Board of Directors. As of December 31, 2016 and 2015, there were 111,556 and 96,664 options to purchase shares of common stock available for future grant under the 2007 Plan, respectively.
A summary of combined stock option activity under the option plans is as follows:
|
|
Number of |
|
Weighted |
| |
|
|
(In thousands) |
|
|
| |
Outstanding at December 31, 2013 |
|
2,434 |
|
$ |
8.27 |
|
Options granted |
|
516 |
|
19.51 |
| |
Options exercised |
|
(788 |
) |
1.67 |
| |
Options cancelled/forfeited |
|
(98 |
) |
15.52 |
| |
Outstanding at December 31, 2014 |
|
2,064 |
|
13.23 |
| |
Options granted |
|
530 |
|
20.00 |
| |
Options exercised |
|
(79 |
) |
3.95 |
| |
Options cancelled/forfeited |
|
(436 |
) |
17.79 |
| |
Outstanding at December 31, 2015 |
|
2,079 |
|
13.23 |
| |
Options granted |
|
341 |
|
18.00 |
| |
Options exercised |
|
(78 |
) |
1.53 |
| |
Options cancelled/forfeited |
|
(356 |
) |
14.60 |
| |
Outstanding at December 31, 2016 |
|
1,986 |
|
$ |
14.59 |
|
Options vested and exercisable at December 31, 2016 |
|
1,245 |
|
$ |
12.64 |
|
Options vested and expected to vest at December 31, 2016 |
|
1,844 |
|
$ |
14.41 |
|
(10) Stock Option Plans (Continued)
Outstanding options have a weighted average remaining life of 6.6 years and 6.5 years, and have an aggregate intrinsic value of $9,143 and $6,591 at December 31, 2016 and 2015, respectively. During 2016, 244,699 options vested with an aggregate intrinsic value of $206. Exercisable options have a weighted average remaining life of 5.0 years and 4.8 years at December 31, 2016 and 2015, respectively. Unrecognized compensation expense amounted to $3,599 and $3,245 at December 31, 2016 and 2015 respectively, which is expected to be recognized over a weighted average period of 3.3 and 3.2 years, respectively. The total intrinsic value of options exercised during 2016 and 2015 was $639 and $1,165, respectively.
The fair value of each stock option grant was estimated on the date of the grant using the Black-Scholes valuation model, with the following assumptions for options granted during 2016, 2015 and 2014:
|
|
2016 |
|
2015 |
|
2014 |
|
Expected option term |
|
1 - 5 years |
|
1 - 5 years |
|
1 - 5 years |
|
Expected volatility |
|
40% |
|
39% |
|
38% |
|
Risk-free interest rate |
|
0.95% - 2.03% |
|
1.31 - 1.75% |
|
1.49 - 1.71 |
|
Expected annual dividend yield |
|
None |
|
None |
|
None |
|
The expected volatility for each grant is determined based on the average of the historical volatility of the stock of comparable companies over a period of time, which approximates the expected option term. The risk-free interest rate for the expected term of the stock option is based on the U.S. Treasury yield.
The weighted average grant date fair value of options granted was $7.24, $4.30 and $5.16 in 2016, 2015 and 2014, respectively.
In connection with the termination of certain employees during 2016, the Company extended the exercise period on 82,000 vested stock options held by such employees. These modifications resulted in an additional share-based compensation expense of approximately $113 being recorded in the year ended December 31, 2016. All modified options retained their original exercise prices but had the time period during which they could be exercised extended from 60 days from termination to 1 year from termination.
(11) Preferred Stock
(a) Authorized Shares of Preferred Stock
The Companys Board of Directors has authorized the issuance of 5,449,491 shares of $0.01 par value preferred stock.
Shares of preferred stock issued and outstanding are as follows:
|
|
December 31, |
|
December 31, |
|
Series: |
|
|
|
|
|
Series G |
|
369,822 |
|
369,822 |
|
Series I |
|
751,510 |
|
751,510 |
|
Series J |
|
27,981 |
|
27,981 |
|
Series K and K-1 |
|
754,161 |
|
|
|
Total issued and outstanding |
|
1,903,474 |
|
1,149,313 |
|
(11) Preferred Stock (Continued)
In August 2015, holders of Series J Preferred Stock converted 2,500,000 shares outstanding into an aggregate of 2,500,000 shares of the Companys common stock. The shares were converted at a conversion rate of 1:1, based on the conversion provision for convertible Series J Preferred Stock designation.
On December 5, 2016, the Company closed its round of preferred stock financing with the Series K preferred stock issuance of 500,000 shares at a price of $20.00 per share for gross proceeds of approximately $10,000. As part of a separate transaction, BBH converted the $5,000 principal amount of the Companys 2016 Notes into 250,000 shares of Series K preferred stock (Note 7). The Company incurred $0 of issuance costs in relation to the Series K Preferred Stock financing. These costs were accounted for as a reduction of the carrying value of the Series K Preferred Stock.
In December 2016, the Company issued 4,161 shares of a newly created Series K-1 Preferred Stock in satisfaction of the Accruing Series K Dividends (as defined below).
The following summarizes certain features of the Companys preferred stock:
(b) Liquidation Priority
As of December 31, 2016, holders of Series I and Series K Preferred Stock have liquidation preference over holders of all other classes of preferred stock. Series J and Series G Preferred Stock have equal liquidation preferences after Series I. The holders of Series K are also entitled to elect two members to the Board of Directors.
(c) Voting Rights
Holders of preferred stock shall be entitled to the number of votes equal to the number of whole shares of common stock into which their shares convert. The holders of shares of preferred stock (of all series) and common stock shall vote together as a single class on all matters submitted to the stockholders.
(d) Conversion
Each share of Series K Preferred Stock may be converted at any time, at the option of the holder, into one share of common stock, adjustable for any further diluting events. Each share of Series K Preferred Stock will be automatically converted into shares of common stock at the then effective conversion price upon the closing of a qualified public offering. The current conversion price as of December 31, 2016 is $20.00 per share.
Each share of Series J Preferred Stock may be converted at any time, at the option of the holder, into one share of common stock, adjustable for any further diluting events. Each share of Series J Preferred Stock will be automatically converted into shares of common stock at the then effective conversion price upon either the closing of a qualified public offering in which the gross proceeds equal or exceed $30,000, and in which the per share price to the public is at least $30 or upon the written approval of the holders of a majority of the outstanding shares of Series J Preferred Stock. The current conversion price as of December 31, 2016 is $18.01 per share.
Each share of Series I Preferred Stock may be converted, at any time, at the option of the holder, into one share of common stock, adjustable for any further diluting events. Each share of Series I Preferred Stock will be automatically converted into shares of common stock at the then effective conversion price upon either the closing of a qualified public offering in which the gross proceeds equal or exceed $30,000 or upon the written approval of the holders of a majority of the outstanding shares of Series I Preferred Stock. The current conversion price as of December 31, 2016 is $26.61 per share.
(11) Preferred Stock (Continued)
Each share of Series G Preferred Stock may be converted, at any time, at the option of the holder, into one share of common stock, adjustable for any further diluting events. Each share of Series G Preferred Stock will be automatically converted into shares of common stock at the then effective conversion price upon either the closing of a qualified public offering in which the gross proceeds equal or exceed $20,000 and in which the per share price offered to the public is at least $20.28 or upon the written approval of the holders of a majority of the outstanding shares of Series G Preferred Stock. The current conversion price as of December 31, 2016 is $6.76 per share.
(e) Liquidation Preference
In the event of any liquidation, dissolution, or winding up of the Company, the holders of Series K Preferred Stock will receive the greater of (1) the original issue price of $20.00 per share plus all unpaid Accruing Series K Dividends (as defined below), plus any other dividends declared but unpaid, plus for each outstanding share of Series K-1 Preferred Stock, the Series K-1 original issue price of $100 (subject to appropriate adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization); or (2) an amount equal to the Series K original issue price of $20.00 multiplied by 1.75 less any cash dividends paid with respect to the Series K Preferred Stock upon redemption of Series K-1 Preferred Stock.
In the event of any liquidation, dissolution, or winding-up of the Company, the holders of Series I Preferred Stock will be entitled to receive a liquidation preference equal to (1) $26.61 per share (subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other similar events affecting such shares), plus declared but unpaid dividends, if any, or (2) such amount per share as would have been payable had each such share been converted to common stock immediately prior to such liquidation, dissolution or winding-up of the Company prior to any distribution to the holders of the common stock of the Company.
The holders of Series G Preferred Stock and Series J Preferred Stock will receive a liquidation preference of the greater of (1) $6.76 per share and $18.01 per share, respectively (each subject to adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization affecting shares), plus accrued but unpaid dividends, if any, or (2) such amount per share as would have been payable had each such share been converted to common stock immediately prior to such liquidation, dissolution or winding-up of the Company prior to any distribution to the holders of the common stock of the Company.
The liquidation preferences for each of the preferred stock series are as follows:
|
|
December 31 |
| ||||
|
|
2016 |
|
2015 |
| ||
Series J |
|
$ |
739 |
|
$ |
677 |
|
Series K |
|
15,083 |
|
|
| ||
Series I |
|
20,000 |
|
20,000 |
| ||
Series G |
|
7,707 |
|
7,118 |
| ||
|
|
$ |
43,529 |
|
$ |
27,795 |
|
The Series I liquidation preferences does not include accruing dividends of $11,061 as of December 31, 2016. Such dividends are payable only upon declaration by the Board of Directors.
(11) Preferred Stock (Continued)
(f) Dividends
The holders of Series K Preferred Stock are entitled to receive cumulative dividends of 7.5% per annum based on the initial share price of $20.00 (subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other similar events affecting such shares) (the Accruing Series K Dividends). All dividends are compounding, accrue from the original issuance date, and are payable: (1) annually in shares of Series K-1 Preferred Stock, or (2) upon Elected Mandatory Conversion. Series K holders are also entitled to a participating dividend in the event the board of directors declares a cash dividend payable on outstanding common stock. In such an event, the holders of Series K Preferred Stock will receive dividends on an as-converted basis in addition to any of the Accruing Series K Dividends.
The holders of Series J Preferred Stock are entitled to receive cumulative dividends of 9% per annum based on the initial share price of $18.01 (subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other similar events affecting such shares). All dividends are compounding, accrue from the original issuance date, and are payable upon (1) liquidation of the Company, or (2) if declared by the Board of Directors.
The holders of Series I Preferred Stock were entitled to receive cumulative dividends of 9.5% per annum based on the initial share price of $26.61 (subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other similar events affecting such shares). In connection to the Series K issuance, the dividend rate on the Series I Preferred Stock was changed from 9.5% to 10.5%, effective April 1, 2016. All dividends are non-compounding. Dividends accrue from the original issuance date and are payable only upon: (1) liquidation of the Company, to the extent dividends are declared but unpaid, (2) redemption of the preferred stock, to the extent of any declared but unpaid dividends, (3) automatic conversion, or (4) 60 days following declaration by the Board of Directors that the Company has achieved net income in excess of $10,000 for such fiscal year. The holders of Series I Preferred Stock participate in the event that the Company declares cash dividends to common stockholders. The amount of cash dividend would be determined as if the holders had converted their preferred stock holdings into common stock. The amendment to Series K was determined to be a modification to the preferred stock.
The holders of Series G Preferred Stock are entitled to receive cumulative dividends of 8% per annum, based on the initial share price of $6.76 (subject to adjustment in the event of any stock dividend, stock split, combination, or similar recapitalization affecting such shares). All dividends are compounding, accrue from the original issuance date and are payable only upon liquidation of the Company. Cumulative dividends are not payable upon conversion of the respective class of preferred stock to common stock for any reason. The holders of Series G Preferred Stock participate in the event that the Company declares cash dividends to common stockholders. The amount of cash dividend would be determined as if the Series G Preferred Stockholders had converted their preferred stock holdings into common stock.
(g) Redemption Rights
Commencing on December 5, 2023, the holders of at least 10% of outstanding Series K Preferred Stock may elect to require the Company to redeem, subject to certain conditions including the equal and pro rata payment of any Accrued Series I Dividends and the equal and pro rata redemption of any then outstanding shares of Series I Preferred Stock, all or a percentage of the shares of the Series K Preferred Stock. The redemption price per share will be equal to the original issue price of $20.00, and subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other similar events affecting such share.
(11) Preferred Stock (Continued)
Commencing on March 31, 2019, the holders of at least 10% of outstanding Series I Preferred Stock may elect to require the Company to redeem, subject to certain conditions including the consent of senior debt holders, all or a percentage of the shares of the Series I Preferred Stock. The redemption price per share will be equal to the initial share price (subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other similar events affecting such shares), plus any declared but unpaid dividends. The redemption amount at December 31, 2016 is $20,000.
(h) Preferred Stock Reclassification
All series of preferred stock have been reclassified from stockholders equity (deficit) to temporary equity to conform to the presentation requirements of Securities and Exchange Commission Regulation S-X and Accounting Series Release No. 268, Presentation in Financial Statements of Redeemable Preferred Stocks.
(12) Income Taxes
Loss from continuing operations before income tax benefit consists of:
|
|
2016 |
|
2015 |
|
2014 |
| |||
Domestic |
|
$ |
(6,281 |
) |
$ |
(23,215 |
) |
$ |
(20,545 |
) |
International |
|
3,077 |
|
1,811 |
|
4,730 |
| |||
|
|
$ |
(3,204 |
) |
$ |
(21,404 |
) |
$ |
(15,815 |
) |
The income tax expense (benefit) is comprised of
|
|
2016 |
|
2015 |
|
2014 |
| |||
Current: |
|
|
|
|
|
|
| |||
Federal |
|
$ |
(261 |
) |
$ |
(162 |
) |
$ |
(4,262 |
) |
State |
|
35 |
|
15 |
|
|
| |||
Foreign |
|
742 |
|
52 |
|
780 |
| |||
Total current expense (benefit) |
|
516 |
|
(95 |
) |
(3,482 |
) | |||
Deferred: |
|
|
|
|
|
|
| |||
Federal |
|
109 |
|
(4,437 |
) |
(1,311 |
) | |||
State |
|
15 |
|
11 |
|
(167 |
) | |||
Foreign |
|
64 |
|
(34 |
) |
6 |
| |||
Total deferred expense (benefit) |
|
188 |
|
(4,460 |
) |
(1,472 |
) | |||
Total income tax expense (benefit) |
|
$ |
704 |
|
$ |
(4,555 |
) |
$ |
(4,954 |
) |
(12) Income Taxes (Continued)
The income tax expense (benefit) differs from the amount computed by applying the statutory federal income tax rate to loss before provision for income taxes. The sources and tax effects of the differences are as follows:
|
|
2016 |
|
2015 |
|
2014 |
| |||
Loss from continuing operations before tax benefit |
|
$ |
(3,204 |
) |
$ |
(21,404 |
) |
$ |
(15,815 |
) |
Federal |
|
$ |
(1,089 |
) |
$ |
(7,492 |
) |
$ |
(5,535 |
) |
State |
|
38 |
|
26 |
|
15 |
| |||
Nondeductible expenses |
|
752 |
|
(1,270 |
) |
(122 |
) | |||
Change in valuation allowance |
|
1,666 |
|
3,987 |
|
4,034 |
| |||
Foreign rate differential |
|
(270 |
) |
(840 |
) |
(323 |
) | |||
Recognition of deferred taxes for outside basis differences |
|
|
|
|
|
(1,574 |
) | |||
Provision to return |
|
(170 |
) |
(453 |
) |
(1,323 |
) | |||
Uncertain tax positions |
|
(261 |
) |
(229 |
) |
(1,556 |
) | |||
Subpart F income |
|
|
|
1,642 |
|
1,500 |
| |||
Other |
|
38 |
|
74 |
|
(70 |
) | |||
|
|
$ |
704 |
|
$ |
(4,555 |
) |
$ |
(4,954 |
) |
In determining the appropriate intraperiod tax allocations for financial statement presentation purposes, the Company has considered income from discontinued operations in determining the amount of tax benefit that results from the loss from continuing operations.
Deferred tax assets and liabilities are comprised of the following:
|
|
December 31 |
| ||||
|
|
2016 |
|
2015 |
| ||
Accrued expenses and compensation |
|
$ |
900 |
|
$ |
1,816 |
|
Uncertain tax positions, including interest |
|
286 |
|
286 |
| ||
Stock-based compensation |
|
2,621 |
|
2,453 |
| ||
Net operating losses |
|
17,181 |
|
15,115 |
| ||
Foreign tax credit and alternative minimum tax credits |
|
4,814 |
|
4,829 |
| ||
Other |
|
1,032 |
|
1,118 |
| ||
Unrealized gain/(loss) on investments |
|
77 |
|
77 |
| ||
Deferred tax asset |
|
26,911 |
|
25,694 |
| ||
Valuation allowance |
|
(24,468 |
) |
(22,980 |
) | ||
Net deferred tax asset |
|
$ |
2,443 |
|
$ |
2,714 |
|
(12) Income Taxes (Continued)
|
|
December 31 |
| ||||
|
|
2016 |
|
2015 |
| ||
Deferred tax liabilities: |
|
|
|
|
| ||
Prepaid expenses |
|
$ |
(429 |
) |
$ |
(250 |
) |
Intangible assets |
|
(2,280 |
) |
(2,617 |
) | ||
Other |
|
(396 |
) |
(320 |
) | ||
Deferred tax liabilities |
|
$ |
(3,105 |
) |
$ |
(3,187 |
) |
Net deferred tax liability |
|
$ |
(662 |
) |
$ |
(473 |
) |
The Company can only recognize a deferred tax asset to the extent this it is more-likely than-not that these assets will be realized. After considering all available positive and negative evidence, the Company established a valuation allowance against deferred tax assets in certain jurisdictions as it is more likely than not that these assets will not be realized. The Companys valuation allowance at December 31, 2016 increased by $1,488 from the balance at December 31, 2015, primarily due to current activity during the year.
At December 31, 2016, the Company has $58,138 and $59,208 of U.S. federal and state net operating loss carryforwards, of which $17,605 and $17,605 are attributable to U.S. federal and state excess tax deductions from share-based payments, respectively. Under current accounting standards, the tax benefit from these excess tax deductions will be recorded as a credit to additional paid-in capital when realized through a reduction of taxes paid in cash. ASU 2016-09 will change the accounting for excess tax deductions. Refer to note 2 for the Companys assessment of the impact of this accounting pronouncement. The U.S. federal and state net operating losses expire in the years 2021 through 2035. It is more likely than not that these net operating losses will not be utilized in the foreseeable future. The Company also has $328 of non-U.S. net operating loss carryforwards that will begin to expire in 2026.
At December 31, 2016, the Company also has U.S. foreign tax credit carryforwards of $5,871, which expire in the years 2021 through 2024. Included in the U.S. foreign tax credit carryforwards is $1,057 attributable to excess tax deductions from share-based payments. The benefit from these credits will be recorded as a credit to additional paid-in capital when realized through a reduction of taxes paid in cash.
The net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has not, as yet, conducted a study to determine if any such changes have occurred that could limit its ability to use the net operating loss and tax credit carryforwards.
The Companys consolidated financial statements provide for any related tax liability on amounts that may be repatriated, aside from undistributed earnings of certain of the Companys foreign subsidiaries that are intended to be indefinitely reinvested in operations outside the U.S. As of December 31, 2016, U.S. income taxes have not been provided on a cumulative total of approximately $12,422 of such earnings. If these earnings were ultimately distributed to the U.S. in the form of dividends or otherwise, or if the shares
(12) Income Taxes (Continued)
of the subsidiaries were sold or transferred, the Company would likely be subject to additional U.S. income taxes, net of the impact of any available foreign tax credits. The Company estimates the amount of unrecognized deferred U.S. income taxes on these undistributed earnings to be approximately $1,090.
The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across our global operations. A tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.
The Company (1) records unrecognized tax benefits as liabilities and (2) adjusts these liabilities when its judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available.
The Company has gross unrecognized tax liabilities, excluding interest and penalties, of approximately $778 as of December 31, 2016, of which $507, if recognized, would reduce the Companys effective tax rate. As of December 31, 2016 the Company anticipates that the liability for unrecognized tax benefits could decrease by approximately $294 over the next 12 months primarily as a result of the expiration of statutes of limitations.
A tabular reconciliation of the amount of unrecognized tax benefits for continuing and discontinued operations is as follows:
|
|
2016 |
|
2015 |
|
2014 |
| |||
Beginning balance |
|
$ |
1,000 |
|
$ |
1,281 |
|
$ |
2,798 |
|
Additions based on positions related to current year |
|
|
|
97 |
|
183 |
| |||
Reductions for tax positions of prior years |
|
(221 |
) |
(64 |
) |
(54 |
) | |||
Statutes of limitation expirations |
|
(1 |
) |
(314 |
) |
(1,646 |
) | |||
Ending balance |
|
$ |
778 |
|
$ |
1,000 |
|
$ |
1,281 |
|
The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2016, $345 of gross interest and penalties were included in its liability for unrecognized tax benefits. In 2016 the income tax provision includes a net release of interest and penalties of $40.
The Company files income tax returns in the U.S. federal jurisdiction, various state jurisdictions, and various foreign jurisdictions. As of December 31, 2016, the Company has not been audited by the Internal Revenue Service (IRS) or foreign taxing authorities in connection with income taxes. In general, U.S. federal and state tax returns for the three most recent years, and certain items carried forward from earlier years and utilized on those tax returns, remain open to examination by the IRS and various state jurisdictions. In major foreign jurisdictions, the years subsequent to 2011 generally remain open and could be subject to examination by the taxing authorities.
(13) Retirement Benefits
The Company has a defined contribution plan covering all full-time employees in the United States. Under the plan, participants may contribute a portion of their compensation within certain defined limitations. The
(13) Retirement Benefits (Continued)
Company makes a contribution partially matching the participants contributions up to 50% of the first 6% of the participants salary. The Companys contributions were approximately $613, $635 and $528 in fiscal 2016, 2015 and 2014, respectively.
The Company has a similar plan in Canada known as a registered retirement savings plan. Under the plan, participants may contribute up to 5% of their base salary. The Company matches the employees contribution (subject to the maximums) and it is placed into a deferred profit sharing plan, another registered retirement vehicle. The Companys contributions were approximately $78, $102 and $119 in fiscal 2016, 2015 and 2014, respectively.
(14) Commitments and Contingencies
Lease Commitments
The Company has operating leases for office space and office equipment with lease terms ranging from twelve months to nine years. Lease expense was approximately $2,644, $2,840 and $3,818 in 2016, 2014 and 2014, respectively.
The following is a schedule of approximate future minimum lease payments under operating lease agreements as of December 31, 2016:
2017 |
|
$ |
3,811 |
|
2018 |
|
3,781 |
| |
2019 |
|
2,838 |
| |
2020 |
|
2,029 |
| |
2021 |
|
1,888 |
| |
Thereafter |
|
3,188 |
| |
Total future minimum payments |
|
$ |
17,535 |
|
Legal Proceedings
There are no legal proceedings pending against or involving the Company that in managements opinion, based on the current known facts and circumstances, are expected to have a material adverse effect on the Companys consolidated financial position, cash flow, or results from operations.
(15) Discontinued Operations and Divestiture
In June 2015, the Company completed the sale of its insurance business (discontinued operations) to Tamsin Holdings LLC and Asia Bright Limited (collectively, the Buyer) for total consideration of $10,339, of which $7,239 was received at closing. The Company is expected to receive the remainder of the consideration of $600 and $2,500 (minimum amount due on earn-out) on December 1, 2017 and March 31, 2019, respectively. The Company has recorded these amounts at their present value using an interest rate of 4.17% and recorded $2,857 in other receivables on the consolidated balance sheet.
The Company is also entitled to receive additional consideration (the Earn Out) not to exceed $5,000, or $7,500 in total when combined with the minimum earnout of $2,500. This additional consideration has not been included in the calculation of the gain on sale, as the collection is not guaranteed. The calculated Earn Out is determined as follows:
(1) If the discontinued operations generate Net Earned Premium (NEP) of $202,000, $240,000, and $273,000 in the years ended December 31, 2016, December 31, 2017 and December 31, 2018,
(15) Discontinued Operations and Divestiture (Continued)
respectively, the Company will receive $1,250 each year, for an aggregate amount of $3,750. This amount would be payable by the Buyers to the Company on March 31, 2019.
(2) If the Medical Loss Ratio is below 55%, the Company will receive $1,875. This amount would be payable by the Buyers to the Company on March 31, 2019.
(3) If the discontinued operations are sold in the future and the Net Sale Proceeds from the sale are $150,000 or more, the Company will receive the lesser of: (i) $1,875 and (ii) 1% of the Net Sale Proceeds.
The Company recorded a gain on sale of approximately $2,807 and incurred approximately $1,010 of costs to sell.
In connection with the sale, the Company will provide certain InterConsultation services to the Buyer for two years at an annual fee of $750. Additionally, the Company entered into a Transition Services Agreement (TSA) pursuant to which the Company will provide certain administrative functions for the Buyer until March 31, 2016. In return for such services, the Company will receive consideration equal to the cost of the services for the first six months of the service period, and cost plus a 6% markup for the remainder of the service period.
Summarized financial information for discontinued operations, for 2016, 2015 and 2014:
|
|
2016 |
|
2015 |
|
2014 |
| |||
Operations: |
|
|
|
|
|
|
| |||
Total revenues |
|
$ |
|
|
$ |
77,833 |
|
$ |
128,278 |
|
Earnings from discontinued operations before income taxes |
|
$ |
|
|
$ |
7,812 |
|
$ |
7,155 |
|
Provision for income taxes |
|
|
|
(5,518 |
) |
(5,586 |
) | |||
Earnings from discontinued operations, net of taxes |
|
$ |
|
|
$ |
2,294 |
|
$ |
1,569 |
|
(15) Discontinued Operations and Divestiture (Continued)
|
|
December 31, |
| |
Assets: |
|
|
| |
Cash and cash equivalents |
|
$ |
21,224 |
|
Marketable securities |
|
39,264 |
| |
Accounts receivable, net |
|
14,195 |
| |
Deferred policy acquisition costs |
|
19,345 |
| |
Prepaid expenses and other current assets |
|
617 |
| |
Total current assets of discontinued operations |
|
94,645 |
| |
Other assets |
|
4,181 |
| |
Total assets of discontinued operations |
|
$ |
98,826 |
|
Liabilities: |
|
|
| |
Accounts payable, accrued expense and other |
|
$ |
12,040 |
|
Reserves for outstanding losses |
|
15,683 |
| |
Deferred revenue and unearned premiums |
|
66,203 |
| |
Total current liabilities of discontinued operations |
|
93,926 |
| |
Long term tax liability |
|
223 |
| |
Total liabilities of discontinued operations |
|
$ |
94,149 |
|
The depreciation and capital expenditures of the discontinued operations were as follow:
|
|
2015 |
|
2014 |
| ||
Depreciation |
|
$ |
|
|
$ |
239 |
|
Capital expenditures |
|
1,170 |
|
2,805 |
| ||
(16) Subsequent Events
The Company has assessed the impact of subsequent events through May 5, 2017, the date the audited financial statements were available for issuance, and identified the following subsequent events.
On January 31, 2017, the Company sold 100% of the common shares of two legal entities comprising the GCM business, including Best Doctors Iberia Underwriting, SL and Best Doctors Underwriting Europe LDA.
Exhibit 99.4
UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION
On June 19, 2017, Teladoc, Inc. (Teladoc or the Company) and Barolo Acquisition Corp., a Delaware corporation (Merger Sub), entered into an Agreement and Plan of Merger (the Merger Agreement) with Best Doctors Holdings, Inc. (Best Doctors), Shareholder Representative Services LLC, BBH Capital Partners IV, L.P. and BBH Capital Partners QP IV, L.P. pursuant to which the Company will, subject to the terms and conditions of the Merger Agreement, acquire Best Doctors through the merger of Merger Sub with and into Best Doctors, with Best Doctors continuing as the surviving entity (the Acquisition). On July 1, 2016, the Company completed the acquisition of HY Holdings, Inc. d/b/a HealthiestYou Corporation (HealthiestYou) through a merger in which HealthiestYou became a wholly owned subsidiary of the Company.
The following unaudited pro forma combined financial statements are based on the Companys historical consolidated financial statements, Best Doctors historical financial statements and HealthiestYous historical financial statements as adjusted to give effect to (x) the acquisition of Best Doctors, including the anticipated borrowings under a $10.0 million senior secured revolving credit facility (the New Revolving Credit Facility) and a $150.0 million senior secured term loan facility (the New Term Loan Facility and, together with the New Revolving Credit Facility, the New Senior Secured Credit Facilities), the anticipated offering of the Companys convertible senior notes due 2022 (the notes), the repayment of the Companys existing indebtedness and the payment of fees and expenses in connection with the foregoing (collectively, the Transactions) and (y) the acquisition of HealthiestYou. The unaudited pro forma combined financial statements are derived from the following items: (1) the Companys audited consolidated financial statements for the year ended December 31, 2016; (2) the Companys unaudited consolidated financial statements as of and for the three months ended March 31, 2017; (3) the unaudited financial statements of HealthiestYou for the six months ended June 30, 2016; (4) the audited consolidated financial statements of Best Doctors for the year ended December 31, 2016; and (5) the unaudited consolidated financial statements of Best Doctors as of and for the three months ended March 31, 2017.
The unaudited pro forma combined statements of operations for the three months ended March 31, 2017 and the year ended December 31, 2016 give effect to the Transactions as if they had occurred on January 1, 2016. The unaudited pro forma combined statement of operations for the year ended December 31, 2016 gives effect to the Transactions and the acquisition of HealthiestYou as if they had occurred on January 1, 2016. The unaudited pro forma combined balance sheet as of March 31, 2017 gives effect to the Transactions as if they had occurred on March 31, 2017. No pro forma adjustments are necessary to the unaudited pro forma combined statement of operations for the three months ended March 31, 2017 or unaudited pro forma combined balance sheet as of March 31, 2017 to reflect the acquisition of HealthiestYou, as this acquisition is fully reflected in the Companys historical financial statements as of and for the three months ended March 31, 2017. The unaudited pro forma combined financial statements do not include the realization of any future cost savings or integration changes that are expected to be achieved.
The pro forma adjustments are based on the best information available and certain assumptions that management believes are reasonable under the circumstances. The assumptions underlying the pro forma adjustments are described in the accompanying notes, which should be read in conjunction with this unaudited pro forma combined financial information. The unaudited pro forma combined financial statements are presented for illustrative and informative purposes only and are not intended to represent or be indicative of what the Companys results of operations would have been had the Transactions or the acquisition of HealthiestYou actually occurred on the dates indicated. The Companys, Best Doctors and HealthiestYous historical audited and unaudited financial statements described above have been adjusted in the unaudited pro forma combined financial statements to give effect to events that are (1) directly attributable to the Transactions or the acquisition of HealthiestYou, as applicable, (2) factually supportable and (3) with respect to the unaudited pro forma combined statements of operations, expected to have a continuing impact on the Company. The unaudited pro forma combined statements of operations do not reflect any non-recurring charges directly related to the Transactions that have already been incurred by the Company. These non-recurring charges are further described in the accompanying notes to the unaudited pro forma combined financial statements and include transaction-related costs such as financial advisory, legal and regulatory filing fees and all related financing fees. The unaudited pro forma combined financial statements should be read in conjunction with the accompanying notes to the unaudited pro forma combined financial statements.
The unaudited pro forma combined financial information has been prepared using the acquisition method of accounting with respect to the Acquisition, with Teladoc considered the acquirer of Best Doctors. Under the acquisition method of accounting, the purchase price will be allocated to the underlying tangible and intangible assets acquired and liabilities assumed based on their respective fair market values, with any excess purchase price allocated to goodwill. The purchase price allocation was based on estimates of the fair market value of the tangible and intangible assets and liabilities of Best Doctors, as described further in the notes to the Companys unaudited pro forma combined financial information below. As of the date of this filing, the Company only has preliminary estimates of the fair market values and the related allocations of the purchase price. In arriving at such estimates, the Company has considered the preliminary appraisals of independent consultants, which were based on a preliminary and limited review of the assets and liabilities of Best Doctors to be acquired by the Company in the Acquisition. The Company expects to complete the purchase price allocation after considering the fair market value of Best Doctors assets and liabilities at the level of detail necessary to finalize the purchase price allocation. The final purchase price allocation will be based, in part, on third-party appraisals and may be different than that reflected in the pro forma purchase price allocation presented herein, and any such differences may be material.
The unaudited pro forma combined financial statements should be read in conjunction with the Companys historical financial statements and related managements discussion and analysis of financial condition and results of operations, which are included in the Companys Annual Report on Form 10-K for the year ended December 31, 2016 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, HealthiestYous historical financial statements, which are included in the Companys Current Report on Form 8-K/A, filed with the SEC on September 8, 2016, and Best Doctors historical financial statements, which are included in the Companys Current Report on Form 8-K, filed with the SEC on June 20, 2017.
UNAUDITED PRO FORMA COMBINED STATEMENT OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 2017
(in thousands, except share and per share information)
|
|
For the Three Months Ended March 31, 2017 |
| |||||||||||||
|
|
Teladoc |
|
Best |
|
Reclassifications |
|
Pro Forma |
|
Pro Forma |
| |||||
Revenue |
|
$ |
42,898 |
|
$ |
24,056 |
|
$ |
|
|
$ |
|
|
$ |
66,954 |
|
Cost of revenue |
|
12,139 |
|
8,530 |
|
|
|
|
|
20,669 |
| |||||
Gross profit |
|
30,759 |
|
15,526 |
|
|
|
|
|
46,285 |
| |||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
| |||||
Advertising and marketing |
|
12,616 |
|
|
|
1,000 |
(a) |
|
|
13,616 |
| |||||
Sales |
|
7,988 |
|
|
|
3,891 |
(a) |
|
|
11,879 |
| |||||
Technology and development |
|
6,512 |
|
|
|
3,460 |
(a) |
|
|
9,972 |
| |||||
Legal |
|
343 |
|
|
|
92 |
(a) |
|
|
435 |
| |||||
Regulatory |
|
1,007 |
|
|
|
|
|
|
|
1,007 |
| |||||
General and administrative |
|
14,488 |
|
|
|
4,950 |
(a) |
|
|
19,438 |
| |||||
Selling, general and administrative |
|
|
|
14,053 |
|
(14,053 |
)(a) |
|
|
|
| |||||
Depreciation and amortization |
|
2,607 |
|
|
|
739 |
(a) |
2,053 |
(b) |
5,399 |
| |||||
Loss from operations |
|
(14,802 |
) |
1,473 |
|
(79 |
) |
(2,053 |
) |
(15,461 |
) | |||||
Foreign currency transaction loss |
|
|
|
32 |
|
(32 |
)(a) |
|
|
|
| |||||
Gain on sale |
|
|
|
(2,369 |
) |
|
|
|
|
(2,369 |
) | |||||
Interest expense, net |
|
702 |
|
1,392 |
|
|
|
6,334 |
(c)(d) |
8,428 |
| |||||
Other expense, net |
|
|
|
(35 |
) |
(47 |
)(a) |
82 |
(e) |
|
| |||||
Net loss before taxes |
|
(15,504 |
) |
2,453 |
|
|
|
(8,469 |
) |
(21,520 |
) | |||||
Income tax provision |
|
150 |
|
151 |
|
|
|
|
|
301 |
| |||||
Net loss |
|
$ |
(15,654 |
) |
$ |
2,302 |
|
$ |
|
|
$ |
(8,469 |
) |
$ |
(21,821 |
) |
Net loss per share, basic and diluted |
|
$ |
(0.30 |
) |
|
|
|
|
|
|
$ |
(0.40 |
) | |||
|
|
|
|
|
|
|
|
|
|
|
| |||||
Weighted-average shares used to compute basic and diluted net loss per share |
|
52,192,859 |
|
|
|
|
|
1,940,878 |
(f) |
54,133,737 |
|
(1) Includes results from a business disposed of by Best Doctors in January 2017, of which revenue and net income were $387 and $223, respectively.
See accompanying notes to unaudited pro forma combined statement of operations.
UNAUDITED PRO FORMA COMBINED STATEMENT OF OPERATIONS
FOR THE YEAR ENDED DECEMBER 31, 2016
(in thousands, except share and per share information)
|
|
For the Year Ended December 31, 2016 |
| ||||||||||||||||
|
|
Teladoc |
|
Best |
|
Healthiest |
|
Reclassifications |
|
Pro Forma |
|
Pro Forma |
| ||||||
Revenue |
|
$ |
123,157 |
|
$ |
96,849 |
|
$ |
8,788 |
|
$ |
|
|
$ |
|
|
$ |
228,794 |
|
Cost of revenue |
|
31,971 |
|
34,699 |
|
2,913 |
|
|
|
|
|
69,583 |
| ||||||
Gross profit |
|
91,186 |
|
62,150 |
|
5,875 |
|
|
|
|
|
159,211 |
| ||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Advertising and marketing |
|
34,720 |
|
|
|
403 |
|
2,866 |
(a) |
|
|
37,989 |
| ||||||
Sales |
|
26,243 |
|
|
|
2,053 |
|
15,736 |
(a) |
|
|
44,032 |
| ||||||
Technology and development |
|
21,815 |
|
|
|
508 |
|
12,518 |
(a) |
|
|
34,841 |
| ||||||
Legal |
|
4,117 |
|
|
|
83 |
|
434 |
(a) |
|
|
4,634 |
| ||||||
Regulatory |
|
3,158 |
|
|
|
|
|
|
|
|
|
3,158 |
| ||||||
Acquisition related costs |
|
6,959 |
|
|
|
|
|
|
|
(6,959 |
)(g) |
|
| ||||||
General and administrative |
|
48,568 |
|
|
|
9,177 |
|
23,509 |
(a) |
(690 |
)(g) |
80,564 |
| ||||||
Selling, general and administrative |
|
|
|
57,479 |
|
|
|
(57,479 |
)(a) |
|
|
|
| ||||||
Depreciation and amortization |
|
8,270 |
|
|
|
90 |
|
3,097 |
(a) |
10,120 |
(b) |
21,577 |
| ||||||
Loss from operations |
|
(62,664 |
) |
4,671 |
|
(6,439 |
) |
(681 |
) |
(2,471 |
) |
(67,584 |
) | ||||||
Amortization of warrants and loss on extinguishment of debt |
|
8,454 |
|
|
|
|
|
|
|
|
|
8,454 |
| ||||||
Foreign currency transaction loss |
|
|
|
236 |
|
|
|
(236 |
)(a) |
|
|
|
| ||||||
Interest expense (income), net |
|
2,588 |
|
6,489 |
|
(38 |
) |
|
|
21,742 |
(c)(d) |
30,781 |
| ||||||
Other expense, net |
|
|
|
1,150 |
|
|
|
(445 |
)(a) |
(705 |
)(e) |
|
| ||||||
Net loss before taxes |
|
(73,706 |
) |
(3,204 |
) |
(6,401 |
) |
|
|
(22,508 |
) |
(106,819 |
) | ||||||
Income tax provision |
|
510 |
|
704 |
|
|
|
|
|
|
|
1,214 |
| ||||||
Net loss |
|
$ |
(74,216 |
) |
$ |
(3,908 |
) |
$ |
(6,401 |
) |
$ |
|
|
$ |
(22,508 |
) |
$ |
(108,033 |
) |
Net loss per share, basic and diluted |
|
$ |
(1.75 |
) |
|
|
|
|
|
|
|
|
$ |
(2.26 |
) | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Weighted-average shares used to compute basic and diluted net loss per share |
|
42,330,908 |
|
|
|
|
|
|
|
5,418,776 |
(f)(h) |
47,749,684 |
|
(1) Includes results from a business disposed of by Best Doctors in January 2017, of which revenue and net income were $4,605 and $1,697, respectively.
See accompanying notes to unaudited pro forma combined statement of operations.
UNAUDITED PRO FORMA COMBINED BALANCE SHEET
AS OF MARCH 31, 2017
(in thousands)
|
|
As of March 31, 2017 |
| ||||||||||
|
|
Teladoc |
|
Best Doctors |
|
Pro Forma |
|
Pro Forma |
| ||||
Assets |
|
|
|
|
|
|
|
|
| ||||
Current assets: |
|
|
|
|
|
|
|
|
| ||||
Cash and cash equivalents |
|
$ |
139,948 |
|
$ |
14,756 |
|
$ |
(91,879 |
)(i) |
$ |
62,825 |
|
Short-term investments |
|
36,005 |
|
|
|
|
|
36,005 |
| ||||
Accounts receivable, net |
|
15,309 |
|
9,895 |
|
|
|
25,204 |
| ||||
Prepaid expenses and other current assets |
|
3,564 |
|
2,730 |
|
|
|
6,294 |
| ||||
Total current assets |
|
194,826 |
|
27,381 |
|
(91,879 |
) |
130,328 |
| ||||
Property and equipment, net |
|
7,441 |
|
9,734 |
|
|
|
17,175 |
| ||||
Goodwill |
|
188,184 |
|
23,316 |
|
304,599 |
(j) |
516,099 |
| ||||
Intangible assets, net |
|
23,078 |
|
5,477 |
|
80,873 |
(k) |
109,428 |
| ||||
Other assets |
|
424 |
|
3,530 |
|
|
|
3,954 |
| ||||
Total assets |
|
$ |
413,953 |
|
$ |
69,438 |
|
$ |
293,593 |
|
$ |
776,984 |
|
Liabilities and stockholders equity |
|
|
|
|
|
|
|
|
| ||||
Current liabilities: |
|
|
|
|
|
|
|
|
| ||||
Accounts payable |
|
$ |
1,949 |
|
$ |
1,232 |
|
$ |
|
|
$ |
3,181 |
|
Accrued expenses and other current liabilities |
|
8,947 |
|
11,513 |
|
(3,809 |
)(l) |
16,651 |
| ||||
Accrued compensation |
|
7,242 |
|
3,943 |
|
|
|
11,185 |
| ||||
Long-term bank and other debt-current portion |
|
|
|
3,908 |
|
(3,908 |
)(m) |
|
| ||||
Total current liabilities |
|
18,138 |
|
20,596 |
|
(7,717 |
) |
31,017 |
| ||||
Other liabilities |
|
8,104 |
|
1,252 |
|
|
|
9,356 |
| ||||
Deferred taxes |
|
1,844 |
|
779 |
|
|
|
2,623 |
| ||||
Long term bank and other debt, net |
|
42,434 |
|
24,291 |
|
76,875 |
(m) |
143,600 |
| ||||
Convertible senior notes |
|
|
|
|
|
147,000 |
(m) |
147,000 |
| ||||
Commitments and contingencies |
|
|
|
|
|
|
|
|
| ||||
Preferred stock |
|
|
|
39,790 |
|
(39,790 |
)(n) |
|
| ||||
Stockholders equity (deficit): |
|
|
|
|
|
|
|
|
| ||||
Common stock, par value |
|
54 |
|
67 |
|
(65 |
)(o) |
56 |
| ||||
Additional paid-in capital |
|
563,832 |
|
61,214 |
|
48,784 |
(p) |
673,830 |
| ||||
Accumulated deficit |
|
(220,449 |
) |
(76,083 |
) |
66,038 |
(q) |
(230,494 |
) | ||||
Accumulated other comprehensive loss |
|
(4 |
) |
(2,468 |
) |
2,468 |
(r) |
(4 |
) | ||||
Total stockholders equity (deficit) |
|
343,433 |
|
(17,270 |
) |
117,225 |
|
443,388 |
| ||||
Total liabilities and stockholders equity |
|
$ |
413,953 |
|
$ |
69,438 |
|
$ |
293,593 |
|
$ |
776,984 |
|
See accompanying notes to unaudited pro forma combined balance sheet.
NOTES TO UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION
(in thousands, except share and per share information)
Preliminary Purchase Price Allocation
The Company has performed a preliminary valuation analysis of the fair market value of Best Doctors assets and liabilities. The following table summarizes the allocation of the preliminary purchase price as of March 31, 2017:
Tangible assets acquired: |
|
|
| |
Current assets |
|
$ |
27,381 |
|
Property and equipment, net |
|
9,734 |
| |
Other |
|
3,530 |
| |
Total |
|
40,645 |
| |
Value assigned to identifiable intangible assets acquired |
|
86,350 |
| |
Liabilities assumed |
|
(14,910 |
) | |
Total assets acquired in excess of liabilities assumed |
|
$ |
112,085 |
|
Goodwill |
|
327,915 |
| |
Total purchase price |
|
$ |
440,000 |
|
This preliminary purchase price allocation has been used to prepare pro forma adjustments in the unaudited pro forma combined balance sheet and statements of operations. The final purchase price allocation will be determined subsequent to acquisition, when the Company has completed the detailed valuations and necessary calculations including a more comprehensive review of leases. The final allocation may differ materially from the preliminary allocation used in the pro forma adjustments.
The Company has performed a valuation analysis of the fair market value of HealthiestYous assets and liabilities. The following table summarizes the allocation of the final purchase price:
Tangible assets acquired: |
|
|
| |
Current assets |
|
$ |
7,556 |
|
Property and equipment, net |
|
1,289 |
| |
Other |
|
80 |
| |
Total |
|
8,925 |
| |
Value assigned to identifiable intangible assets acquired |
|
14,400 |
| |
Liabilities assumed |
|
(3,683 |
) | |
Total assets acquired in excess of liabilities assumed |
|
$ |
19,642 |
|
Goodwill |
|
131,842 |
| |
Total purchase price |
|
$ |
151,484 |
|
This final purchase price allocation has been used to prepare pro forma adjustments in the pro forma statement of operations.
Pro Forma Adjustments
The pro forma adjustments are based on our preliminary estimates and assumptions that are subject to change. The following adjustments have been reflected in the unaudited pro forma combined financial information:
(a) Reflects the reclassification of certain components of the statement of operations to conform to the financial results of the combined companies.
(b) As part of the preliminary valuation analysis of Best Doctors, the Company identified intangible assets, including client lists, non-compete agreements and trademark. These amounts represent the estimated additional amortization as a result of the identified intangible assets.
The following table summarizes the estimated fair values of Best Doctors identifiable intangible assets and their estimated useful lives and the associated amortization for the three months ended March 31, 2017 and for the year ended December 31, 2016:
|
|
Estimated |
|
Estimated |
|
Three Months |
|
Year Ended |
| |||
Customer relationships |
|
$ |
57,480 |
|
10 years |
|
$ |
1,437 |
|
$ |
5,748 |
|
Trademark |
|
24,830 |
|
15 years |
|
414 |
|
1,655 |
| |||
Non-compete |
|
4,040 |
|
5 years |
|
202 |
|
808 |
| |||
Total |
|
$ |
86,350 |
|
|
|
$ |
2,053 |
|
$ |
8,211 |
|
These preliminary estimates of fair value and estimated useful lives may differ from final amounts the Company will calculate subsequent to the Acquisition after completing a detailed valuation analysis, and the difference could have a material impact on the accompanying unaudited pro forma combined financial statements.
Additionally, the Company identified HealthiestYous intangible assets, including client lists, non-compete agreements, trademark and technology. The following table summarizes the fair values and their useful lives and the associated amortization for the period prior to the acquisition of HealthiestYou from January 1, 2016 through June 30, 2016:
|
|
Estimated |
|
Estimated |
|
Year Ended |
| ||
Customer relationships |
|
$ |
10,930 |
|
10 years |
|
$ |
1,325 |
|
Trademark |
|
1,180 |
|
3 years |
|
197 |
| ||
Non-compete |
|
70 |
|
2 years |
|
17 |
| ||
Technology |
|
2,220 |
|
3 years |
|
370 |
| ||
Total |
|
$ |
14,400 |
|
|
|
$ |
1,909 |
|
(c) Reflects (i) the elimination of interest expense and amortization of debt issuance costs associated with the Companys existing mezzanine term loan facility and line of credit facility of $888 and $2,958 for the three months ended March 31, 2017 and the year ended December 31, 2016, respectively, and (ii) estimated interest expense on debt incurred, amortization of debt issuance cost and fair value of the equity component of the notes in connection with the Transactions of $7,797 and $31,188 for the three months ended March 31, 2017 and the year ended December 31, 2016, respectively. An increase or decrease of 0.25% per annum related to the interest rate associated with the debt incurred in connection with the Transactions would increase or decrease pro forma interest expense by approximately $219 for the three months ended March 31, 2017 and $875 for the year ended December 31, 2016.
(d) Reflects the elimination of interest expense associated with Best Doctors existing credit facilities and subordinated convertible promissory notes and other debt in the aggregate amount of $575 and $6,488 for the three months ended March 31, 2017 and for the year ended December 31, 2016, respectively.
(e) Represents the elimination of the change in fair value of the warrants issued in 2016 associated with Best Doctors subordinated convertible promissory notes of $82 and $705 for the three months ended March 31, 2017 and the year ended December 31, 2016, respectively.
(f) Reflects the issuance of 1,940,878 (based on an average of the volume-weighted average trading price for the five full trading days ending on and including June 19, 2017 of $33.49) shares of Teladoc common stock in connection with the Acquisition.
(g) Represents the elimination of nonrecurring transaction costs incurred of $7,649 principally due to transaction costs for bankers and other professional fees and contract termination costs that are directly related to the acquisition of HealthiestYou.
(h) Reflects the increase in the weighted average shares of 3,477,898 in connection with the issuance of 6,955,796 shares of Teladoc common stock for the acquisition of HealthiestYou.
(i) Represents the preliminary cash purchase price for the Acquisition of $375,000 plus transaction costs of $7,720 and fees associated with the establishment of the New Term Loan Facility and the repayment of the Companys existing debt in the amount of $42,490 less proceeds from the New Term Loan Facility, net of discount of $143,581, and the issuance of the notes, net of fees of $192,000.
(j) Represents the preliminary net increase to goodwill as a result of the Acquisition.
(k) Represents the preliminary net increase to identifiable intangible assets as a result of the Acquisition.
(l) Reflects the elimination of warrants and interest accrued for Best Doctors associated with its subordinated convertible promissory notes and other debt in the amount of $3,049 and $760, respectively.
(m) Reflects (i) the establishment of the New Term Loan Facility, net of debt issuance costs of $6,400, (ii) the issuance of the notes, net of debt issuance costs of $8,000, and the fair value of the equity component of the notes of $45,000, (iii) the repayment of the Companys existing $25,000 mezzanine term loan facility and $17,490, net of $56 of debt discount, outstanding under its line of credit facility and (iv) the satisfaction of Best Doctors subordinated convertible promissory notes and other debt of $20,100 and $8,099, respectively.
(n) Reflects convertible preferred stock of Best Doctors eliminated as a result of the Acquisition.
(o) Reflects the issuance of 1,940,878 (based on an average of the volume-weighted average trading price for the five full trading days ending on and including June 19, 2017 of $33.49) shares of Teladoc common stock of $2 in connection with the Acquisition, less $67 of the par value of Best Doctors common stock eliminated in connection with the Acquisition. The actual number of shares to be issued will not be determined until the closing of the Acquisition and will be based on our stock price at the time.
(p) Reflects the issuance of 1,940,878 (based on an average of the volume-weighted average trading price for the five full trading days ending on and including June 19, 2017 of $33.49) shares of Teladoc common stock of $64,998 in connection with the Acquisition and the fair value of the equity component of the notes of $45,000, less $61,214 of additional paid-in capital of Best Doctors eliminated in connection with the Acquisition. The actual number of shares to be issued will not be determined until the closing of the Acquisition and will be based on our stock price at the time.
(q) Reflects the accumulated deficit of Best Doctors eliminated as a result of the Acquisition, net of transaction costs of $7,720, expenses associated with the loss on extinguishment of debt of $2,250 and other charges in the amount of approximately $75.
(r) Reflects the elimination of Best Doctors other comprehensive loss for foreign currency translation adjustments.